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ABBREVIATIONS 
cDNA  complementary DNA 
CEL  carboxyl esther lipase 
CLPS  procolipase gene 
CN  copy number (of a gene) 
CP  chronic pancreatitis 
Ct  threshold cycle 
CTLA4  cytotoxic T-lymphocyte-associated protein 4 gene 
CTRB2 human chymotrypsinogen B2 protein 
CTRC  human chymotrypsinogen C protein 
Ctrb  mouse chymotrypsinogen B protein 
Ctrc  mouse chymotrypsinogen C protein 
CXCL1 chemokine (C-X-C motif) ligand 1 
DEFA1 human α1-defensin gene 
DEFA3 human α3-defensin gene 
DEFB1 human β1-defensin gene 
DM  diabetes mellitus 
DM1  type 1 diabetes mellitus, insulin-dependent diabetes mellitus 
DM2  type 2 diabetes mellitus, non-insulin dependent diabetes mellitus 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
FAM  6-carboxyfluorescein 
GAPDH glyceraldehyde-3-phosphate dehydrogenase gene 
GFR  glomerular filtration rate 
HBD1  human β1-defensin protein 
HBD2  human β2-defensin protein 
HCl  hydrogen chloride 
HLA  human leukocyte antigen 
HNP  human neutrophil peptide 
Hu1  human cationic trypsinogen protein 
Hu2  human anionic trypsinogen protein 
Hu3  human mesotrypsinogen protein 
IFIH1  interferon-induced helicase C domain-containing protein 1 
IFNγ  interferon gamma 
IL1R1  interleukin receptor type 1 
IL1RN  interleukin-1 receptor antagonist 
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IL-1β  interleukin-1β 
IL2RA  interleukin 2 receptor alpha  
IL-6  interleukin-6 
INS  insulin gene 
LDL  low density lipoprotein 
LXR  liver X receptor 
MMP  matrix metalloproteinase 
MODY maturity onset diabetes of the young, monogenic diabetes 
MPO  myeloperoxidase gene 
mRNA  messenger ribonucleic acid 
MWCO molecular weight cut off 
NaCl  sodium chloride 
NCBI  National Center for Biotechnology Information, USA 
NF-κB  nuclear factor-κB 
OR  odds ratio 
PAGE  polyacrylamide gel electrophoresis 
PCR  polymerase chain reaction 
PMN  polymorphonuclear immune cells 
PPARµ2 peroxisome proliferator-activated receptor µ2 
PRSS1  human cationic trypsinogen gene 
PRSS2  human anionic trypsinogen gene 
PRSS3  human mesotrypsinogen gene 
PTPN22 protein tyrosine phosphatase, non-receptor type 22 
PVDF  polyvinylidene fluoride 
qPCR  quantitative (real time) polymerase chain reaction 
RNA  ribonucleic acid 
RT PCR reverse transcription polymerase chain reaction 
SBDS  Shwachman-Bodian-Diamond Syndorme gene 
SDF1  stromal cell-derived factor 1 (or chemokine (C-X-C motif) ligand 12) 
SDS  sodium dodecyl sulfate 
SNP  single nucleotide polymorphism 
SUMO4 small ubiquitin-like modifier 4 gene 
TAP  trypsinogen activation peptide 
TIMP  tissue inhibitors of metalloproteinases 
TLR4  Toll-like receptor 4 
TNF-α  tumor necrosis factor alpha 
UBR1  Ubiquitin-protein ligase E3 component N-recognin 1 gene 
UV  ultraviolet light 
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1. INTRODUCTION 
Disorders of the pancreas, both endocrine (e.g. diabetes mellitus) and exocrine (e.g. 
chronic pancreatitis or cystic fibrosis), can be triggered by different genetic factors. There 
exist specific mutations which can directly lead to the development of certain pancreatic 
diseases. A little more than a half century ago, mankind knew a significant amount about 
these disorders clinically, however at that time not much was known about their genetic 
background. 
In 1889, Minkowski and von Mering reported, that dogs developed diabetes after 
pancreatectomy [112]. This was the first evidence proving the role of the pancreas in 
pathogenesis of diabetes mellitus. In 1921, the first effective therapy in dogs using pancreatic 
extracts containing insulin against diabetes mellitus was carried out by Banting and Best [11]. 
Today we know that genetic factors (including the insulin gene) have significant roles in the 
development of diabetes mellitus in combination with environmental factors. However, 
diabetes can also develop due to a mutation in a single gene (monogenic diabetes). 
One of the most common genetic diseases among the Caucasian (white) population is 
cystic fibrosis (OMIM: 219700) with an incidence of 1 in 2500 live births [88]. In 1938, it 
was first distinguished from coeliac disease by Dorothy H. Andersen [5]. Mutations in the 
cystic fibrosis transmembrane conductance regulator gene (CFTR, OMIM: 602421)                
-identified in 1989 [52]- are responsible for the development of this disorder. The CFTR gene 
codes for a chloride channel whose malfunction hinders the physiological role of the pancreas 
and other organs of the digestive, respiratory and reproductive systems. Mutations causing 
cystic fibrosis can be found under the homepage http://www.cftr2.org/. 
In 1896, Hans Chiari has described for the first time the post mortem autodigestion of 
the pancreas and he proposed that this might be mediated by pancreatic enzymes [23]. In 
1952, Comfort and Steinberg were the first to describe a familial accumulation of chronic 
pancreatitis [24], and in 1996, the PRSS1 gene encoding human cationic trypsinogen was 
identified as the first gene associated with chronic pancreatitis by Whitcomb et al. [116]. 
Since then other genes (CTRC, SPINK1, CPA1 and the above mentioned CFTR) have also 
been shown to have roles in the development of chronic pancreatitis. Under the 
http://www.pancreasgenetics.org/ homepage a summary of published mutations of genes 
(except for CFTR) associated with chronic pancreatitis can be found. 
In the past 2-3 decades, investigators began studying genetic factors which can lead to 
pancreatic diseases. Despite the fact that large steps have been made in the understanding of 
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the genetics and pathophisiology of pancreatic diseases, clearly, these investigations have not 
reached their endpoint yet. In this thesis the results of recent genetic investigations regarding 
hereditary chronic pancreatitis and diabetes mellitus have been reviewed together with a 
description of the author's experimental data in order to gain a deeper comprehension of the 
pathophisiology of pancreatic diseases and their complications. 
1.1. GENETIC RISK FACTORS OF DIABETES 
Based on the definitions provided by the American Diabetes Association, diabetes is a 
group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin 
secretion, insulin action, or both. Type 1 diabetes (~5-10% of all cases of diabetes) is caused 
by β-cell destruction in the Langerhans islets of the pancreas, usually leading to absolute 
insulin deficiency. Characteristics of type 2 diabetes (~90-95% of all cases of diabetes) range 
from predominant insulin resistance with relative insulin deficiency to predominant insulin 
secretory defect with insulin resistance [3]. The long term complications affect several organs 
including the eyes, kidneys, nerves and blood vessels, making diabetes a lifelong disease 
which predisposes to secondary malfunction of almost all organs in the whole body, primarily 
due to the metabolic changes characteristic of diabetes. 
1.1.1. Genetic risk factors of type 1 diabetes mellitus (DM1) 
Type 1 diabetes mellitus (DM1, OMIM: 222100) is a genetically heterogeneous 
autoimmune disease of glucose homeostasis that is characterized by susceptibility to 
ketoacidosis in the absence of insulin therapy [111]. β-cells of the pancreas suffer 
autoimmune destruction in which several autoantibodies can have a pathogenic role against 
islet cells, including insulin, glutamic acid decarboxylase 65, and tyrosine phosphatases IA-2. 
In this type of diabetes patients are rarely obese [3]. 
Based on functional, structural and genetic evidence, haplotypes DR3 and DR4 of the 
human leukocyte antigene (HLA) class II loci are considered strong triggering factors, while 
DR2 haplotype protects from DM1 [13]. Other genes which are involved in disease 
pathogenesis are: INS (insulin gene on 11q15), PTPN22 (protein tyrosine phosphatase, non-
receptor type 22 on 1p13), CTLA4 (cytotoxic T-lymphocyte-associated protein 4 on 2q33), 
CD25 / IL2RA (on 10p15), interferon-induced helicase C domain-containing protein 1 (IFIH1 
gene on 2q24), small ubiquitin-like modifier 4 (SUMO4 gene on 6q25). However, certain 
alleles of these genes confer relatively low risk for development of DM1 compared to HLA 
class II haplotypes of which genetic association studies have shown clear correlation to DM1 
[13]. 
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Since DM1 is known to be principally an autoimmune disease, genetic factors which 
influence the physiology of the immune system, might have a significant role in the 
pathophysiology. Certain alleles of the TNF-α locus, as a part of an extended haplotype of the 
HLA DR4 haplotype on chromosome 6, have been found to play a direct role in the 
pathogenesis of DM1 [82]. 
Lanng et al. did not find an association between certain IL-1β alleles and the 
development of diabetes in cystic fibrosis patients [57], however, the IL-1β*2 allele, which 
correlates with a high secretor phenotype was associated significant susceptibility to 
nephropathy in DM1 patients [62], as well as to an interleukin-1 receptor antagonist allele 
(IL1RN*2) [16]. Investigation of the interleukin receptor type 1 gene (IL1R1) led also to the 
conclusion that certain IL1R1 alleles are associated with DM1 development [14, 71]. 
Awata et al. suggested that a CA-repeat polymorphism within the first intron of the 
IFNγ gene may contribute to the pathogenesis of DM1 in patients of Japanese origin and may 
be a genetic marker for DM1 [9]. Pociot et al. did not find an association between the 
presence of the same IFNγ allele and DM1 in Danish population, however in the Finnish 
population they found a modestly significant disease association of the studied IFNγ allelic 
pattern [83]. 
1.1.2. Genetic risk factors of type 2 diabetes mellitus (DM2) 
Type 2 diabetes mellitus (DM2, OMIM: 125853) accounts for 90–95% of those with 
diabetes. This type encompasses individuals who have insulin resistance and usually have 
relative insulin deficiency. Most patients with this form of diabetes are obese. Obesity itself is 
known to cause some degree of insulin resistance. Although, many different etiological 
factors can be responsible for the development of DM2, the specific causes are not known. In 
this type of diabetes, autoimmune destruction of β-cells does not occur. Ketoacidosis is not 
characteristic of DM2, but occurs rarely. Hyperglycaemia develops gradually and at its earlier 
stage it is often not severe enough for the patient to notice any of the classic symptoms of 
diabetes. Insulin deficiency due to β-cell dysfunction impacts skeletal muscle, liver and 
adipose tissues. Nevertheless, such patients are at increased risk for the development of 
macrovascular and microvascular complications [3, 8]. DM2 is known to be a multifactorial 
disease with clear association with different environmental and genetic factors. 
Although there are several genes found to be associated with DM2, only genes that 
have a role in the function of the innate immune system, and are also associated with DM2, 
are reviewed in this thesis. The innate immune system is the first line of defense against 
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microbial, fungal and viral infections. Tumor necrosis factor alpha (TNF-α), interleukin-1β 
(IL-1β) and interleukin-6 (IL-6) are released when toll-like receptor 4 (TLR4) binds certain 
danger- or pathogen-associated molecules [70]. These molecules can directly increase insulin 
resistance in fat, muscle and liver cells [15, 46], which can lead to impaired glucose 
tolerance, the major characteristic of DM2. Different alleles of these cytokine genes may 
influence the innate immunity pathway resulting in altered response to dietary factors which 
can also bind to TLR4 [10]. 
Arora et al. investigated DM2 patients in a cross-sectional study, and found genetic 
association between several SNPs in IL-6 and triglyceride levels, furthermore between SNPs 
of IL-6, TNF-α and fasting insulin levels. Other associations were found also between SNPs 
of TNF-α, and levels of CRP and HDL cholesterol. The strongest association was observed 
between CRP SNPs and CRP levels; SNPs rs1205 was inversely and rs1417938 was directly 
associated with CRP levels [8].  
Saxena et al. investigated IL-6, TNF-α and IL-10 polymorphisms in DM2 patients and 
controls of Indian origin. Genotypes IL-6 -597AA and TNF-α -308GG together, or -597AA, 
TNF-α -308GG and IL-10 -592CA together markedly increased the risk of DM2 if they were 
present in the same individual. However, the individual presence of the above mentioned 
genotypes did not lead to an increase in risk [96]. 
The “Pro” allele of p.P12A (rs1801282) polymorphism of peroxisome proliferator-
activated receptor µ2 (PPARµ2) gene is associated with higher glucose and insulin levels in 
obese patients [48]. However, if the Ala allele of polymorphism p.T92A (rs225014) of type 2 
deiodinase is present in the same patient together with the Ala allele of PPARµ2 p.P12A 
polymorphism, the chance of developing significant insulin resistance is highly elevated [31]. 
1.1.3. Defensins in diabetes 
Defensins are small antimicrobial peptides of the innate immune system, which have 
3 major type in vertebrates: α -, β- and θ-defensins. In humans only α- and β-defensins are 
expressed, while the genes encoding human θ-defensins are pseudogenes [20, 38, 108]. 
1.1.3.1. α-defensins 
The human chromosome locus 8p23.1 harbors 6 different α-defensin genes (DEFA1, 
DEFA3, DEFA1B, DEFA4, DEFA5, DEFA6) and 5 α-defensin pseudogenes. There are 6 
different types of α-defensins / human neutrophil peptides (HNP) expressed in humans. The 
protein product of DEFA1, DEFA3, DEFA4 genes are HNP-1,-2,-3 and -4 derived from 
polymorphonuclear immune cells, while intestinal human defensins (HD-5 and HD-6) are 
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derived from Paneth cells and are the protein products of DEFA5 and DEFA6 genes [19, 22, 
118]. 
The cluster of human α-defensin genes include DEFA1 (OMIM: 125220) and DEFA3 
(OMIM: 604522) lying on chromosome 8 with high variability of copy numbers. These genes 
encode human neutrophil peptide 1, 2 and 3 (HNP1-3) which are almost identical in their 
mature peptide sequence. The only difference between these mature peptides is the N-
terminal amino acid, which is Ala in the case of HNP-1, while at the same position HNP-3 
has an Asp residue. Mature HNP-2 peptide lacks this amino acid residue, and this peptide 
might be a result of a proteolytic cleavage of the other two peptides, because no separate gene 
has been identified to encode HNP-2 [100]. Differencies in copy number are the major source 
of genetic polymorphisms in the DEFA1 and DEFA3 genes. These are present in a cluster 
that is close to but independent of the β-defensin cluster on 8p23.1. Total DEFA1/DEFA3 
copy number was found to range between four and 11 copies per diploid genome with five to 
nine copies being the most common [1]. 
Today, these peptides are characterized as danger signals (alarmins) playing important 
roles in inflammation and immunity [77]. In addition to antimicrobial effects, α-defensins 
have an important role in chemotaxis and they induce proinflammatory cytokines [19, 22, 
118]. HNPs increase LDL (low density lipoprotein cholesterol) binding to the endothelial 
surface suggesting that α-defensins may modulate the development of atherosclerosis [86]. 
Neutrophil granulocytes are considered to be the primary cellular origin of HNP 1-3; which 
comprise 30-50 % of the granule proteins. HNPs can be released into the extracellular milieu 
following granulocyte activation as a consequence of degranulation, leakage, cell death, and 
lysis during inflammation [37]. In the formation of neutrophil extracellular traps (NETs)       
α-defensins are also involved [80]. 
1.1.3.2. β-defensins 
Human β-defensins are also antimicrobial peptides, which are thought to control the 
microbial flora on epithelial surfaces. [38, 81]. According to currently accessible data from 
the HUGO Gene Nomenclature Committee (http://www.genenames.org/), 38 different genes 
were identified encoding potentially expressed β-defensins in humans (17 genes on 8p23.1, 1 
gene on 11q13.4, 5 genes on 6p12.3, 4 genes on 20q11.1, 4 genes on 20q11.21, 6 genes on 
20p13, 1 gene on 4p16.1), while 9 genes are referred to as β-defensin pseudogenes. 
There is a wide body of knowledge regarding human β1-defensin, which is 
constitutively expressed from the HBD1 gene (OMIM: 602056) on chromosome 8, in close 
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proximity to DEFA1/DEFA3 sites. The main sources of human β1-defensin are the epithelial 
cells throughout in body: skin, small intestine, respiratory and urogenital tissues, pancreas, 
kidneys, male and female internal genital organs and thymus [121]. Human β1-defensin kills 
E.coli at micromolar concentrations, and other Gram-negative bacteria at concentrations 
ranging from 60 to 500 µg/µL [98]. The antibacterial and antifungal characteristics of HBD1 
is well characterized [114, 119] and their function is thought to be important in protection 
also against viral infections [41]. In addition to their antimicrobial effects, the 
chemoattractive function of these defensins have been shown to play a role in immunological 
reactions that protect the host from various pathogens [30]. While the expression of HBD1 is 
generally constitutive, the levels of human β2-defensin (HBD2) is inducible by 
proinflammatory cytokines and bacteria [17, 26, 81]. 
Several SNPs have been characterized in the HBD1 gene. Three frequent SNPs at 
positions c.-20G>A (rs11362), c.-44C>G (rs 1800972) and c.-52G>A (rs1799946) in the 5’-
untranslated region (5' UTR) of DEFB1 were described earlier [28]. The untranslated variants 
influence HBD-1 expression or function [103]. 
1.1.3.3. Role of defensins in diabetes mellitus 
Although it has been shown that some polymorphisms in certain cytokine genes are 
associated either with DM1 or DM2, little is known about the genetics and the functions of α- 
and β-defensins in diabetes. Infections are frequent in diabetic patients, because the 
antimicrobial function of their immune response is impaired. It has been reported that mRNA 
levels of rat β1-defensin are decreased in the kidneys, which may explain the high incidence 
of urinary tract infections in diabetes mellitus [35]. Recently, the effect of glucose and insulin 
on β-defensin expression have been described [12]. However, no connection was found 
between genetic polymorphisms of the HBD1 gene and diabetes in a Brasilian study 
investigating diabetic children [42]. 
Increased levels of human neutrophil peptide 1, 2 and 3 in type 1 diabetic patients 
with nephropathy and with cardiovascular complications has recently been reported [50, 95]. 
It is tempting to speculate that copy number polymorphisms and alterations of 
DEFA1/DEFA3 mRNA levels in granulocytes may influence the levels of HNP1-3 in patients 
with diabetes type 1 and type 2. 
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1.1.4. Connections between endocrine and exocrine pancreatic diseases at the genomic 
level 
Diabetes is a multifactorial disease, with both environmental and genetic factors 
playing a role in its development. Mutations in only a single gene, can also lead to the 
development of diabetes. Monogenic diabetes, also termed maturity onset diabetes of the 
young (MODY), develops before the age of 25, and presents as a nonketotic form of diabetes. 
Its inheritance follows an autosomal dominant pattern, and mutations associated with MODY 
cause a primary defect in the function of the beta cells of the endocrine pancreas [33]. 
Exocrine pancreas function is not affected in the majority of the 11 different types of MODY 
[34]. However, in MODY8 (CEL MODY), in which there is a defect in the carboxyl ester 
lipase (CEL, OMIM: 114840) gene, insufficiency of both endocrine and exocrine pancreatic 
function is observed [87]. 
Another example when a single malfunctioning gene may lead to both endocrine and 
exocrine insufficiency of the pancreas is the procolipase gene (CLPS, OMIM: 120105). The 
products of CLPS gene are the precursors of colipase and enterostatin. They are secreted 
mainly by the exocrine pancreas, but are also expressed in stomach, liver and regions of the 
central nervous system. The mature form of colipase is the essential cofactor of lipase, which 
has a significant role in the digestion of triglycerides emulsified by bile salts. Enterostatin 
acts as a pentapeptide hormone, which selectively down-regulates fat intake, and hampers 
insulin secretion in animal models. Certain SNPs of the CLPS gene (rs3748050 and 
rs378051) are associated in altered insulin secretion in non-diabetic Caucasians [115]. 
Furthermore, CLPS gene mutant p.R109C (also called p.R92C according to procolipase 
numbering) was found to be associated with DM2 [60]. In a functional study, the same 
mutant was found to be defective in its ability to anchor triglycerides to pancreatic lipase 
[29]. 
The simultaneous appearance of diabetes mellitus and exocrine pancreas insufficiency 
is surprisingly common. In most cases they do not develop together due to a single genetic 
disorder as described above in the case of CEL MODY, but as a result of disorders which can 
diffusely damage the pancreatic tissue (pancreatitis, trauma, pancreatectomy, neoplasia, 
cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy or surgical pancreas 
resection), which is classified as type 3c diabetes mellitus [3]. According to the publication 
by Ewald et al. [32], diabetes type 3c is often misclassified as type 2. Upon reclassification, 
the authors found that out of 1868 patients, 172 had type 3c diabetes mellitus (9.2%), of 
which 78.5% had chronic pancreatitis. In a publication by Hardt et al. [43] a high prevalence 
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of patients with type 1 and type 2 diabetes were found to have pathological exocrine function 
of the pancreas, which was correlated with an early onset of endocrine failure, long-lasting 
diabetes mellitus and low body mass index levels. 
Though endocrine and exocrine malfunction of the pancreas usually have different 
genetic risk factors, they might have a common genetic origin due to certain mutations in 
CLPS and CEL genes mentioned above. Living with chronic pancreatitis leads to the 
development of endocrine pancreas disfunction over time. Therefore, investigation of the 
mechanisms leading to chronic pancreatitis may not only result in a deeper understanding of 
the function of the exocrine pancreas and related diseases, but may also elucidate the 
mechanism of disease pathogenesis in certain types of diabetes. 
1.2. CHRONIC PANCREATITIS 
Chronic pancreatitis (CP) is defined as a relapsing or continuing inflammatory disease 
of the pancreas and is characterized by irreversible morphological changes, upper abdominal 
pain and, in some patients, permanent impairment of exocrine or endocrine function or both. 
The incidence of CP is 3.5-23 cases / 100.000 persons [4, 69, 88]. Excessive alcohol 
consumption is the most frequently identified etiological factor of chronic pancreatitis. In 
addition, smoking can accelerate the progression of the disease [65], and increase the risk of 
developing pancreatic adenocarcinoma. The incidence of pancreatic cancer among chronic 
pancreatic patients ranges between 3% and 13% [63, 69, 74], however, the incidence is close 
to 70% in patients with hereditary CP [69]. 
1.2.1. Hereditary chronic pancreatitis 
The first description of familial accumulation of chronic pancreatitis cases was 
provided in 1952 by Comfort and Steinberg [24]. However, it took 44 years before the first 
gene associated with hereditary pancreatitis was identified by Whitcomb et al. in 1996 [116]. 
The first reports about Hungarian cases of hereditary pancreatitis were published by Ruszinkó 
et al. and Oláh et al. in 2001 [76, 90], and these cases were also mentioned in a 2004 study by 
Howes et al. [47]. The first case report describing a Hungarian family affected by hereditary 
pancreatitis was published in 2012 by Major et al. [66]. 
The definitions of familial and hereditary pancreatitis need to be distinguished. 
Clinically, both are recurrent acute or chronic pancreatitis. If two first-degree relatives or 
three or more third-degree relatives in two or more generations are affected and have no other 
precipitating factors, the diagnosis of hereditary pancreatitis is established. The diagnosis of 






Figure 1. Effect of pancreatitis-associated PRSS1 mutations on the chymotrypsin C (CTRC) 
dependent activation and degradation of human cationic trypsinogen. CTRC cleaves the Leu81-Glu82 
peptide bond and trypsin cleaves the Arg122-Val123 peptide bond; these two cleavages result in the 
eventual degradation of trypsinogen. CTRC also stimulates autoactivation of cationic trypsinogen by 
cleaving the Phe18-Asp19 peptide bond in the activation peptide. The shortened activation peptide is more 
susceptible to trypsin-mediated activation at the Lys23-Ile24 peptide bond. The dominant effect of CTRC is 
degradation. (A) PRSS1 mutations can increase conversion of trypsinogen to trypsin by inhibition of 
CTRC-dependent trypsinogen degradation (red arrow) or by increasing CTRC-dependent stimulation of 
autoactivation (green arrow). (B) Proteolytic cleavage of human cationic trypsinogen by CTRC and 
trypsin. Primary structure of trypsinogen with disulfide bonds is shown. CTRC cleavage sites are 
highlighted in orange and trypsin cleavage sites are shown in blue. The activation peptide is in green. Note 
the yellow peptide segment not stabilized by disulfide bonds between the Leu81 and Arg122 cleavage sites. 
Figure 1B is modified from Szmola and Sahin-Tóth (2007) [107]. 
familial pancreatitis is made if more than one affected family member was diagnosed with CP 
in the same generation [47]. 
Hereditary chronic pancreatitis is a human genetic disorder caused by heterozygous 
mutations in the serine protease 1 gene (PRSS1, OMIM: 276000) on chromosome 7q35 
encoding human cationic trypsinogen [116], the precursor for the most abundant digestive 
enzyme secreted by the human pancreas [97]. Besides PRSS1, the locus also contains five 
A 
B 
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trypsinogen pseudogenes, a relic gene, and PRSS2, which encodes anionic trypsinogen, the 
other major human trypsinogen isoform. The PRSS3 gene coding for mesotrypsinogen, the 
relatively minor third human isoform, is found on chromosome 9p13. 
Mutations in the PRSS1 gene associated with hereditary chronic pancreatitis result in 
early activation of trypsinogen inside the pancreas due to altered regulation by chymotrypsin 
C (CTRC) [106]. High penetrance trypsinogen mutations such as p.N29I and p.R122H are 
associated with an autosomal dominant inheritance pattern, whereas mutations with lower 
penetrance (e.g. mutation p.A16V), may be found not only in hereditary but also in sporadic 
cases without family history [109]. 
Figure 1 shows the functional effects of the most frequent human cationic trypsinogen 
mutations. Shortening of the activation peptide by CTRC-mediated cleavage of Phe18-Asp19 
peptide bond results in increased autoactivation [72]. This cleavage is stimulated by 
pancreatitis-associated mutations p.N29I and p.A16V [106, 72]. Cleavage of the Leu81-
Glu82 peptide bond in the calcium binding loop, together with the trypsin-mediated autolytic 
cleavage of the Arg122-Val123 peptide bond, results in rapid degradation and inactivation of 
cationic trypsinogen [107]. Mutations p.N29I and p.R122H inhibit CTRC-mediated 
degradation and thereby increase trypsinogen autoactivation [106]. 
1.2.2. Syndromes associated with chronic pancreatitis 
Goobie et al. mapped the susceptibility gene of Shwachman-Diamond syndrome 
(OMIM: 260400) to chromosome 7 [40]. This disease follows an autosomal recessive 
inheritance pattern and is characterized mainly by exocrine pancreatic insufficiency 
(lipomatosis of pancreas), hematologic (neutropenia, anemia, thrombocytopenia) and skeletal 
abnormalities (delayed maturation, metaphyseal chondordysplasia of the long bones and 
thoracic-cage abnormalities with costochondrial thickening). The susceptibility gene is the 
Shwachman-Bodian-Diamond Syndrome gene (SBDS, OMIM: 607444) mapped to 7q11.21 
[18]. 
In 1971, Johanson and Blizzard described a congenital syndrome characterized by 
aplasia of the alae nasi, deafness, hypothyroidism, dwarfism, absent permanent teeth and 
malabsorption [49]. The most consistently affected organ in this syndrome is the pancreas, 
and the intrauterin onset of pancreatitis is characterized by gradual destruction of previously 
formed acinar cells with unaffected primary zymogen synthesis and no sign of apoptosis at 
the cellular level. The susceptibility gene of Johanson-Blizzard syndrome (OMIM: 243800) 
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with multiple pathogenic alleles is the ubiquitin-protein ligase E3 component N-recognin 1 
gene (UBR1, OMIM: 605981) at position 15q15.2, containing 47 exons [120]. 
1.3. MOUSE TRYPSINOGENS 
Considering the widespread use of mice in experimental studies of the pancreas, it is 
surprising how little is known about mouse trypsinogens. In 1982, Watanabe reported the 
purification of three trypsinogen isoforms from the mouse pancreas [113]. In 1986, Stevenson 
et al. cloned a trypsinogen cDNA, corresponding to isoform T20, from the pancreas and 
demonstrated that the mouse genome contained multiple different trypsinogen genes [102]. 
This was later confirmed by Leroy Hood's laboratory in 1997 when they sequenced the 
mouse T cell receptor beta locus on chromosome 6 and identified 20 trypsinogen genes 
organized into two groups, one comprising genes T1-T7 and the other containing genes T8-
T20 [39]. 
Using the currently accessible NCBI (National Center for Biotechnology Information, 
USA) online genomic database (http://www.pubmed.org/) we found that eleven of the 20 
genes are potentially functional (T4, T5, T7, T8, T9, T10, T11, T12, T15, T16, T20; as shown 
in Suppl. Figure 1), while the other nine genes are either pesudogenes (T1, T2, T3, T14) or 
relic genes (T6, T13, T17, T18, T19). In 1999, Ohmura et al. cloned the cDNA for isoform 
T9 from sperm acrosome [75]. It remained unknown, however, which isoforms of the 11 
potentially functional trypsinogen genes are expressed at the protein level in the mouse 
pancreas. More recently, genetic deletion of T7 indicated that this isoform may contribute to 
as much as 60% of pancreatic trypsinogens [25, 91]. The authors also found that despite the 
presence of other trypsinogen isoforms, mice deficient in T7 did not respond to secretagogue 
hyperstimulation with the characteristic intra-acinar cell trypsinogen activation, which is an 
early event in acute pancreatitis. 
These findings suggest that the different mouse trypsinogen isoforms vary in their 
activation kinetics and highlight the need for their comparative biochemical characterization. 
Therefore, identification of major trypsinogen isoforms in the mouse pancreas, and a study of 
their autoactivation and regulation by mouse chymotrypsins is needed. 
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3. AIMS 
Like other members of the innate immune system, defensins can also have a role in 
the development of type 1 and type 2 diabetes mellitus and their macro- and microvascular 
complications. In order to gain deeper comprehension about the role of defensins in diabetes, 
the aims of this study were: 
• to measure plasma levels of human neutrophil peptides 1-3 (HNP 1-3) and to 
examine their possible association with diabetes and / or its complications, 
• to determine gene copy number polymorphism and mRNA expression levels 
of DEFA1/DEFA3 genes in diabetes mellitus, 
• to investigate the association of single nucleotide polymorphisms c.-20G>A, 
c.-44C>G and c.-52G>A in the promoter region of the β1-defensin (DEFB1) 
gene with type 1 and type 2 diabetes mellitus. 
Research into the pathomechanism of hereditary chronic pancreatitis has been 
hindered by the lack of good animal models which mimic the human disease and develop 
spontaneous pancreatitis. In order to create a mouse model, biochemical characterisation of 
mouse trypsinogens was necessary. The aims of the study of mouse trypsinogens were: 
• to identify the major trypsinogen isoforms expressed in the mouse pancreas, 
• to characterize the autoactivation of mouse trypsinogens and study their 
interaction with mouse chymotrypsins, 
• to investigate the biochemical characteristics of the most frequent pathogenic 
human cationic trypsinogen mutation p.R122H introduced into mouse 
trypsinogen isoforms T7 and T8. 
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2. PATIENTS AND METHODS 
2.1. NOMENCLATURE 
Nucleotide residues are numbered starting with nucleotide A of the ATG-translation 
initiation codon. Amino acid residues are numbered starting with the initiator methionine of 
the primary translation product. Note that because of an extra Asp residue (Asp23) in the 
activation peptide of T7 mouse trypsinogen isoform, amino-acid numbering in this isoform is 
shifted by one relative to human and other mouse trypsinogens. Autolysis loop refers to the 
flexible region between residues 146 and 154 in trypsinogen (Suppl. Figure 1). 
2.2. PATIENTS AND CONTROLS IN GENETIC ASSOCIATION STUDY 
All cases and controls were of Hungarian ethnic origin and were residents of 
Hungary. Informed consent was obtained from all subjects, and the local Ethics Committee of 
University of Szeged gave prior approval to the study. All subjects consented to the study and 
were treated according to the Patient Right Protection Act of our institutions and international 
guidelines. 
2.2.1. Control group 
The 221 age- and gender matched members of the control group were selected from 
healthy blood donors from the regional Centre of Hungarian National Blood Transfusion 
Service, Szeged, Hungary. Blood donors with diabetes mellitus, nephropathy, hypertension or 
ischemic heart disease were excluded from this study. 
2.2.2. Patients with diabetes mellitus 
257 diabetic patients (122 men, 135 women) were enrolled in the study; which 
included 117 patients with type 1 and 140 patients with type 2 diabetes. Diagnosis of diabetes 
of all patients was based on the ADA criteria [2]. 
71 of the cohort had diabetic nephropathy (32 with type 1 diabetes and 39 with type 2 
diabetes), defined as an albumin-to-creatinine ratio in a random spot collection higher than 
3.4 mg/mM or protein content over 300 mg/day in collected urine. Abnormal kidney function 
was detected if glomerular filtration rate (GFR) was lower than 60 mL/min/1.73 m2. 
115 patients suffered from retinopathy (47 with type 1 diabetes and 68 with type 2 
diabetes). This complication was evidenced as the presence of background or proliferative 
retinopathy, macular edema or diabetes-related blindness or the use of retinal 
photocoagulation therapy. The retinopathy status was checked by color stereo-
ophtalmography and fluorescence angiography. Neuropathy was diagnosed in 95 patients (35 
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with type 1 and 60 with type 2 diabetes). Neuropathy was proven if abnormal peripheral 
sensory functions or altered lower limb tendon reflexes as well as impaired cardiovascular 
reflex tests were detected. 54 diabetic patients (14 with type 1 diabetes, 40 with type 2 
diabetes) had previously been diagnosed with macrovascular disease including major 
coronary events, stroke or transient ischemic attack, peripheral artery disease or amputation. 
High number of patients (182) had treated hypertension. (50 with type 1 diabetes and 132 
with type 2 diabetes). 
2.3. METHODS USED IN GENETIC ASSOCIATION STUDY 
2.3.1. DNA isolation 
Genomic DNA purification was carried out from 300 µl buffy coat of the 
anticoagulated (EDTA), centrifuged (1200 rpm/min for 15 min), peripheral blood using the 
High Pure PCR Template Preparation Kit (Roche Diagnostic GmbH, Mannheim, Germany). 
DNA concentrations were measured with a Qubit™ fluorometer (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer's instructions. Genomic DNA was stored at –20ºC. 
2.3.2. Determination of DEFA1/DEFA3 gene copy number by quantitative real-time 
PCR 
Genomic DNA was purified from peripheral blood. Gene copy number determination 
was carried out as previously described by Linzmeier et al. [61] with minor modifications. 
For quantitation BIO-RAD CFX 96 instrument (Bio-Rad, Hercules, CA, USA) was used. The 
reaction volume was 15 µL, containing 3 µL of DNA, 1 µM of each primers, 7,5 µL of 
reaction buffer (Fermentas Probe/ROX qPCR MasterMix, Fermentas, Lithuania) and 0,6 µL 
EVAGreen (20x EVAGreen™ Biotium Inc., Hayward, CA, USA). In order to amplify the 
DEFA1/DEFA3 target genes we used the forward primer "DEFA1 1 F" (5’ TAC CCA CTG 
CTA ACT CCA TAC 3’), and the reverse primer "DEFA1 1 R" (5’ GAA TGC CCA GAG 
TCT TCC C 3’). To amplify the reference gene MPO (myeloperoxidase) we used the forward 
primer "MPO 1 F" (5’ CCA GCC CAG AAT ATC CTT GG 3’), and the reverse primer 
"MPO 1 R" (5’ GGT GAT GCC TGT GTT GTC G 3’). The real time PCR conditions were 
as follows: initial denaturation at 95 oC for 10 min followed by 40 cycles of denaturation (95 
oC for 15 s) and extension (54 oC for 1 min). 
Quantification was performed by monitoring the emitted fluorescence after each cycle 
of PCR reaction of genomic DNA samples in order to identify the exact time point at which 
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the logarithmic linear phase could be distinguished from the background (crossing point). 
Each DNA sample was analyzed in triplicate, in two independent experiments. 
Using the formula "A" we calculated the ∆Ct value which was characteristic for each 
DNA sample. The copy number of the reference gene MPO was known to be 2 per diploid 
genome [61]. The total copy number (CN) of target genes DEFA1 and DEFA3 per diploid 
genome was calculated using the formula "B". 
   A:  ∆Ct = Ct reference - Ct target  
   B: CNtarget = 2∆Ct x (CNreference)  
2.3.3. RNA extraction and reverse transcription 
For RNA extraction 300 µL buffy coat was prepared from the same peripheral blood 
samples which were used for genomic DNA extraction. Total RNA was extracted with High 
Pure RNA isolation kit (Roche) according the manufacturer’s instruction. RNA concentration 
was determined by the A260 value of the sample. Complementary DNA (cDNA) was 
generated from 1 µg total RNA using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) in a final volume of 20 µL. 
2.3.4. DEFA1/DEFA3 mRNA expression measurement using quantitative RT PCR 
Using the reverse transcription polymerase chain reaction (RT PCR), we examined 
the relative expression levels of DEFA1/DEFA3 mRNA in 20 patients with diabetes (10 cases 
of type 1, and 10 cases of type 2 diabetes). RNA samples were prepared from buffy coat and 
quantification were performed according to our previously used method [110]. After reverse 
transcription, quantitative PCR amplification was carried out using Light Cycler Fast Start 
DNA MasterPLUS SYBR Green I mix (Roche). Samples were loaded into capillary tubes and 
placed in the fluorescence thermocycler (LightCycler). Initial denaturation at 95 °C for 10 
min was followed by 45 cycles of 95 °C for 10 s, annealing at 58 °C for 8 s, and elongation at 
72 °C for 12 s. To amplify specific products from cDNA of DEFA1/DEFA3, the following 
primers were used: sense 5’-TCC CAG AAG TGG TTG TTT CC-3’; and antisense, 5’-GCA 
GAA TGC CCA GAG TCT TC-3’. To measure expression of GAPDH, the housekeeping 
gene, sense primer 5′-AAG GTC GGA GTC AAC GGA TTT-3′; and antisense primer 5′-
TGG AAG ATG GTG ATG GGA TTT-3′ were used. At the end of each run, melting-curve 
profiles were achieved by cooling the sample to 40 °C for 15 s and then heating the sample 
slowly at 0.20 °C/s up to 95 °C with continuous measurement of the fluorescence to confirm 
the amplification of specific transcripts. Cycle-to-cycle fluorescence emission readings were 
monitored and analyzed by the LightCycler software (Roche Diagnostics GmbH). Expression 
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data were normalized to the housekeeping GAPDH gene. Relative gene expression was 
determined using the ∆∆Ct method. 
2.3.5. Genotyping of SNPs of human β1-defensin (DEFB1) 
Genotyping was performed using Custom TaqMan® SNP Genotyping Assays 
(Applied Biosystems, CA). Fluorogenic minor groove binder probes with the dyes 6-
carboxyfluorescein FAMTM (excitation, 494 nm) and VIC® (excitation, 538 nm) were used in 
each cases in order to determine the genotypes of different SNPs: β1-defensin (DEFB1) 
polymorphisms c.-20G>A (rs11362, Applied Biosystems code c_11636793_20), c.-44C>G 
(rs1800972, c_11636794_10) and c.-52G>A (rs1799946, c_11636795_20). Thermal cycling 
was performed on ABI Prism 7000 sequence-detection PCR systems. The amplification mix 
contained the following ingredients: 7.5 µL of TaqMan® universal PCR master mix (Applied 
Biosystems, CA), 0.375 µL of primer-probe mix, 6.375 µL of RNase- and DNase-free water 
(Sigma), and 0.8 µL of sample DNA, in a total volume of 15 µL per single tube reaction. 
Assay conditions were 2 min at 50 °C, 10 min at 95 °C, and 40 cycles of 95 °C for 15 s and 
60 °C for 1 min. Each 96-well plate contained 90 samples of an unknown genotype and six 
reactions with reagents but no DNA. DNase-free water used as nontemplate control. Initial 
and post-assay analysis was performed using the Sequence Detection System version 2.1 
software (Applied Biosystems, CA) as outlined in the TaqMan Allelic Discrimination Guide. 
Genotypes were determined visually based on the dye-component fluorescent emission data 
depicted in the X-Y scatter plot of the Sequence Detection System software. Genotypes were 
also determined automatically by the signal processing algorithms in the software. Results of 
each scoring method were saved in two separate output files for later comparison.  
2.3.6. Assay of HNP 1-3 concentration 
The same peripheral blood samples we used for genomic DNA and RNA extraction 
from patients and controls were also used for isolation of plasma, which was stored at -80oC 
until further analysis. Plasma HNP1-3 concentrations were determined by ELISA (Hycult-
Biotech HK324, Uden, The Netherlands) according to the instructions of the manufacturer. 
2.3.7. Statistical analysis 
Comparisons of plasma concentrations were carried out by Mann-Whitney test and 
with two-tailed paired Student’s test. The level of significance of the genotype frequency of 
different DEFB1 SNPs was analysed by using the χ2 test and Fischer test. Levels p<0.05 
indicated statistical significance. All statistical calculations were performed with the Graph 
Pad Prism 5.0 statistical program (GraphPad Software,San Diego, CA USA). The genotype 
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frequencies for each polymorphism of DEFB1 were tested for deviation from the Hardy-
Weinberg equilibrium by the χ2 test, with 1 degree of freedom. 
2.4. EXPERIMENTAL PROCEDURES USED IN MOUSE TRYPSINOGEN 
EXPERIMENTS 
2.4.1. Plasmid construction and mutagenesis 
Construction of the pTrapT7-intein-Hu1 and pcDNA3.1(-)-CTRB2 expression 
plasmids harboring the coding sequence for human cationic trypsinogen (Hu1) and human 
chymotrypsinogen B2 (CTRB2) was reported previously [54, 107]. Mutation p.S150F was 
introduced into human cationic trypsinogen using overlap-extension PCR mutagenesis. 
Expression plasmids for mouse trypsinogens were created in the pTrapT7 plasmid previously 
designed for bacterial expression of human trypsinogens [93, 94]. The coding DNA was PCR 
amplified from commercial I.M.A.G.E. clones and cloned into pTrapT7 using NcoI and SalI 
restriction sites. In all constructs the N-terminal secretory signal peptide was replaced with a 
Met-Ala sequence. In T20, the stop codon was changed from amber (TAG) to ochre (TAA). 
T7 was amplified from I.M.A.G.E. clone #30306963 (GenBank accession BC061093.1) 
using T7 NcoI sense (5'- AAA TTT CCA TGG CTC TCC CCC TGG ATG ATG ATG ATG 
-3', where the NcoI site is underlined) and T7 SalI antisense (5'- AAA TTT GTC GAC TTA 
GTT GGC AGC GAT GGT CTG CTG -3', where the SalI site is underlined) primers. T8 was 
amplified from I.M.A.G.E. clone #30306436 (GenBank accession BC061135.1) using T8 
NcoI sense (5'- AAA TTT CCA TGG CTT TCC CTG TGG ATG ATG ATG ACA -3', where 
the NcoI site is underlined) and T8 SalI antisense (5'- AAA TTT GTC GAC TTA GTT TGC 
AGC AAT GGT GTT TTG -3,' where the SalI site is underlined) primers. T9 was amplified 
from I.M.A.G.E. clone #6433372 (GenBank accession CF581321.1) using T8 NcoI sense and 
T9 SalI antisense (5'- AAA TTT GTC GAC TTA GTT TGC GGC AAT GGT GTC CTG -3', 
where the SalI site is underlined) primers. T20 was amplified from I.M.A.G.E. clone 
#6433384 (GenBank accession CF581305.1) using T20 NcoI sense (5'- AAA TTT CCA 
TGG CTT TCC CTG TGG ATG ATG ATG ACA -3', where the NcoI site is underlined) and 
T20 SalI antisense (5'- AAA TTT GTC GAC TTA GTT GTC AGC AAT TGT GTT CTG -3', 
where the SalI site is underlined) primers. Mutations p.L82A, p.R123H, and p.L149A in T7 
and p.R122H and p.F150S in T8 were created by overlap extension PCR and cloned into the 
pTrapT7 plasmid. 
Expression plasmids for mouse chymotrypsinogens carrying a 10His affinity tag were 
created in the pcDNA3.1(-) plasmid. The coding DNA for mouse chymotrypsinogen C (Ctrc) 
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Figure 2. Identification of major trypsinogen isoforms expressed by the mouse pancreas. 
Chromatographic separation of trypsinogen isoforms. Trypsinogens were purified from pancreas tissue 
extracts of CD-1 mice using ecotin affinity chromatography and the ecotin eluate was loaded onto a MonoS 
column equilibrated with 20 mM Na-acetate (pH 5.0). The column was developed with a linear gradient of 
0-0.5 M NaCl. Peaks were analyzed by SDS-PAGE, N-terminal sequencing and mass spectrometry. 
was PCR amplified from a cDNA preparation from CD-1 mouse pancreas, using mCTRC 
XhoI sense (5'-AAA TTT CTC GAG ACC TGA ACC ATG TTG GGA ATT ACA GTC-3', 
where the XhoI site is underlined) and mCTRC EcoRI antisense (5'-AAA TTT GAA TTC 
GGC GTC GAG ACT TCT GGA ACC GTC TCT-3', where the EcoRI site is underlined) 
primers and cloned into pcDNA3.1(-) using XhoI and EcoRI. A 10His affinity tag was added 
to the C terminus using gene synthesis (GenScript, Piscataway, NJ) and the XcmI and EcoRI 
sites. In this synthetic construct Leu268 was deleted to prevent autolytic cleavage of the His-
tag. The coding DNA for mouse chymotrypsinogen B (Ctrb, GenBank accession 
NM_025583.2) with a C-terminal 10His tag was custom synthesized (GenScript) and cloned 
into pcDNA3.1(-) using XhoI and BamHI. 
2.4.2. Purification and identification of trypsinogens from CD-1 mouse pancreas  
Pancreata (2-3) were homogenized in 10 mL of 20 mM Na-HEPES (pH 7.4) buffer, 
briefly sonicated, centrifuged at 13,500 rpm for 10 min and ~4 mL supernatant was loaded 
onto a 2 mL ecotin column. Ecotin is a pan-serine protease inhibitor from E. coli which can 
bind the inactive zymogen forms of pancreatic serine proteases [58, 79]. 
The ecotin column was washed with 20 mM Tris-HCl (pH 8.0), 0.2 M NaCl and 
trypsinogens were eluted with 50 mM HCl. The flow-through contained no trypsinogen, as 
judged by the lack of trypsin activity after incubation with enteropeptidase. The ecotin-eluate 
contained all trypsinogen isoforms and low levels of chymotrypsinogen and proelastase. Four 
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mL eluate was loaded onto a 2 mL MonoS column equilibrated with 20 mM Na-acetate (pH 
5.0) and trypsinogens were eluted with a 0-0.5 M NaCl gradient at 1 mL/min flow rate 
(Figure 2). The eluted proteins were separated by SDS-PAGE, transferred to PVDF 
membrane and individual bands were subjected to N-terminal protein sequencing by Edman 
degradation (Midwest Analytical, St. Louis, MO). Peaks corresponding to T8, T9 and T20 
were also subjected to in-gel digestion followed by LC-MS/MS mass spectrometry 
(ProtTech, Phoenixville, PA). Relative abundance of trypsinogen isoforms were calculated 
from the peak areas corrected for the ultraviolet extinction coefficient differences. The T9-T8 
peaks were also corrected for Ctrb contamination, which was determined from the relative 
trypsin and chymotrypsin activities after activation with enteropeptidase. Because of the poor 
separation of T8 and T9, these two isoforms were calculated as one. 
2.4.3. Expression and purification of trypsinogens 
Human cationic trypsinogen was expressed in the aminopeptidase P deficient LG-3 E. 
coli strain as fusions with a self-splicing mini-intein, as decribed in [53, 54]. Mouse 
trypsinogens were expressed in E. coli BL21(DE3), as described for human trypsinogens 
previously [93, 94]. Isolation of cytoplasmic inclusion bodies, in vitro refolding and 
purification with ecotin affinity chromatography were performed according to published 
protocols [53, 54, 58, 93, 94]. The preparations were more than 90% pure, as judged by SDS-
PAGE and Coomassie Blue staining. Concentrations of trypsinogen solutions were calculated 
from their UV absorbance at 280 nm using the following extinction coefficients: 37,525      
M-1cm-1 (human cationic trypsinogen), 39,140 M-1cm-1 (mouse T7), 34,670 M-1cm-1 (mouse 
T8 and T9) and 43,150 M-1cm-1 (mouse T20). 
2.4.4. Expression and purification of chymotrypsinogens 
Human CTRB2, mouse Ctrb and Ctrc carrying 10His affinity tags were expressed in 
transiently transfected HEK 293T cells using Lipofectamine® 2000 (Life Technologies) and 
purified from 450 mL conditioned medium using nickel-affinity chromatography as reported 
previously [105, 106]. Aliquots (75 µL) of the eluted 5 mL fractions were analyzed by 15% 
SDS-PAGE and Coomassie Blue staining and peak fractions with >90% purity were pooled 
and dialyzed for 72 hours against three changes of 1 liter of 0.1 M Tris-HCl (pH 8.0) buffer 
containing 150 mM NaCl. The dialyzed chymotrypsinogen solutions were concentrated using 
a Vivaspin 20 concentrator (10 kDa MWCO). Chymotrypsinogens were activated with 
trypsin and active chymotrypsin concentrations were determined by active site titration with 
ecotin, as described [104]. 
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2.4.5. Trypsinogen autoactivation 
Trypsinogen at 2 µM concentration was incubated in the absence or presence of 25 
nM chymotrypsin, as indicated. Autoactivation was induced by 10 nM trypsin in 0.1 M Tris-
HCl (pH 8.0), 1 or 10 mM CaCl2 and 0.05% Tween 20 (final concentrations) at 37 ºC. At 
given times, 1.5 µL aliquots were withdrawn and mixed with 48.5 µL assay buffer containing 
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20. Trypsin activity was measured 
by adding 150 µL 200 µM N-CBZ-Gly-Pro-Arg-p-nitroanilide substrate dissolved in assay 
buffer and following the release of the yellow p-nitroaniline at 405 nm in a SpectraMax 
plus384 microplate reader (Molecular Devices, Sunnyvale, CA) for 1 min. Reaction rates 
were calculated from fits to the initial linear portions of the curves. 
2.4.6. Trypsinogen activation with enteropeptidase 
Complete activation of 2 µM trypsinogen (100 mM Tris-HCl (pH 8.0), 10 mM CaCl2 
and 0.05% Tween 20 as final concentrations) was carried out using 140 ng/mL final 
concentration of human enteropeptidase (R&D Systems, Minneapolis MN) on 37 ºC for 1 
hour. Maximal trypsin activity was measured as described above. This activity was 
designated as 100% and trypsin activity measured in autoactivation experiments was 
expressed relative to this value. The 100% values corresponded to 500 (T7), 400 (T8), 400 
(T9) and 300 (T20) mOD / min readings. 
2.4.7. SDS polyacrylamide gel electrophoresis 
Seventy-five µL of 2 µM trypsinogen samples were precipitated with 10 % 
trichloroacetic acid (final concentration). After centrifugation at 13.000 rpm for 10 minutes, 
the supernatant was discarded and the precipitate was dissolved in 15 µL Laemmli sample 
buffer (20% glycerol, 120 mM Tris, pH=6.8, 2% SDS, 0.003% bromphenol blue) containing 
100 mM DTT (final concentration). The precipitate was heat-denatured at 95 °C for 5 min. 
15% SDS-PAGE mini gels (running gel: 15% acrilamide, 375 mM Tris, 0.1% SDS, pH=8.8 
and stacking gel: 5% acrilamide, 125 mM Tris, 0.1% SDS, pH=6.8) were used for 
electrophoretic separation in standard Tris-glycine buffer (24.76 mM Tris, 19.18 mM glycine 
and 0.1 % SDS). Gels were stained with Coomassie blue (containing 3 grams of Brilliant 
Blue R-250 dissolved in 50% methanol and 10% acetic acid). The Coomassie stained gels 
were destained in a solution containing 60% methanol and 10% acetic acid as described 
earlier [56]. Quantitation of bands was carried out with the GelDoc XR+ gel documentation 
system and Image Lab 3.0 software (Bio-Rad, Hercules, CA). 
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3. RESULTS 
3.1. α-DEFENSINS IN DIABETES 
3.1.1. Plasma levels of HNP1-3 in patients with type 1 and type 2 diabetes 
Plasma levels of α-defensin -human 
neutrophil peptide- (HNP1-3) in 50 
patients with type 1 and in 60 patients 
with type 2 diabetes were determined and 
compared to 50 healthy blood donors. 
There was high individual variation in 
plasma levels of α-defensin, but a 
significant difference between healthy 
subjects and both groups of diabetic 
patients was observed. The mean value ± 
S.E.M. was 28.78 ± 4.2 ng/mL in type 1 
diabetes, and 29.82 ± 5.36 ng/mL in type 
2 diabetes, versus 11.94 ± 2.96 ng/mL in 
controls; p<0.01 respectively. No 
significant difference was found 
concerning the high plasma 
concentrations of HNP 1-3 between the 
patients with type 1 and type 2 diabetes 
(Figure 3). 
3.1.2. Plasma levels of HNP1-3 in 
diabetic patients with complications 
Subsequent investigations were 
focused on the generally high levels of 
HNP1-3 found in the peripheral blood of 
both group (type 1 and type 2) of diabetic 
patients, which were further divided in subgroups with different diabetes-related 
complications. Nephropathy was diagnosed in 71 patients (32 with type 1 and 39 with type 2 
diabetes), and neuropathy in 95 cases (35 with type 1 and 60 with type 2 diabetes). 115 
 
Figure 3. Plasma levels of human neutrophil 
peptides (HNP1-3) in patients with type 1 and type 
2 diabetes (DM1 and DM2) and healthy controls. 
The lines represent the mean plasma levels of HNP1-3. 
Significant differences determined by Mann-Whitney 
test are indicated. 
 
 
Figure 4. Plasma levels of human neutrophil 
peptides (HNP1-3) in diabetic patients with 
different complications relative to those without 
complications, and to healthy controls. Mean and 
S.E.M. are indicated; significant differences between 
groups were determined by unpaired t test. 
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patients suffered from retinopathy (47 with type 1, and 68 with type 2 diabetes), 54 patients 
(14 with type 1 diabetes, 40 with type 2 diabetes) had cardiovascular diseases and 182 (50 
with type 1 and 132 with type 2 diabetes) had hypertension. Data of these subgroups 
concerning HNP1-3 levels were compared with 67 patients who did not suffer from these 
complications, and with the data of 100 healthy subjects (Figure 4). The highest 
concentrations of α-defensin levels were found in diabetic patients with nephropathy (49.4 ± 
4.8 ng/mL), and with neuropathy (38.7 ± 4.8 ng/mL) or with cardiovascular complications 
(45.6.± 1.45 ng/mL) which were significantly higher in comparison with HNP1-3 plasma 
levels of diabetic patients without complications (25.4 ± 3.5 ng/mL). These data are in 
accordance with previous observations [50, 95] reporting high level of HNP 1-3 in type 1 
diabetic patients with cardiovascular mortality, or in type 1 diabetic patients with 
nephropathy. These results suggest that in diabetic complications, such as nephropathy, 
neuropathy and cardiovascular diseases, HNP 1-3 is elevated in the circulation independently 
of the type of diabetes. In summary, all of the diabetic patients, with or without complications 
exerted significantly higher levels of HNP1-3 in their plasma, than controls.(Figure 4) 
3.1.3. Copy number poly-
morphism of DEFA1/DEFA3 
The cumulative copy 
numbers of DEFA1/DEFA3 were 
detected using quantitative PCR 
analysis. From the control 
population 133 DNA samples were 
used for copy number 
determination, and 100-100 DNA 
samples of diabetic patients with 
type 1 or type 2 diabetes were 
investigated. There was no 
significant difference in 
DEFA1/DEFA3 copy number between controls and patients or between patients in the two 
types of diabetes groups (Figure 5). In the control group DEFA1/DEFA3 copy numbers 
ranged from 4 to 15 per genome, with a median number of 10 copies. The median copy 
number of DEFA1/DEFA3 in the patients with type 1 diabetes was 10 copies per genome 
(from 5 to 16 copies) and the median copy number of DEFA1/DEFA3 in patients with type 2 
 
Figure 5. Genomic copy number of DEFA1/DEFA3 in 
patients with diabetes and in healthy blood donors. 
Quantitative box-plot analysis (median, minimum, maximum 
value, 25% and 75% percentiles) of DEFA1/A3 copy numbers 
determined in  DNA samples from 133 controls, 100 patients 
with type 1 diabetes (DM1) and 100 patients with type 2 
diabetes (DM2). 
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diabetes was also 10 (ranging from 5 to 15). No significant correlation was observed between 
α-defensin plasma levels and genomic DEFA1/DEFA3 copy numbers (r2 = 0.01; Figure 6). 
3.1.4. DEFA1/DEFA3 gene expression 
Furthermore, determination of relative mRNA expression levels of DEFA1/DEFA3 in 
peripheral leukocytes from diabetic patients was carried out. DEFA1/DEFA3 mRNA were 
obtained from blood samples of patients (10 with type 1 and another 10 with type 2 diabetes). 
Relative expression levels of 
DEFA1/DEFA3 were compared 
to the DEFA1/DEFA3 copy 
number of the same patients. Our 
data support that peripheral 
leukocytes have the ability to 
transcribe DEFA1/DEFA3 genes 
and to produce HNP1-3 peptides. 
However, no positive correlation 
was observed between the copy 
numbers and the expression 
levels of the human neutrophil 














Figure 7. Relative mRNA expression levels of DEFA1/DEFA3 
in diabetic patients versus copy numbers of DEFA1/DEFA3. 
The DEFA1/A3 copy numbers were determined by quantitative 
PCR analysis and compared to the DEFA1/DEFA3 mRNA 
measured by RT-PCR of the same patient (10 with type 1 and 10 
with type 2 diabetes). 
 
Figure 6. Plasma levels of human neutrophil peptides (HNP1-
3) in diabetic patients versus copy number of 
DEFA1/DEFA3. The DEFA1/A3 copy number were determined 
by quantitative PCR analysis and compared to the HNP1-3 
plasma level of the same patient (50 with type 1 and 50 with type 
2 diabetes). 
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3.2. DEFB1 C.-20G>A, C.-52G>A AND C.-44C>G POLYMORPHISMS IN 
DIABETES 
The distribution of the DEFB1 c.-20G>A genotypes (Table 1) was in accordance with 
the Hardy-Weinberg equilibrium both in the control population and in the patients.(p = 0.449 
and p = 0.989, respectively). There was no significant difference in genotype distribution 
between the patients overall and the healthy controls. Similarly, no significant differences in 
genotypes were observed when the patients were grouped as type 1 and type 2 diabetes 
mellitus.  
As to the DEFB1 c.-52G>A SNP (Table 2), distribution of the genotypes was in 
accordance with the Hardy-Weinberg equilibrium both in the control population and in the 
patients (p=0.610 and p=0.065 respectively). We did not detect significant differences in 
genotypes between the patients and the controls, neither in type 1 diabetes, nor in type 2 
diabetes. 
Table 1. DEFB1 c.-20G>A genotypes in patients with diabetes 
 GG GA AA χ2 test* 
Patients with diabetes  
n = 257 82 (32 %) 131 (51 %) 44 (17 %) 0.568 
Type 1 diabetes 
n = 117 36 (31 %) 60 (51 %) 21 (18 %)
 0.775 
Type 2 diabetes 
n = 140 46 (33 %) 71 (51 %) 23 (16 %) 0.573 
Controls 
n = 200 62 (31 %) 96 (48 %) 42 (21 %)  
 
* chi square test versus control 
Table 2. DEFB1 c.-52G>A genotypes in patients with diabetes 
 GG GA AA χ2 test* 
Patients with diabetes 
n = 257 114 (44 %) 104 (40 %) 39 (15 %) 0.572 
Type 1 diabetes 
n = 117 52 (44 %) 47 (40 %) 18 (17 %) 0.702 
Type 2 diabetes 
n = 140 62 (44 %) 57 (41 %) 21 (15 %) 0.658 
Controls 
n = 200 80 (40 %) 84 (42 %) 36 (18 %)  
 
* chi square test versus control 
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Table 3. DEFB1 c.-44G>C genotypes in patients with diabetes 
 CC CG GG χ2 test* 
Patients with diabetes 
n = 257 156 (61 %)+ 95 (37 %) 6 (2 %) ** 0.002 
Type 1 diabetes 
n = 117 70 (60 %) 44 (37 %) 3 (2.5 %) 0.01 
Type 2 diabetes 
n = 140 86 (61 %) 51 (36 %) 3 (2 %) 0.003 
Controls 
n = 200 90 (45 %) 92 (46 %) 18 (9 %)  
 
* chi square test versus control 
** Fisher test versus control p = 0.001, OR = 9.136, 95 % CI: 3.512 – 23.82 
+ Fisher test versus control p = 0.0009, OR = 2.005, 95 % CI: 1.218- 2.746 
 
The genotypic distribution of DEFB1 c.-44C>G polymorphism is shown in Table 3, 
where the distribution of genotypes was also in accordance with the Hardy-Weinberg 
equilibrium among the patients with diabetes (p =0.610, χ2 = 0.260) and also in the control 
population (p=0.597, χ2=0.279). There was a significant difference in genotype distribution 
between patients and healthy controls (χ2 test, p = 0.002). The frequency of GG genotype was 
significantly lower in both types of diabetes (2.5% and 2%, respectively) than in healthy 
controls (9%), (Fisher test versus control p=0.002, OR=4.121, 95% CI: 1.604 – 10.59). 
Conversely, the prevalence of the CC genotype was 61% in the group of diabetic patients vs. 
45 % of controls (Fisher test: p = 0.02, OR = 2.055, 95% CI: 1.27 – 3.745). When the patients 
were sorted according to their diabetic complications, lower frequency of GG genotype 
among the patients with nephropathy and among the patients with neuropathy was found 
(1.4% and 1% respectively). 
3.3. RESULTS OF MOUSE TRYPSINOGEN EXPERIMENTS 
3.3.1. Identification of major trypsinogen isoforms in the mouse pancreas 
Ecotin affinity chromatography was used to purify trypsinogen isoforms from the 
mouse pancreas. Outbred CD-1 mice expressed 4 trypsinogen isofroms to high levels (T7, 
T8, T9 and T20), which were identified from homogenized whole mouse pancreata using N-
terminal sequenceing and mass spectrometry. Trypsinogens were eluted under acidic 
conditions from the ecotin column and immediately loaded onto a MonoS cation exchange 
column equilibrated with 20 mM Na-acetate (pH 5.0). The MonoS column was developed 
with a NaCl gradient, resulting in five peaks (Figure 2). 
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Figure 8. Strategy for the the identification of mouse trypsinogen isoforms by N-terminal sequencing. 
T4, T5, T7 and T12 trypsinogens have unique N-termini which allowed us to distinguish them from other 
isoforms, which were identical in their N-terminal sequences. Therefore, these isoforms were activated to 
trypsin, which allowed us to distinguish them from each other by N-terminal sequencing. Unique amino acid 
residues in the N-terminal sequence of given isoforms are in red letters. 
Edman-degradation identified the small fourth peak as elastase 3 (N terminus is 
CGQPS) and the large fifth peak as the cationic T7 trypsinogen isoform, which has a unique 
N-terminal sequence, LPLDD (Suppl. Figure 1 and Suppl. Figure 2A). The same N-termini 
(FPVDD) was observed in case of the other three peaks, which proved to be trypsinogens. 
These were subjected to in-gel tryptic digestion followed by mass spectrometric 
nanosequencing, which revealed the identity of the first peak as isoform T20. The second and 
third peaks were indistinguishable from each other, however it was proven that they are T9 
and T8 isoforms (Figure 2), which are almost identical in their amino-acid sequence (99% 
identity, Suppl. Figure 1 and Suppl. Figure 2B). They had a slight difference in their ionic 
character, which helped to assign T9 as the second peak and T8 as the third peak. 
Identification strategy of trypsinogen isoforms based on N-terminal sequenceing is 
shown in Figure 8. N-terminal sequencing of the combined second/third peaks after 
activation of trypsinogen to trypsin indicated a mixture of Val/Ile amino-acids at position 35 
(IVGGYTCRENS(V/I)P), with a preponderance of Val, confirming that the smaller second 
peak is T9 (containing Ile35) and the larger third peak is T8 (containing Val35) (Figure 2). 
Both N-terminal sequencing (CGVPA) and mass spectrometry indicated that the T9/T8 peaks 
were contaminated with some Ctrb. Quantitative evaluation of trypsinogen peaks were 
performed as described under Patients and Methods and the following relative expression 
levels were obtained (mean±SD, n=4): 41 ± 1 % for T7; 47 ± 3 % for T8 and T9 combined 
and 12 ± 2 % for T20. 
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Figure 9. Autoactivation of mouse trypsinogens. Trypsinogens 
were incubated at 2 µM concentration with 10 nM initial trypsin 
in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, (A) or 10 mM CaCl2 
(B) and 0.05% Tween 20, at 37 °C. Aliquots (1.5 µL) were 
withdrawn at the indicated times and trypsin activity was 
determined as described in Patients and Methods. Trypsin 
activity was expressed as percentage of the maximal activity 
determined by full activation with enteropeptidase. 
Representative experiments from four replicates are shown. 
3.3.2. Autoactivation of mouse trypsinogens. 
Large-scale purification of different trypsinogen isoforms from the mouse pancreas is 
impractical and preparations may be contaminated with low levels of other pancreatic 
proteases. In contrast, recombinant expression should provide highly purified, homogeneous 
enzyme preparations. Reliable methodology for the expression and purification of human 
trypsinogens [93, 94] is well known and the same approach has been used to obtain 
functionally competent mouse trypsinogen preparations. Trypsinogens were expressed in E. 
coli as inclusion bodies, renatured 
in vitro and purified by ecotin-
affinity chromatography. When 
mouse trypsinogens were 
incubated in 1 mM CaCl2 at pH 
8.0, isoforms T7, T8 and T9 
autoactivated and reached about 
40-60% of potentially attainable 
trypsin levels, indicating that 
some autocatalytic (trypsin-
mediated) degradation occurred 
(Figure 9A) during 
autoactivation. In contrast, T20 
did not autoactivate under these 
conditions. As expected, high 
concentrations of calcium (10 
mM) increased the rate of 
autoactivation and stabilized 
trypsinogens against degradation, 
yielding 80-100% of attainable 
trypsin levels. The stimulatory 
effect of calcium on the 
autoactivation of T20 was 
particularly striking (Figure 9B). 
- 34 - 
 
 
Figure 10. Effect of mouse chymotrypsin C (Ctrc) on mouse trypsinogen T7. (A) Autoactivation was 
measured in 1 mM and 10 mM CaCl2, in the absence (solid symbols) or presence (open symbols) of 25 nM 
mouse Ctrc, as described in Patients and Methods. (B) SDS-PAGE analysis of autoactivation in 1 mM CaCl2. 
Samples were withdrawn at the indicated time points, precipitated with trichloroacetic acid, electrophoresed and 
stained as described in Patients and Methods. (C) Cleavage of T7 trypsinogen by 25 nM mouse Ctrc. 
Incubations were performed with 2 µM trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence or presence of 10 
mM CaCl2. Samples were precipitated with trichloroacetic acid and analyzed by SDS-PAGE and Coomassie 
blue staining. Representative experiments from three replicates are shown. (D) Cleavage of the activation 
peptide of trypsinogen T7 by mouse Ctrc. Primary structure of the native T7 activation peptide with 
proteolytic cleavage sites for Ctrc and trypsin are also indicated. Note that the N-terminal amino acid of mature 
trypsinogen is Leu16, as the 15 amino-acid long secretory signal peptide is removed in the endoplasmic 
reticulum. Trypsinogen was incubated at 2 µM concentration with 25 nM Ctrc in 0.1 M Tris-HCl (pH 8.0) and 0 
or 10 mM CaCl2 (final concentrations), at 37 °C. To prevent autoactivation, 25 nM human SPINK1 trypsin 
inhibitor was included. At the indicated times reactions were terminated by precipitation with 10% 
trichloroacetic acid (final concentration) and samples were analyzed by 15% non-reducing SDS-PAGE and 
Coomassie Blue staining. Relevant segments of representative gels (from two replicates) demonstrate the small 
mobility shift of the trypsinogen band caused by Ctrc-mediated cleavage of the Leu18-Asp19 peptide bond. 
Note that the rapid rate of cleavage is partly due to the added Met-Ala sequence at the N terminus of 
recombinant T7. 
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3.3.3. Effect of mouse Ctrc on T7 trypsinogen 
Mouse chymotrypsin C (Ctrc) in 25 nM final concentration reduced the final mouse 
T7 trypsin levels by ~35% during autoactivation in 1 mM CaCl2, while in 10 mM CaCl2 it 
slightly stimulated the rate of autoactivation (Figure 10A). 
In the absence of Ctrc, SDS-PAGE analysis of the autoactivation reaction in 1 mM 
calcium confirmed conversion of the T7 trypsinogen band to trypsin and also indicated 
degradation fragments generated by cleavages of trypsin-sensitive peptide bonds Arg123-
Val124 and Lys194-Asp195 (Figure 10B, left panel, see also Suppl. Figure 1 and Suppl. 
Figure 2A). These were identified by N-terminal sequencing, similarity to the published 
degradation fragments of rat anionic trypsinogen-2 [92] and comparison of the banding 
pattern with that of the T7 p.R123H mutant (Figure 12). Note that because of an extra amino 
acid in the activation peptide of T7, amino-acid numbering is shifted by one relative to 
human and other mouse trypsinogens (Suppelementary Figure 1). Cleavage after Arg123 
should result in a fully active, two-chain trypsin [55, 67], whereas cleavage after Lys194 
causes inactivation [92, 101]. Ctrc caused a small shift of the T7 trypsinogen band, 
suggesting cleavage of the activation peptide (Figure 10B, right panel). In addition, the 
banding pattern of degradation fragments became more complex, which is consistent with the 
lower trypsin activity attained during autoactivation in 1 mM calcium in the presence of Ctrc. 
To identify Ctrc-mediated cleavages of trypsinogen, digestion experiments with short 
incubation times was performed; when no trypsinogen activation took place yet and no 
trypsin activity was present. Under these conditions, slow cleavage of the Leu149-Ser150 
peptide bond in the autolysis loop was observed in the absence of calcium (Figure 10C, left 
panel) and this was completely inhibited by 10 mM calcium (Figure 10C, right panel, see also 
Suppl. Figure 2A). The Leu82-Glu83 peptide bond (corresponding to Leu81-Glu82 in human 
trypsinogens and other studied mouse isoforms) in the calcium binding loop was not cleaved 
to a detectable extent. This finding suggested that in T7 the moderate degradation observed 
during autoactivation in 1 mM calcium in the presence of Ctrc is mediated by cleavage of the 
Leu149-Ser150 peptide bond. To confirm this assumption, we compared autoactivation of the 
T7 p.L82A and p.L149A mutants in 1 mM calcium and found that only mutation p.L149A 
protected against degradation in the presence of Ctrc (Figure 11). Interestingly, mutant 
p.L82A suffered Ctrc-dependent degradation during autoactivation to an even larger extent 
than wild type T7. 
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Figure 11. Effect of mutations p.L82A and p.L149A on mouse trypsinogen T7. (A) Autoactivation was 
measured in 1 mM CaCl2 as described in Patients and methods. Trypsin activity was expressed as 
percentage of the maximal activity determined by full activation with enteropeptidase. (B) Cleavage of wild 
type and p.L82A T7 trypsinogen by 25 nM mouse Ctrc. (C) Cleavage of wild type and p.L149A T7 
trypsinogen by 25 nM mouse Ctrc. Incubations were performed with 2 µM trypsinogen in 0.1 M Tris-HCl 
(pH 8.0) in the absence of calcium. Trypsinogen samples were precipitated with 10% trichloroacetic acid 
(final concentration) and analyzed by SDS-PAGE and Coomassie blue staining. Representative experiments 
from two replicates are shown. 
3.3.4. N-terminal processing of T7 trypsinogen by mouse Ctrc 
Among the activation peptide sequences of mouse trypsinogens only T7 contains a 
potentially Ctrc-sensitive peptide bond, Leu18-Asp19 (Suppl. Figure 1 and Suppl. Figure 
2A). Inspection of Figure 10B revealed that the T7 trypsinogen band became slightly shifted 
as a result of treatment with Ctrc, suggesting that the activation peptide might be cleaved at 
Leu18-Asp19. When the samples were run under non-reducing conditions, the mobility shift 
caused by N-terminal processing of the T7 activation peptide became more apparent (Figure 
10D) and N-terminal sequencing confirmed the predicted cleavage site. However, in contrast 
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Figure 12. Effect of mutation p.R123H on mouse trypsinogen T7. (A) Autoactivation was measured in 1 
mM CaCl2 as described in Pateints and methods. Trypsin activity was expressed as percentage of the 
maximal activity determined by full activation with enteropeptidase. (B) SDS-PAGE analysis of the 
autoactivation reaction. Samples were withdrawn at indicated times, precipitated with trichloroacetic acid, 
electrophoresed and stained as described in Pateints and methods. (C) Cleavage of wild-type and p.R123H 
T7 trypsinogen by 25 nM mouse Ctrc. Incubations were performed with 2 µM trypsinogen in 0.1 M Tris-
HCl (pH 8.0) in the absence of calcium. Samples were precipitated with trichloroacetic acid and analyzed by 
SDS-PAGE and Coomassie blue staining. Cleavage products were identified with N-terminal sequencing. 
Representative experiments from two replicates are shown. 
to human cationic trypsinogen, the rate of autoactivation of N-terminally processed T7 was 
only negligibly stimulated (see Figure 10A, 10 mM calcium panel), indicating that Ctrc does 
not regulate activation of mouse trypsinogens through cleavage of the activation peptide. 
3.3.5. Effect of the p.R123H mutation on T7 trypsinogen.  
Mutation p.R123H protected T7 trypsinogen against degradation during 
autoactivation in 1 mM calcium in the presence of Ctrc (Figure 12); however, it had no effect 
on the cleavage of the Leu149-Ser150 peptide bond per se. This observation indicates that 
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Figure 13. Effect of mouse chymotrypsin C (Ctrc) on mouse trypsinogen T8. (A) Autoactivation was 
measured in 1 mM and 10 mM CaCl2, in the absence (solid symbols) or presence (open symbols) of 25 nM 
mouse Ctrc, as described in Patients and Methods. Where indicated, 2 µL of 1.4 µg/mL human 
enteropeptidase (EP) was added. (B) SDS-PAGE analysis of the autoactivation reaction in 1 mM CaCl2. 
Samples were withdrawn at indicated times, precipitated with trichloroacetic acid, electrophoresed and 
stained as described in Patients and Methods. (C) Cleavage of trypsinogen by 25 nM mouse Ctrc. 
Incubations were performed with 2 µM trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence or presence 
of 10 mM CaCl2. Samples were precipitated with trichloroacetic acid and analyzed by SDS-PAGE and 
Coomassie blue staining. Cleavage products were identified with N-terminal sequencing. In the absence of 
calcium (left panel), the faint bands above and below the major cleavage products correspond to fragments 
of trypsinogen cleaved at the Leu81-Glu82 peptide bond. The faint band visible in the presence of 10 mM 
calcium (right panel) could not be identified. Representative experiments from three replicates are shown. 
moderate degradation of T7 during autoactivation is due to the combined effects of Ctrc-
mediated and tryptic cleavages after Leu149 and Arg123, respectively (Suppl. Figure 2A). 
3.3.6. Effect of mouse Ctrc on T8 and T9 trypsinogen 
Mouse Ctrc almost completely inhibited autoactivation of T8 and T9 trypsinogen in 1 
mM calcium and markedly reduced it in 10 mM calcium (Figures 13, 14). This inhibitory 
effect was not due to degradation, as addition of enteropeptidase to the Ctrc-treated samples 
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Figure 14. Effect of mouse chymotrypsin C (Ctrc) on mouse trypsinogen T9. See Figure 13 for 
experimental details. 
resulted in the appearance of highly significant trypsin activity. SDS-PAGE analysis of 
autoactivation in 1 mM calcium, in the absence of Ctrc, demonstrated conversion of 
trypsinogen to trypsin with the characteristic degradation fragments generated by tryptic 
cleavage of the Arg122-Val123 and Lys193-Asp194 peptide bonds (Figures 13B, 14B, left 
panel, see also Suppl. Figure 2B). In dramatic contrast, when autoactivation was followed in 
the presence of Ctrc, no trypsin band or any of the tryptic degradation bands were observed. 
Instead, Ctrc rapidly and completely cleaved T8 and T9 trypsinogen at a single site, which N-
terminal sequencing revealed as the Phe150-Gly151 peptide bond (Figures 13B, 14B, right 
panel, see also Suppl. Figure 2B). This peptide bond lies within the so-called autolysis loop, a 
flexible segment between residues 146 and 154 (Suppl. Figure 1). When cleavage of T8 and 
T9 trypsinogen by Ctrc was studied with short incubation times (i.e. before autoactivation 
occurred), both isoforms were primarily cleaved at the Phe150-Gly151 peptide bond, with 
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Figure 15. Effect of mouse chymotrypsin B (Ctrb) on mouse trypsinogen T8. (A) Autoactivation was 
measured in 1 mM CaCl2 as described in Patients and Methods, in the absence or presence of 25 nM mouse 
Ctrb or Ctrc, as indicated. (B) Cleavage of trypsinogen by 25 nM Ctrb and Ctrc was compared in the 
absence of calcium, as described in Figure 13C. Representative experiments from two replicates are shown. 
(C) The disappearance of the intact trypsinogen band was quantitated by densitometry and data from two 
experiments were plotted. For clarity, error bars were omitted, the error was within 10% of the mean.  
minimal cleavage observed at the Leu81-Glu82 peptide bond in the absence of calcium 
(Figures 13C, 14C). Cleavage of the Phe150-Gly151 peptide bond was slower but still readily 
detectable in 10 mM calcium. 
 
3.3.7. Cleavage of the Phe150-Gly151 peptide bond by mouse chymotrypsin B (Ctrb) 
Regulation of autoactivation of human cationic trypsinogen by human CTRC is 
highly specific and other chymotrypsins and elastases do not cleave the CTRC cleavage sites. 
To test whether the same Ctrc specificity exists in the mouse, we compared the effect of 
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Figure 16. Effect of mutation p.R122H on mouse trypsinogen T8. (A) Autoactivation of wild-type and 
p.R122H mutant T8 trypsinogen was measured in 1 mM CaCl2 as described in Patients and Methods. (B) 
The effect of 25 nM mouse Ctrc on the autoactivation of the p.R122H mutant T8. Conditions were the same 
as in panel A. (C) Cleavage of wild-type and p.R122H mutant T8 trypsinogen by 25 nM mouse Ctrc in the 
absence of calcium. Samples were incubated and analyzed as described in Figure 13C. Representative 
experiments from two replicates are shown. 
mouse Ctrb and Ctrc on T8 trypsinogen. As shown in Figure 15A, autoactivation of T8 was 
much less effectively inhibited by 25 nM Ctrb than by an equimolar concentration of Ctrc. In 
degradation experiments, Ctrb cleaved the Phe150-Gly151 peptide bond at a more than 7-fold 
slower rate than Ctrc (Figures 15B and 15C). 
3.3.8. Effect of the p.R122H mutation on T8 trypsinogen 
Mutation p.R122H slightly stimulated autoactivation of T8 trypsinogen in 1 mM 
calcium, in the absence of Ctrc (Figure 16A). In the presence of Ctrc, however, autoactivation 
was strongly inhibited by Ctrc, approximately to the same extent as seen with wild type T8 
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(Figure 16B, cf. Figure 13A). Consistent with the robust inhibitory effect, the Phe150-Gly151 
peptide bond was cleaved by Ctrc almost as well in T8 p.R122H trypsinogen as in wild type 
T8 (Figure 16C), indicating that mutation p.R122H does not influence this regulatory 
mechanism. 
3.3.9. Cleavage of the autolysis loop in the p.S150F human cationic trypsinogen 
mutant inhibits autoactivation 
The majority of mammalian trypsinogens do not contain Phe150 in their autolysis 
loop. To test whether introduction of Phe150 would reconstitute the chymotrypsin-dependent 
 
 
Figure 17. Effect of human chymotrypsin B2 (CTRB2) on the autoactivation of wild-type and p.S150F 
mutant human cationic trypsinogen (Hu1). (A, B) Autoactivation was measured in 1 mM CaCl2, in the 
absence or presence of 25 nM CTRB2, as described in Patients and Methods. (C) Cleavage of wild-type and 
p.S150F mutant human cationic trypsinogen by 25 nM CTRB2 in the absence of calcium. Incubations were 
performed and samples were analyzed as given in Figure 13C. To prevent autoactivation, 25 nM human 
SPINK1 trypsin inhibitor was included. Representative experiments from two replicates are shown. 
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autoactivation inhibition in another mammalian trypsinogen, we mutated Ser150 in human 
cationic trypsinogen to Phe. Because human CTRC cleaves the Leu81-Glu82 peptide bond 
and causes trypsinogen degradation, we used human CTRB2 to selectively cleave the newly 
created Phe150-Gly151 peptide bond. CTRB2 at 25 nM concentration had no effect on the 
autoactivation of wild type cationic trypsinogen (Figure 17A), whereas it inhibited activation 
of the p.S150F mutant (Figure 17B), via cleavage at the Phe150-Gly151 peptide bond (Figure 
17C). 
3.3.10. Effect of mouse Ctrc on T20 trypsinogen 
Mouse Ctrc had essentially no effect on trypsinogen T20, except for a slight 
stimulation of the activation rate in 10 mM calcium (Suppl. Figure 3A). On SDS-PAGE, no 
trypsinogen to trypsin conversion was evident in 1 mM calcium, in the absence or presence of 
Ctrc (Suppl. Figure 3B). Note that T20 trypsinogen ran as a doublet on gels, which seem to 
represent differently denatured conformers, as N-terminal sequencing and mass spectrometry 
indicated molecular homogeneity (not shown). Finally, cleavage of T20 with Ctrc resulted in 
very faint degradation bands even in the absence of calcium, indicating that this isoform is 
resistant to Ctrc (Suppl. Figure 3C). 
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4. DISCUSSION 
4.1. RELEVANCE OF α-AND β-DEFENSINS IN DIABETES MELLITUS 
4.1.1. The role of α-defensins 
In this work, HNP1-3 levels from the plasma of venous blood were measured. From 
the buffy coat, copy number variation and mRNA expression levels of DEFA1/DEFA3 genes 
of the same individual were investigated. Intriguingly, our results showed significantly higher 
HNP 1-3 plasma levels in patients with both type 1 and type 2 diabetes mellitus compared to 
healthy controls. Moreover, the plasma of diabetic patients with nephropathic and 
neuropathic complications showed the highest concentrations of HNPs. It seems possible that 
the elevation of HNP1-3 in the plasma of patients with nephropathy is the consequence of the 
decreased renal degradation of the peptides together with advanced nephropathy [95]. The 
cause of high levels of HNP1-3 in patients with neuropathy in type 1 and type 2 diabetes 
remains unknown.  
Further investigations were performed in order to clarify whether increased gene 
expression was responsible for the elevated plasma levels of α-defensins. In our study no 
correlation was observed between HNP1-3 plasma levels and copy numbers of 
DEFA1/DEFA3 genes. The effect of copy number variations in DEFA1/DEFA3 on the 
disease or even on the plasma concentrations of the peptides remain unclear. 
There are contradictory data about the correlation between DEFA1/DEFA3 copy 
numbers and α-defensin peptide concentrations. Linzmeier and Ganz [61] showed that the 
HNP1-3 peptide levels in human neutrophils were proportional to the copy number of the 
DEFA1 and DEFA3 genes. Copy numbers of DEFA1/DEFA3 may be proportional to the 
intracellular levels of HNP1-3 in neutrophil granulocytes, but possibly not to the circulating 
HNP1-3 levels. Additionally, a recent study in septic patients [21] showed the discrepancy 
between gene copy number and protein levels. There are several possibilities to explain why 
DEFA1/DEFA3 copy numbers and HNP 1-3 plasma levels are not correlated. The human     
α-defensins are stored primarily in the granules of neutrophils and released into the 
circulation during the activation of neutrophils. Also, yet unrevealed transcriptional 
mechanisms or an increased distance between the regulators of the genes might modulate the 
expression of these genes [21, 45]. 
In our study no significant correlation was observed between the genomic copy 
number variation of DEFA1/DEFA3 and the mRNA expression levels (Figure 7), suggesting 
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that degranulation rather than increased gene expression may be responsible for increased 
HNP plasma levels in diabetes. In a study by Aldred et al. [1] the combined expression levels 
of DEFA1/DEFA3 and the genomic copy number were also not correlated, suggesting the 
superimposed influence of trans-acting factors. It is noteworthy that there are several 
examples for the abscence of correlation between copy number polymorphisms and relative 
transcription levels [45]. 
These results are in a good correlation with our recent observations, suggesting that 
modulation of the HNP1-3 secretion by neutrophils following kynurenic acid treatment might 
be independent from the mRNA expression levels of DEFA1 / DEFA3 [110]. 
In a recent study, eosinophils with active α-defensin production have been detected in 
capillary blood of diabetic patients [73]. In this investigation eosinophils but not neutrophils 
displayed augmentation of transcriptional activation of α-defensin expression. In our study 
the majority of the cells in peripheral venous blood were neutrophils, therefore our purified 
DNA and RNA samples were derived also mostly from neutrophils. 
4.1.2. Polymorphisms of β1-defensin gene 
The present study has demonstrated that the distribution of DEFB1 c.-44C>G 
genotypes were different between patients with diabetes and healthy controls. Our results 
showed that the frequency of the GG genotype was significantly higher in the control 
population. The presence of G allele might lead to strengthened HBD1 antimicrobial activity, 
which is less frequent among patients with diabetes. The G allele of the c.-44C>G SNP 
generates a putative binding site for nuclear factor-κB (NF-κB), and induces overexpression 
of HBD1 gene. The proposed effect of this SNP could partially explain why the GG genotype 
was considered to be a protective genotype in atopic dermatitis [84] and also in case of 
Candida colonization in diabetic patients [51]. Conversely, in these studies subjects carrying 
the CC genotype were at a greater risk of aquiring infection. Recently, it has been suggested 
that the C allele of c.-44C>G SNP probably abrogates NF-κB-dependent DEFB1 
upregulation [85]. 
These earlier observations are consistent with our present finding that the GG 
genotype could also be protective in diabetes, and the presence of CC genotype might be 
connected with lower expression of human β1-defensin. Among 257 patients with diabetes, 
only 6 (2%) were GG homozygotes, and 61% of the patients were CC homozygotes, 
comparing with 45% of CC homozygotes in control group. Furthermore, the number of GG 
homozygotes was even less (1%) in nephropathy and neuropathy. These observations draw 
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attention to the importance of DEFB1 polymorphisms in diabetes, especially in case of 
nephropathy and neuropathy. High blood glucose itself can result in low levels of β-defensin 
[35] and as it was earlier mentioned, its expression might be downregulated in humans 
carrying the C allele of c.-44C>G polymorphism. It is noteworthy that insulin is also an 
important factor mediating HBD-1 expression [12]. 
Taken together, in our study elevated levels of α-defensin (HNP1-3) was observed in 
type 1 and type 2 diabetes, and this increase was more pronounced in diabetic complications. 
However, correlation of circulating HNP1-3 levels with DEFA1/DEFA3 copy number was 
absent. Similarly, no correlation between mRNA expression and copy number variations was 
found. Further studies are needed to explore whether the elevated α-defensin levels of the 
plasma in diabetes are causally linked to this disease and its complications, or are simply the 
consequences of the degranulation of neutrophils in pathologic conditions. According to our 
results, elevated HNP1-3 levels might not be genetically determined, or at least they are 
independent from the copy number variation of the DEFA1/DEFA3 genes. In contrast, the 
CC genotype, and the C allele of c.-44C>G SNP in the promoter region of DEFB1 gene was 
more frequent among diabetic patients than in healthy controls, which drew attention to the 
genetic background of a potentially impaired function of hBD1 in diabetes. These data 
support the hypothesis that both α- and β-defensins might have important roles in the 
pathogenesis of diabetes and diabetic complications. 
4.2. CTRC REGULATES AUTOACTIVATION OF MOUSE TRYPSINOGENS 
VIA CLEAVAGE OF THE AUTOLYSIS LOOP 
4.2.1. Genetic mouse models of chronic pancreatitis 
Available mouse models of acute and chonic pancreatitis has been reviewed in a 
recent publication by Lerch and Gorelick [59]. In the past decade there were several attempts 
to create mouse models, which develop chronic pancreatitis due to different genetic 
manipulations. Dimagno et al. described a CFTR knock out mouse model in the C57BL/6 
background, which had mild pancreatic insufficiency, and developed more severe pancreatitis 
in response to cerulein injenction compared to wild type mice [27]. 
Rat elastase promoter controlled human interleukin-1β (IL-1β) expression in mice 
resulted in chronic pancreatitis with early onset and severe fibrosis. In this model T-cell 
dominated inflammatory response was seen together with increased expression of other 
cytokines (TNF-α), chemokines (CXCL1, SDF1), growth factors (TGF-β1), metalloproteases 
(MMP2, 7, 9, and TIMP1) and cyclooxigenase 2. These observations generally suggest that 
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IL-1β might have a major role in the persistent activation of the immune system leading to 
chronic pancreatitis. It is important to mention that there was no evidence whether these mice 
developed diabetes. Interlukin-1β is a well-described activator of pancreatic stellate cells, and 
also an inflammatory cytokine of the innate immune system. Cytokine polymorphisms can 
affect the immune response, and were shown to play an important role in the pathogenesis of 
pancreatitis [68]. 
Liver X receptors (LXRs) α and β are nuclear oxysterol receptors with a key role in 
cholesterol, triglyceride, and glucose metabolism and also control the expression of water 
transporter aquaporin-1. LXRβ−/− male and female mice developed pancreatic exocrine 
insufficiency at 11 month of age [36]. 
None of the models above tried to make an attempt to manipulate genes of digestive 
enzymes. Human cationic trypsinogen (PRSS1), chymotrypsinogen C (CTRC) and 
carboxypeptidase A1 (CPA1) are known to have a role in the development of pancreatitis 
according to described plethora of biochemical and clinical studies [72, 89, 107, 116, 117]. 
Transgenic mice carrying the coding DNA for human cationic trypsinogen with the p.R122H 
mutation (see Figure 1B and Suppl. Figure 1) did not develop spontaneous pancreatitis, 
although small differences in the pathological responses were noted when pancreatitis was 
artificially induced [99]. In contrast, when mice were made transgenic with the p.R122H 
mutation introduced into mouse trypsinogen isoform T8 (Suppl. Figure 2B), the resulting 
animals developed acute and eventually chronic pancreatitis [7], however any replication 
study with this last model has not been published since 2006. It is unclear whether the 
observed phenotype was related to the expression of the mutant trypsinogen. Nonetheless, 
this thesis raises the question whether the biochemical effects of the p.R122H mutation are 
similar in the context of mouse and human trypsinogens and whether we can utilize mouse 
trypsinogens to model the human condition. Although considerable progress has been made 
in clarifying the mechanism of PRSS1 mutations at the biochemical level, until this time, only 
the two publications above [7, 99] documented attempts to generate such models. Animal 
models that recapitulate the characteristics of human hereditary pancreatitis are still lacking. 
Genetic deletion of mouse T7 was recently shown to abolish intra-acinar trypsinogen 
activation in response to hyperstimulation with cerulein; while severity of acute pancreatitis 
was somewhat decreased but not diminished [25]. Furthermore, development of cerulein-
induced chronic pancreatitis was unaffected by the absence of T7 [91]. These observations 
seem to call into question the direct role of trypsinogen in the development of pancreatitis. 
However, a more likely explanation for the apparent contradiction is that the 
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hyperstimulation model employed in these studies does not mimic the pathological pathway 
associated with human hereditary pancreatitis. 
We wanted to clarify whether introduction of trypsinogen mutations associated with 
human hereditary pancreatitis into mouse trypsinogens would offer a viable approach to 
model hereditary pancreatitis in mice. Therefore, identification of the major trypsinogen 
isoforms expressed by the mouse pancreas and characterization of their regulation of 
autoactivation by mouse Ctrc was necessary. 
4.2.2. Trypsinogens expressed by the mouse pancreas 
Investigating the commonly used outbred mouse strain CD-1, we found that only four 
trypsinogen isoforms, T7, T8, T9 and T20, are expressed to high levels (Figure 2) in the 
mouse pancreas, even though the mouse genome contains 20 trypsinogen genes, of which 11 
are potentially functional (Suppl. Figure 1). The cationic isoform T7 was deleted in the 
C57BL/6 strain and judging from the residual trypsinogen content the authors suggested that 
T7 contributes 60% of total mouse trypsinogens [25, 91]. In our investigations we found 
smaller values (41%), however, these difference seem to fall within experimental error and 
may represent strain-specificity. In our experiments we used unstimulated mouse pancreas 
and it is possible, even likely, that upon hormonal stimulation, the trypsinogen expression 
pattern may change, as shown previously for rat p23, the ortholog of mouse T4 and T5, 
which becomes drastically upregulated upon cerulein stimulation [64]. Marked upregulation 
of T5 was observed in a knock-out mouse strain deficient in interferon regulatory factor 2 
[44]. 
4.2.3. Biochemical characteristics of mouse trypsinogens 
Autoactivation of mouse trypsinogens T7, T8 and T9 was comparable, whereas T20 
autoactivated more slowly, particularly in 1 mM calcium (Figure 9). Surprisingly, regulation 
of autoactivation by mouse Ctrc was isoform specific and mechanistically different from the 
actions of human CTRC on human cationic trypsinogen. Thus, Ctrc-mediated cleavage of the 
activation peptide was observed only with the T7 isoform, however, this N-terminal 
processing had no effect on autoactivation. Cleavage of the Leu81-Glu82 peptide bond in the 
calcium binding loop was detectable in T7 but was inefficient and resulted in minimal 
degradation, when compared to the effect of human CTRC on human cationic trypsinogen. 
Slow cleavage of the Leu81-Glu82 peptide bond was also seen in T8 and T9, whereas 
isoform T20 was not cleaved by Ctrc. 
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In contrast, isoforms T8 and T9 were rapidly cleaved at the Phe150-Gly151 peptide 
bond in the autolysis loop and this cleavage resulted in marked inhibition of autoactivation 
without degradation. The Phe150-Gly151 peptide bond was also cleaved by Ctrb at a 7-fold 
slower rate. However, considering that Ctrb is the most abundant chymotrypsin in the mouse 
pancreas, physiological regulation of activation of T8 and T9 may be also dependent on Ctrb. 
The vast majority of mammalian trypsinogens do not contain Phe in position 150 in 
their primary amino acid sequence. Trypsinogens of some rodents has been investigated 
either in a functional study (guinea pig -Cavia porcellus- [78]), or only at the genomic level 
(rabbit -Oryctolagus cuniculus- [6]), but the Phe150 residue has not been found in the 
investigated rodent trypsinogen isoforms. According to the online genomic database of NCBI 
(http://www.pubmed.org) some rodent species (rat -Rattus norvegicus-, chinese hamster -
Cricetulus griseus- and naked mole rat -Heterocephalus glaber-) have at least one possible 
trypsinogen isoform which carries a Phe residue at the 150th amino acid position. 
Surprisingly, in one marsupial, the tasmanian devil -Sarcophilus harrisii- and also, in some 
primates (Rhesus macaque -Macaca mulatta- , gorilla -Gorilla gorilla gorilla- and the olive 
baboon -Papio anubis-) Phe150 can be found in the primary structure of one of their 
potentially functional trypsinogen isoforms. More interestingly, human mesotrypsinogen also 
contains Phe150 (Suppl. Figure 1) and cleavage at this site by human CTRC was 
demonstrated previously [107], suggesting that activation of mesotrypsinogen may be under a 
similar regulation. Human anionic and cationic trypsinogens contain Ser at position 150, but 
mutation S150F of human cationic trypsinogen confers sensitivity to CTRB2-mediated 
cleavage of the autolysis loop, which inhibits autoactivation in a manner that is similar to the 
Ctrc-dependent inhibition of T8 and T9 in the mouse. 
The Ctrc-dependent inhibition of autoactivation of T8 and T9 trypsinogens may have 
evolved as a protective mechanism to curtail unwanted trypsinogen activation in the 
pancreas. In this regard, this is highly analogous to the regulation of human trypsinogens by 
human CTRC even though mechanistic details are dissimilar. Interestingly, we found that 
cleavage of the Phe150-Gly151 peptide bond in T8 and T9 trypsinogens also inhibits 
activation by enteropeptidase, the physiological trypsinogen activator in the duodenum. 
Although inhibition of digestive enzyme activation in the gut may seem counterintuitive, this 
chymotrypsin-dependent feed-back mechanism likely ensures that intestinal trypsinogen 
activation proceeds with a slower, more prolonged kinetics which may be more favorable for 
food digestion. 
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Intra-acinar cell activation of trypsinogen in cytoplasmic vesicles of autophagic origin 
is an early event in experimental models of acute pancreatitis. Genetic deletion of T7 was 
recently shown to abolish intra-acinar trypsinogen activation in response to hyperstimulation 
with cerulein; a somewhat perplexing observation as other trypsinogen isoforms could have 
potentially be activated [25, 91]. The results presented in this thesis offer a plausible 
explanation for this puzzle. When trypsinogen activation occurs, isoforms T8 and T9 may be 
inhibited in a Ctrc- or Ctrb-dependent manner, whereas T7 is relatively insensitive to 
chymotryptic regulation. Due to its lower concentration and poor activation, isoform T20 is 
unlikely to contribute to intra-acinar trypsinogen activation to a detectable extent. Taken 
together, the biochemical properties of mouse trypsinogens suggest that T7 is the isoform 
responsible for intra-acinar trypsinogen activation, which is the exact conclusion that Dawra 
et al offered in their study [25]. 
Finally, our data argue that the previously published mouse model in which a T8 
transgene carrying the p.R122H mutation was introduced could not have developed the 
described phenotypic changes as a result of a mutation-dependent increase in trypsinogen 
activation [7]. We found that mutation p.R122H did not affect inhibition of autoactivation by 
Ctrc in T8 trypsinogen, which stands in contrast to the robust negative effect of this mutation 
on CTRC-dependent degradation of human cationic trypsinogen [106]. Thus, it seems more 
likely that in the published mouse model increased gene dosage or nonspecific effects of the 
transgene may have been the cause of the described pancreas pathology. 
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5. SUMMARY AND NEW RESULTS 
I.  
1. We confirmed earlier findings of elevated HNP 1-3 plasma levels in patients with 
diabetes mellitus compared to healthy controls. Furthermore, we found that diabetic 
patients with nephropathy, neuropathy, or cardiovascular complications all had 
significantly higher HNP1-3 levels compared to diabetic patients without 
complications and also to healthy controls. 
2. Our results demonstrated that the median gene copy number of human 
DEFA1/DEFA3 gene is 10 per diploid genome in the Hungarian population; not only 
among controls but also in diabetic patients. DEFA1/DEFA3 gene copy numbers did 
not correlate with mRNA expression levels in peripheral leukocytes, nor with the     
α-defensin (HNP 1-3) levels measured in the plasma of peripheral blood. Therefore 
the elevated HNP 1-3 levels might not be genetically determined, or at least  
independent of the copy number variation of the DEFA1/DEFA3 genes. 
3. The C allele of the c.-44C>G SNP located in the promoter region of the DEFB1 gene 
was found to be more frequent among diabetic patients than in healthy controls, 
indicating that impaired human β-defensin function might have a role in the 
development of diabetes mellitus. 
II. 
1. There are 4 trypsinogen isoforms (T7, T8, T9 and T20) expressed at high levels in the 
mouse pancreas under physiological conditions. In 1 mM CaCl2, at pH=8.0, only T7, 
T8 and T9 autoactivated, while T20 did not autoactivate. 
2. Ctrc and Ctrb almost completely inhibited autoactivation of T8 and T9 isoforms by 
enzymatic cleavage of their autolysis loop, but had no significant effect on the 
autoactivation of T7 isoform. 
3. Introduction of the p.R123H mutation in T7, or the analogous p.R122H mutation in 
T8, did not significantly change the autoactivation characteristics of mouse 
trypsinogens. Therefore, the biochemical characteristics of these mutants did not 
mimic the pathogenic phenotype of the p.R122H mutation in human cationic 
trypsinogen. 
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Supplementary Figure 1. Amino acid sequence alignment of human cationic (Hu1), anionic (Hu2), 
mesotrypsinogen (Hu3) and 11 potentially expressed mouse trypsinogen isoforms (T4, T5, T7, T8, T9, T10, T11, 
T12, T15, T16 and T20). Numbering starts with the initiator methionine. Note that due to insertions in T4, T5 and 
T7, the numbering is shifted by one after the insertion sites, relative to the indicated numbers. Similarly, a deletion in 
T12 shifts numbering. Trypsin cleavage sites are highlighted in blue and chymotrypsin C (Ctrc) cleavage sites in red. 
Cys residues are indicated in green and the catalytic triad in orange. The original annotation predicted deletion of 
Arg69 (in red letter) in T4 and T5 but more recent annotations include this residue. 
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Supplementary Figure 2A. Primary structure of T7 moue trypsinogen. The activation peptide 
containing Lys24 is designated by yellow circles. Red circles indicate cleavage sites of chymotrypsin C 
(L18, L82 and L149), while blue background shows tryptic cleavage sites (K24, R123 and K194). Cys 
residues which form disulfide bonds are designated by green circles (C31-C161, C49-C65, C133-C234, 
C140-C207, C172-C186 and C197-C221). Members of the catalytic triad are shown by orange circles 




Supplementary Figure 2B. Primary structure of T8 and T9 mouse trypsinogens. The activation 
peptide containing Lys23 is designated by yellow circles. Solid red circles indicate cleavage sites of 
chymotrypsin C (L81 and F150), while blue background shows tryptic cleavage sites (K23, R122 and 
K193). Cys residues which form disulfide bonds are designated by green circles (C30-C160, C48-C64, 
C132-C233, C139-C206, C171-C185 and C196-C220). Members of the catalytic triad are shown by orange 
circles (H46, D107 and S200). Amino acid differences in T9 trypsinogen are indicated in empty red circles. 
"Ca" indicates a calcium ion (Ca2+). 
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Supplementary Figure 3. Effect of mouse chymotrypsin C (Ctrc) on mouse trypsinogen T20. (A) 
Autoactivation was measured in 1 mM and 10 mM CaCl2, in the absence (solid symbols) or presence (open 
symbols) of 25 nM mouse Ctrc, as described in Patients and Methods. Where indicated, 2 µL of 1.4 µg/mL 
human enteropeptidase (EP) was added. (B) SDS-PAGE analysis of the autoactivation reaction in 1 mM 
CaCl2. Samples were withdrawn at the indicated time points, precipitated with trichloroacetic acid, 
electrophoresed and stained as described in Patients and Methods. (C) Cleavage of T20 trypsinogen by 25 
nM mouse Ctrc. Incubations were performed and samples were analyzed as in Figure 13C. The faint Ctrc 
cleavage products seen in the absence of calcium were not identified. Representative experiments from 
three replicates are shown. 
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AIM: To investigate the genetic background of human defensin expression in type 1 and 2 
diabetes.  
METHODS: Associations between DEFA1/DEFA3 gene copy number polymorphism and 
diabetes as well as between the promoter polymorphisms of DEFB1 and diabetes were 
studied. The copy number variation of the DEFA1/DEFA3 genes was determined in 257 
diabetic patients (117 patients with type 1 and 140 with type 2 diabetes). The control group 
consisted of 221 age- and gender-matched healthy blood donors. The cumulative copy 
numbers of the DEFA1/DEFA3 genes were detected by using quantitative PCR analysis. To 
evaluate the HNP 1-3 (human neutrophil peptide 1-3 or α-defensin) levels in the circulation, 
plasma HNP 1-3 concentrations were measured by ELISA. The expression of DEFA1/A3 in 
peripheral leukocytes ofthe diabetic patients was measured by quantitative RT PCR analysis. 
Three SNPs of the human DEFB1 (human defensin β-1) gene: DEFB1 G-20A (rs11362), 
DEFB1 C-44G (rs1800972) and DEFB1 G-52A (rs1799946) were genotyped by Custom 
TaqMan® Real Time PCR assay.  
RESULTS: Significant differences were observed in HNP1-3 levels between the healthy 
subjects and both groups of diabetic patients. The mean ±SE was 28.78 ± 4.2 ng/ml in type 1 
diabetes, and 29.82  ± 5.36 ng/ml in type 2 diabetes, vs. 11.94 ± 2.96 ng/mL in controls; 
p<0.01 respectively. There was no significant difference between patients with type 1 and 
type 2 diabetes in the high plasma concentrations of HNP1-3. The highest concentrations of 
α-defensin were found in diabetic patients with nephropathy (49.4  ± 4.8 ng/mL), neuropathy 
(38.7 ± 4.8 ng/mL) or cardiovascular complications (45.6 ± 1.45 ng/L). 
There was no significant difference in the cumulative copy numbers of DEFA1/DEFA3 genes 
between controls and patients, or between patients with the two types of diabetes. 
Comparisons of HNP 1-3 plasma level and DEFA1/A3 copy number of the same patient did 
not reveal significant relationship between defensin-α levels and the gene copy numbers (r2 = 
0.01). Similarly, no positive correlation was observed between the copy numbers and the 
mRNA expression levels of DEFA1/A3. Regarding the C-44G polymorphism of DEFB1, the 
GG “protective” genotype was much less frequent (1–2%) among both groups of patients than 
among controls (9%). 
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CONCLUSION: Elevated HNP1-3 levels in diabetes are independent of DEFA1/DEFA3 copy 
numbers, but GG genotype of C-44G SNP in DEFB1 gene may result in decreased defensin  
β-1 production. 
 
Key words: α-defensins, HNP1-3, β-defensin 1, diabetes, copy number polymorphism, single 
nucleotide polymorphism 
 
CORE  TIP: 
There is  growing evidence of the role of innate immunity in diabetes To our knowledge our 
data provide the first report on a complex investigation of defensin-α and defensin β-1 in type 
1 and type 2 diabetes. The main conclusion of our manuscript is, that the elevated HNP1-3 
levels in diabetes are independent of  the DEFA1/DEFA3 copy numbers, but the GG 
genotype of C-44G SNP in the DEFB1 gene may result in a decreased level of  defensin β-1 
production. Our data support the view that both alpha and beta-defensins may have an 





Defensins are members of small antimicrobial peptides of the innate immune system[1,2]. 
However, today these peptides are also known as danger signals or ”alarmins” playing 
important roles in inflammation and immunity[3]. Mammalian defensins are divided into two 
major families, the α- and β-defensins.  Human α-defensins include human neutrophil peptide 
1-4 (HNP1-4) and intestinal human defensins (HD-5 and HD-6) produced by Paneth cells. 
Besides the antimicrobial effects, alpha defensins display chemotactic activity and induce 
proinflammatory cytokines[4,5,6]. HNPs increase the binding of LDL (low density lipoprotein 
cholesterol) to the endothelial surface suggesting that alpha defensins may modulate the 
development of atherosclerosis [7]. Neutrophil granulocytes are considered to be the primary 
cellular origin of α-defensins; HNP 1-3 comprise 30–50% of the granule proteins. HNPs can 
be released into the extracellular milieu following granulocyte activation as a consequence of 
degranulation, leakage, cell death, and lysis during inflammation[8]. α-defensins are also 
involved in the formation of neutrophil extracellular traps[9]. 
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Human β-defensins make up another family of antimicrobial peptides[1, 10]. In addition to their 
antibacterial and antiviral effects, the chemoattractive function of these defensins has been 
shown to play a role in immunological reactions that protect the host from various 
pathogens[11]. While the expression of human defensin beta-1 (HBD1) is generally 
constitutive, the levels of human defensin beta-2 (HBD2) are inducible by proinflammatory 
cytokines and bacteria[10, 12, 13 ]. Human beta defensins are expressed by epithelial cells of the 
skin, gut, respiratory and urogenital tissues, the pancreas and the kidneys. HBD1 is also 
constitutively expressed by leukocytes[14, 15, 16]. 
The level of defensin expression varies among individuals, and it has been suggested that this 
variation is due to genetic differences in the genes encoding defensins. Defensin genes have 
been mapped to 8p22-p23[17]. Two types of genetic polymorphisms have been identified in 
genes encoding defensins: copy number polymorphisms and single nucleotide poymorphisms 
(SNPs). Human defensin beta-1 (HBD-1) is encoded by the gene DEFB1 (OMIM: 602056), 
in which several SNPs (single nucleotide polymorphisms) have been characterized. Three 
frequent SNPs at positions G-20A (rs11362), C-44G (rs 1800972) and G-52A (rs1799946) in 
the 5’-untranslated region (UTR) of DEFB1 were described[18]. The untranslated variants 
influence HBD-1 expression or function[19]. 
The cluster of human alpha-defensin genes on chromosome 8 includes the genes DEFA1 
(OMIM: 125220) and DEFA3 (OMIM: 604522), which are copy-variables. The genes DEFA1 
and DEFA3 differ only in a single base substitution in the coding sequence, corresponding to 
a single amino acid difference between the peptides encoded[20]. HNP 1-3 differs only in a 
single N-terminal acid, and the HNP-2 peptide lacks this residue and might be a proteolytic 
product of the other two peptides because no separate gene has been identified to encode 
HNP-2[21]. Several copy number polymorphisms form the major source of genetic 
polymorphism of α-defensin genes DEFA1 and DEFA3, encoding human neutrophil peptides 
HNP-1, -2 and 3[20, 22].These genes are present in a cluster that is close to but independent 
from the β-defensin cluster on 8p23. The total DEFA1/DEFA3 copy number has been found 
to range between 4 and 11 copies per diploid genome with 5 to 9 copies being the most 
common[22]. 
To date, little is known about the genetic basis and the functions of α- and β-defensins in 
diabetes. Infections are frequent in diabetic patients because the antimicrobial function of 
their immune response is impaired. It has been reported that mRNA levels of rat β-defensin-1 
are significantly low in the kidneys, which may explain the high incidence of urinary tract 
infections in diabetes mellitus[23]. The effects of glucose and insulin on the β-defensin 
 6 
expression have recently been demonstrated[24], but no connection has been found between 
genetic polymorphisms of the HBD1 gene and diabetes in a Brazilian study on diabetic 
children[25]. 
Increased levels of alpha-defensin -1, -2 and -3 have recently been reported in patients with 
type 1 diabetes with nephropathy and in cardiovascular complications[26, 27]. It is tempting to 
speculate whether copy number polymorphisms and the DEFA1/DEFA3 mRNA in the 
granulocytes may influence the levels of HNP1-3 in patients with types 1 and 2 diabetes. 
The aim of our study was to investigate the genetic background of human defensin-α and 
human defensin β-1 production in adult patients with type 1 and type 2 diabetes, especially 
with complications. Therefore, we carried out an association study between DEFA1/DEFA3 
copy number polymorphism and diabetes, and between the promoter polymorphisms of 
DEFB1 and diabetes. We also measured the plasma levels of HNP 1-3 in both types of 
diabetes, and the mRNA expression of DEFA1/DEFA3 in leukocytes.  
 




257 diabetic patients (122 men and 135 women) were enrolled in our study, which included 
117 patients with type 1 and 140 patients with type 2 diabetes. All patients participating in the 
study were diagnosed according to the ADA criteria: Diagnosis and classification of diabetes 
mellitus. Diabetes Care 36 (Suppl.1.) 2013. S64-S74. 
The mean age of type 1 diabetic patients was 40.6 years±1.51 years, the mean duration of 
diabetes was 17.7±1.12 years, and their mean HbA1c was 8.86±0.17%. In type 2 diabetic 
subjects, the mean age was 58.4±1.27 years, the mean duration of diabetes was 14.5±0.8 years, 
and the mean HbA1c was 8.03±0.13%.  
71 subjects in the cohort had diabetic nephropathy (32 with type 1 and 39 with type 2 
diabetes) defined as an albumin-to-creatinine ratio in a random spot collection being higher 
than 3.4 mg/mmol, or the protein content being over 300 mg/day in collected urine. Abnormal 
kidney function was described when the glomerular filtration rate (GFR) was lower than 60 
mL/min/1.73 m2. 
115 patients suffered from retinopathy (47 with type 1 and 68 with type 2 diabetes). This 
complication was evidenced as the presence of background or proliferative retinopathy, 
macular edema or diabetes-related blindness, or the administration of retinal photocoagulation 
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therapy. The retinopathy status was checked by color stereo-ophthalmography and 
fluorescence angiography. Neuropathy was diagnosed in 95 patients (35 with type 1 and 60 
with type 2 diabetes). Neuropathy was proven when abnormal peripheral sensory functions or 
altered lower limb tendon reflexes as well as impaired cardiovascular reflex tests were 
detected. 54 diabetic patients (14 with type 1 diabetes and 40 with type 2 diabetes) had 
previously been diagnosed with macrovascular disease including major coronary events, 
stroke or a transient ischemic attack, peripheral artery disease or amputation. A high number 
of the patients (182) had controlled hypertension (50 with type 1 and 132 with type 2 
diabetes).  
The control group consisted of 221 age- and gender-matched healthy blood donors. These 
control subjects were selected from blood donors at the regional Center of Hungarian 
National Blood Transfusion Service, Szeged, Hungary. The exclusion criteria for blood 
donors were diabetes, nephropathy, hypertension, or ischemic heart disease. All cases and 
controls were of Hungarian ethnic origin and resident in Hungary. Informed consent was 
obtained from all patients and controls, and the local Ethics Committee gave prior approval to 
the study. All patients consented to the study and were treated according to the Patient Right 
Protection Act of our institutions and according to international guidelines. 
 
Assay of HNP 1-3 concentration 
Blood samples containing EDTA were obtained from patients and controls. Plasma was 
isolated after the blood was centrifuged at 3,000g for 3 min and stored at -80oC for further 
analysis. The HNP1-3 concentrations in plasma were determined by ELISA (Hycult-Biotech 
HK324, Uden, The Netherlands) according to the instructions of the manufacturer. 
 
DNA isolation 
Genomic DNA purified from peripheral blood was used. Leukocyte DNA was isolated using 
the High Pure PCR Template Preparation Kit according to the instructions of the 
manufacturer (Roche Diagnostic GmbH, Mannheim, Germany). DNA concentrations were 
measured with a Qubit™ fluorometer (Invitrogen, Carlsbad, CA, USA) according to the 
instructions of the manufacturer. Genomic DNA was stored at -20º C until further use.  
Determination of DEFA1/DEFA3 gene copy numbers by quantitative real-time PCR 
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Genomic DNA purified from peripheral blood was used. Gene copy number determination 
was carried out as previously described by Linzmeier [20] with slight modifications. BIO-RAD 
CFX 96 instrument (Bio-Rad, Hercules, CA, USA) was used for quantitation. The reaction 
volume was 15 µL, containing 3 µL of DNA, 1 µmol L-1 each of the primers, 7.5 µL of 
reaction buffer (Fermentas Probe/ROX qPCR MasterMix, Fermentas, Lithuania) and 0.6 µL 
EVAGreen (20x EVAGreen™ Biotium Inc., Hayward, CA, USA). Forward primer: DEFA1 1 
F (5’ TAC CCA CTG CTA ACT CCA TAC 3’), reverse primer: DEFA1 1 R (5’ GAA TGC 
CCA GAG TCT TCC C 3’); MPO (myeloperoxidase) reference gene primer set MPO 1 F (5’ 
CCA GCC CAG AAT ATC CTT GG 3’), MPO 1 R (5’ GGT GAT GCC TGT GTT GTC G 
3’). PCR conditions were as follows: initial denaturation at 95oC for 10 min followed by 40 
cycles of denaturation (95oC for 15 sec) and extension (54oC for 1 min).  
Quantification was performed by monitoring the emitted fluorescence after each cycle of PCR 
reaction of genomic DNA samples in order to identify the exact time point at which the log-
linear phase could be distinguished from the background (crossing point). The precise amount 
of DNA added to each reaction mix was based on optical density. Each DNA sample was 
analyzed in triplicate, in 2 independent experiments. 
 
DEFA1/DEFA3 mRNA quantification by RT PCR 
 
We collected further 2 mL of venous blood in EDTA tubes from patients with diabetes and 
controls. Leukocytes from blood were separated by centrifugation at 1200 rpm/min for 15 min. 
By using the reverse transcription polymerase chain reaction (RT-PCR), we examined the 
expression of DEFA1/DEFA3 mRNA in 24 patients with diabetes (12 cases of type 1 and 12 
cases of type 2 diabetes). Total RNA was extracted with High Pure RNA isolation kit (Roche) 
according the manufacturer’s instruction. RNA concentration was determined by the A260 
value of the sample. Complementary DNA (cDNA) was generated from 1 µg total RNA using 
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in a final volume 
of 20 µL. After reverse transcription, amplification was carried out by using Light Cycler Fast 
Start DNA MasterPLUS SYBR Green I mix (Roche). Samples were loaded into capillary tubes 
and placed in the fluorescence thermocycler (LightCycler). Initial denaturation at 95°C for 10 
min was followed by 45 cycles of 95°C for 10 sec, annealing at 58°C for 8 sec, and elongation 
at 72°C for 12 sec. DEFA1/DEFA3 sense, 5’-TCC CAG AAG TGG TTG TTT CC-3’; and 
antisense, 5’-GCA GAA TGC CCA GAG TCT TC-3’, and for the housekeeping gene 
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GAPDH (glyceraldehyde-3-phosphate dehydrogenase) sense, 5′-AAG GTC GGA GTC AAC 
GGA TTT-3′; antisense, 5′-TGG AAG ATG GTG ATG GGA TTT-3′ primers were used to 
amplify specific products from cDNA samples. At the end of each run, melting-curve profiles 
were achieved by cooling the sample to 40°C for 15 sec, and then heating the sample slowly 
at 0.20°C/sec up to 95°C with continuous measurement of the fluorescence to confirm the 
amplification of specific transcripts. Cycle-to-cycle fluorescence emission readings were 
monitored and analyzed by using LightCycler software (Roche Diagnostics GmbH). All 
quantifications were normalized to the housekeeping GAPDH gene. Relative gene expression 




Genotyping of SNPs of human defensin beta -1 (DEFB1) 
Genotyping was performed by means of Custom TaqMan® SNP Genotyping Assays (Applied 
Biosystems, CA). Fluorogenic minor groove binder probes were used for each case using the 
dyes 6-carboxyfluorescein (FAM; excitation, 494 nm) and VIC (excitation, 538 nm): beta-
defensin-1 polymorphisms DEFB1 G-20A (rs11362) Applied Biosystems code 
c_11636793_20, DEFB1 C-44G (rs1800972) c_11636794_10 and DEFB1 G-52A 
(rs1799946) c_11636795_20. Thermal cycling was performed on ABI Prism 7000 sequence-
detection PCR systems. The amplification mix contained the following ingredients: 7.5 µL of 
TaqMan® universal PCR master mix (Applied Biosystems, CA), 0.375 µL of primer-probe 
mix, 6.375 µL of RNase- and DNase-free water (Sigma), and 0.8 µL of sample DNA, in a 
total volume of 15 µL per single tube reaction. Assay conditions were 2 min at 50°C, 10 min 
at 95°C, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. Each 96-well plate contained 
90 samples of an unknown genotype and six reactions with reagents but no DNA. DNase-free 
water was used as nontemplate control. Initial and postassay analysis was performed by using 
the Sequence Detection System (SDS) version 2.1 software (Applied Biosystems, CA) as 
outlined in the TaqMan Allelic Discrimination Guide. Genotypes were determined visually 
based on the dye-component fluorescent emission data depicted in the X-Y scatter plot of the 
SDS software. Genotypes were also determined automatically by the signal processing 
algorithms in the software. Results of each scoring method were saved in two separate output 
files for later comparison.  
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Statistical analysis 
Comparisons of plasma concentrations were carried out by the Mann–Whitney test and with 
two-tailed paired Student test. The level of significance of the genotype frequency of different 
DEFB1 SNPs was analyzed by using the χ2 test and the Fischer test. Levels p<0.05 indicated 
statistical significance. All statistical calculations were performed with the Graph Pad Prism 
5.0 statistical program (GraphPad Software, San Diego CA. USA). The genotype frequencies 
for each polymorphism of DEFB1 were tested for deviation from the Hardy–Weinberg 




Plasma levels of human neutrophil peptide (HNP1-3) in patients with type 1 and type 2 
diabetes 
In a pilot study, plasma levels of α-defensin, human neutrophil peptide (HNP1-3), in 50 
patients with type 1 diabetes and in 60 patients with type 2 diabetes were determined and 
compared with those of 50 healthy blood donors. There was a high individual variation in the 
plasma levels of α-defensin, but significant differences were observed between the healthy 
subjects and both groups of diabetic patients. The mean value ±SE was 28.78±4.2 ng/mL in 
patients with type 1 diabetes and 29.82±5.36 ng/mL in patients with type 2 diabetes vs. 
11.94±2.96 ng/mL in controls (p<0.01 respectively). The difference between the high plasma 
concentrations of HNP1-3 in patients with type 1 or type 2 diabetes was not significant 
(Fig.1.).  
Plasma levels of human neutrophil peptide (HNP1-3) in diabetic patients with complications 
After that, we checked whether the generally high level of HNP1-3 in the peripheral blood of 
both groups (type 1 and type 2) of diabetic patients was connected to diabetic complications. 
Nephropathy was diagnosed in 71 patients (32 with type 1 and 39 with type 2 diabetes) and 
neuropathy in 95 ones (35 with type 1 and 60 with type 2 diabetes). 115 patients suffered 
from retinopathy (47 with type 1 and 68 with type 2 diabetes), 54 patients had cardiovascular 
diseases (14 with type 1 diabetes and 40 with type 2 diabetes), and 182 had hypertension (50 
with type 1 and 132 with type 2 diabetes). Their data concerning the HNP1-3 levels were 
compared with those of the 67 patients who did not suffer from these complications, and with 
the data of the 100 healthy subjects (Fig.2.). The highest HNP 1-3 concentrations were found 
in the diabetic patients with nephropathy (49.4±4.8 ng/mL) and with neuropathy (38.7±4.8 
ng/mL) or with cardiovascular complications (45.6±1.4 ng/mL). These concentrations were 
significantly higher than those in the diabetic patients without complications (25.4±3.5 
ng/mL). These data are in accordance with previous observations[26, 27] of high levels of HNP 
1-3 in type 1 diabetic patients with cardiovascular diseases. In a relatively smaller group of 
patients (n =28) with diabetic foot ulcer (20 with type 1 diabetes and 8 with type 2 diabetes), 
the HNP1-3 plasma levels were 35.9±1.1 ng/mL. These high HNP1-3 levels might be the 
consequence of the degranulation of recruited neutrophils from the skin frequently following 
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infections. Our results suggest that in diabetic complications such as nephropathy, neuropathy 
and cardiovascular diseases, the HNP1-3 level in the circulation is elevated independently of 
the type of diabetes. All diabetic patients, with or without complications, exhibited 
significantly higher plasma levels of HNP1-3 than the control subjects (Fig.2). 
Copy number polymorphism of DEFA1/DEFA3 
The cumulative copy numbers of DEFA1/DEFA3 were determined by using quantitative PCR 
analysis. In the control group, 133 DNA samples were used for copy number determination 
and 100 DNA samples of diabetic patients with type 1 or type 2 diabetes. There was no 
significant difference in copy number between the controls and the patients or between the 
patients with the two types of diabetes (Fig.3). In the control group, DEFA1/DEFA3 copy 
numbers ranged from 4 to 15 per genome with a median number of 10 copies. The median 
copy number of DEFA1/DEFA3 in the patients with type 1 diabetes was 10 copies per 
genome (range 5 to16 copies), and that in the patients with type 2 diabetes was also 10 (range 
5 to 15). Comparing the HNP 1-3 plasma level and the DEFA1/A3 copy number of the same 
patient, no significant correlation was observed between defensin levels and genomic copy 
numbers (r2=0.01; Fig.4.). 
 
DEFA1/DEFA3 gene expression 
The expression of DEFA1/A3 was measured in the peripheral leukocytes of diabetic patients. 
DEFA1/DEFA3 mRNA was determined in blood samples from 12 patients with type 1 and 
another 12 with type 2 diabetes, and the relative expressions of DEFA1/DEFA3 were 
compared with the DEFA1/DEFA3 copy numbers of the same patients (Fig.5). The data 
indicated that peripheral leukocytes had the ability to transcribe DEFA1/DEFA3 genes ( mean 
± SE of relative expression 1.5±0.28) and to biosynthetize HNP1-3 peptides. However, no 
positive correlation was observed between the copy numbers and the expression levels of the 
human neutrophil peptide 1-3 (Fig.5). The variation in expression levels between individuals 
did not exhibit a positive correlation with the copy number. Similarly, the expression of 
specific mRNA in the leukocytes for HNP 1-3 did not parallel the HNP 1-3 plasma levels 
(data not shown). 
DEFB1 G-20A, DEFB1 G-52A and DEFB1 C-44G polymorphisms 
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The genotypic distributions of DEFB1 G-20A, and DEFB1 G-52A and DEFB1 C-44G 
polymorphisms are presented in Table 1. 
The distribution of the DEFB1 G-20A genotypes was in accordance with the Hardy–
Weinberg equilibrium both in the control population and in the patients ( p = 0.912 and p = 
0.795, respectively). There was no significant difference in genotype distribution between the 
patients overall and the healthy controls. Similarly, no significant differences in genotypes 
were observed when the patients were grouped according to type 1 and type 2 diabetes. 
As concerns the DEFB1 G-52A SNP , distribution of the genotypes was in accordance with 
the Hardy–Weinberg equilibrium both in the control population and in the patients ( p = 0.252  
and  p = 0.181, respectively). We did not detect any significant difference in genotypes 
between the patients and the controls, either in type 1 or type 2 diabetes. 
The genotypic distribution of DEFB1 C– 44G polymorphism is shown in Table 1. 
The distribution of genotypes was in accordance with the Hardy–Weinberg equilibrium 
among the patients with diabetes (p = 0.151) and also in the control population (p = 0.722). 
But there was a significant difference in genotype distribution between the patients overall 
and the healthy controls (χ2 test, p = 0.002). The frequency of the GG genotype was 
significantly lower in both types of diabetes (2.5% and 2%, respectively) than in the healthy 
controls (9%) (Fisher test vs. control, p = 0.001, OR=9.136, 95% CI: 3.512–23.82). 
Conversely, the prevalence of the DEFB1 CC genotype was 61 % in the group of diabetic 
patients vs. 45% in the controls (Fisher test: p = 0.0009, OR=2.055, 95% CI: 1.248–2.746). 
When the patients were grouped according to the diabetic complications, there was a lower 
frequency of the GG genotype among the patients with nephropathy and among those with 





HNP1-3 levels in the circulation were measured, and the copy number variation of 
DEFA1/A3 genes was determined in diabetic patients. The diabetic patients exhibited 
overall higher plasma levels of HNP 1-3 (α-defensin) with either type 1 or type 2 form of 
the disease than the healthy controls. The highest concentrations of HNPs were detected in 
patients with nephropathic or neuropathic and cardiovascular  complications. An essential 
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question arises as to why an increased concentration of plasma α-defensin (HNP1-3) level 
is associated with type 1 and type 2 diabetes, especially in the event of diabetic 
complications such as nephropathy, neuropathy or  cardiovascular problems. The 
explanation might be that the elevation in the plasma HNP1-3 level is the consequence of 
the decreased renal degradation of the peptides in patients with advanced nephropathy [26]. 
HNP 1-3 promote the accumulation of low density lipoprotein in the vasculature, inhibit 
fibrinolytic activity on the surface of vascular cells, and accumulate in the intima of 
atherosclerotic plaques. Therefore, HNP 1-3 may have clinical implications in diabetic 
patients with hypercholesteremia or vascular dysfunction[7,  27].   
The association of high levels of HNP1-3 in patients with neuropathy in type 1 and type 2 
diabetes is yet to be clarified. The next question is whether there is an increased gene 
expression responsible for the elevated plasma levels of α-defensins. Our study revealed 
that there was no correlation between HNP1-3 plasma levels and the copy numbers of 
DEFA1/A3 genes. The effect of copy number variations in DEFA1/DEFA3 on the disease 
or even on the plasma concentrations of the peptides remain unclear. Controversal data 
have been published about the correlation between DEFA1/A3 copy number and the α-
defensin peptide concentration. Linzmeier and Ganz [20] have shown that the intracellular 
HNP1-3 levels in human neutrophils are proportional to the copy numbers of the DEFA1 
and DEFA3 genes Copy numbers of DEFA1/A3 may be proportional to the intracellular 
levels of HNP1-3 in neutrophil granulocytes but possibly not to the circulating HNP1-3 
levels. Additionally, a discrepancy between gene copy number and the HNP1-3 protein 
levels has recently been reported in septic patients[28]. There are several potential 
explanations of the discrepancy between the gene copy number and the plasma levels. 
HNP1-3 is stored primarily in the granules of neutrophils and is released into the 
circulation during the activation of the neutrophils. Moreover, it might also be due to 
different transcriptional mechanisms modulating these genes or to an increased distance 
between the regulators of the genes [28, 29]. 
The fact that in our study no significant correlation was observed between the genomic 
copy number variation of DEFA1/DEFA3 and the mRNA expression levels (Fig. 5.) 
suggests that the degranulation rather than the increased gene expression may be 
responsible for the increased plasma HNP 1-3 levels in diabetes. 
Similar observations have been published about the copy number polymorphism and 
expression level variation of DEFA1 and DEFA3 genes[22]. In that study, the combined 
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expression levels of DEFA1/A3 and the genomic copy number have not been correlated, 
suggesting the superimposed influence of trans-acting factors. 
It is noteworthy that there are several examples of the absence of a correlation between 
copy number polymorphisms and the relative transcription level[29]. 
There are no direct data showing that exaggerated degranulation is linked to diabetic 
complications, or it is higher in DM patients than in controls. However, it has recently 
been published that pro-inflammatory conditions during hyperglycemia favor NET – 
neutrophil extracellular traps – formation [30], and HNP 1-3 are also involved in the 
formation of neutrophil extracellular traps[9]. It is noteworthy that diabetes is associated 
with low grade, sub-clinical and chronic inflammation characterized by abnormal 
cytokine production. Therefore, the diabetic microenvironment can induce NET formation, 
which may result in a basic high HNP-1 concentration in the circulations 
In order to detect whether increased mRNA expression is responsible for elevated 
defensin levels in diabetic patients,  quantitative RT-PCR reactions were performed. 
Expression of specific mRNA in the leukocytes was observed for HNP 1-3 but not parallel 
with HNP1-3 plasma levels. The mRNA values between patients and controls were rather 
equal (mean ± SE of relative expression 1.5±0.28 vs. 1.49±0.35, respectively) suggesting 
that not an increased gene expression may be responsible for increased plasma levels of 
HNP 1-3. Our findings were in good correlation with the observations of Fang X. M. et al. 
[31]
, that is, α-defensin genes were constitutively transcribed at low level in mature 
neutrophils, but they were not inducible 
Eosinophils with transcriptionally active α-defensin production have recently been 
detected in the capillary blood of diabetic patients[32]. Eosinophils but not neutrophils 
displayed the augmentation of transcriptional activation of α-defensin expression. In our 
study, the majority of the cells in peripheral venous blood were neutrophils; therefore, our 
purified DNA and RNA samples were derived mostly from neutrophils.  
The present study demonstrated that the distributions of the C-44G genotypes were 
different between patients with diabetes and healthy controls, whereas the frequency of 
the GG genotype was significantly higher in the control population. It indicates that the 
presence of G allele probably leads to strengthened HBD1 antimicrobial activity, which is 
less frequent in patients with diabetes. The G allele of C-44G SNP generates a putative 
binding site for nuclear factor κ B (NF-κB), and it is very likely to induce an 
overexpression. The proposed effect of this SNP could partially explain why the GG 
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genotype was considered to be a protective genotype in atopic dermatitis[33] and also in the 
susceptibility to Candida colonization in diabetic patients[34]. Conversely, in these studies, 
subjects carrying the CC genotype at the -44 locus site of the gene were at a greater risk of 
acquiring infection. It has been recently suggested that the C allele of DEFB1 C-44G SNP 
probably abrogates NF-κB-dependent DEFB1 upregulation[35].  
These data are consistent with our present observation that the GG phenotype could also 
be protective in diabetes, and vice versa, the higher frequency of CC genotype might be 
connected with lower expression of human defensin β-1. Among the 257 patients with 
diabetes, only 6 (2%) were GG homozygotes, and 61% of the patients were CC 
homozygotes, as compared with 45% of CC homozygotes in the control group. 
Furthermore, the number of GG homozygotes was even lower (1%) among patients with 
nephropathy and neuropathy. These observations draw the attention to the importance of 
DEFB1 polymorphisms in diabetes, especially in the cases with nephropathy and 
neuropathy. Foot ulcerations in diabetic patients are often combined with infections. None 
of  the 28  patients with foot ulcer displayed GG genotype of C- 44G SNP of DEFB1 gene 
. A high blood glucose level itself can result in low levels of β-defensin[23], and it might 
be further downregulated in humans as a consequence of C-44G polymorphism. It is 
noteworthy that insulin is an important factor mediating hBD-1 expression[24]. 
Taken together, our study demonstrated elevated levels of α-defensin (HNP1-3) in type 1 
and type 2 diabetes, which were more pronounced when there were diabetic complications. 
However, there was no correlation between the circulating HNP1-3 levels and the 
DEFA1/DEFA3 copy number. Similarly, no correlation was found between the mRNA 
expression and the copy number variation. Further studies are needed to explore whether 
the elevated α-defensin levels of the plasma in diabetes are causally linked to this disease 
and its complications, or they are simply the consequences of the degranulation of 
neutrophils under pathologic conditions. Whatever the mechanism, the elevated HNP1-3 
level might not be genetically determined or at least independent of the copy number 
variation of the DEFA1/DEFA3 genes. In contrast, the CC genotype of  the C-44G SNP of 
DEFB1 was more frequent in diabetic patients than in healthy controls, which draws the 
attention to the genetic background of a potentially impaired function of hBD1 (human 
defensin β-1) in diabetes. These data support the view that both alpha and beta-defensins 
may have important roles in the pathogenesis of diabetes and diabetic complications. Our 
results should be regarded as preliminary results, which should be confirmed on a larger 





We thank Mrs.Györgyi Müller for expert technical assistance. This work was supported by 





There is a growing evidence of the role of innate immunity in diabetes. Defensins are 
members of small antimicrobial peptides of the innate immune system. In addition to their 
antibacterial and antiviral effects, immunologic functions of  defensins has been shown to 
play a role in the homeostasis. To date, little is known about the genetic basis and the 
functions of α- and β-defensins in diabetes. The aim of our study was to investigate the 
genetic background of human defensin-α and human defensin β-1 production in adult patients 
with type1 and type 2 diabetes, especially with complications. 
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Research Frontiers 
Neutrophil granulocytes are considered to be the primary cellular origin of α-defensins; HNP 
1-3 . HNPs can be released into the extracellular milieu following granulocyte activation as a 
consequence of degranulation, leakage, cell death, and lysis during inflammation . Human 
beta defensins are expressed mainly by epithelial cells of the skin, gut, respiratory and 
urogenital tissues, the pancreas and the kidneys . The level of defensin expression varies 
among individuals, and it has been suggested that this variation is due to genetic differences 
in the genes encoding defensins 
 
Innovations and breakthroughs 
To our knowledge our data provide the first report about a complex investigation of defensin-
alpha and defensin β-1 in type 1 and type 2 diabetes.  Increased levels of alpha-defensin -1, -2 
and -3 have recently been reported in patients with  type 1 diabetes with nephropathy and in 
cardiovascular complications (Ref 26, 27)..In our study not only HNP1-3 levels in the 
circulation were measured, but also  the copy number variation of DEFA1/A3 genes was 
determined in diabetic patients , together  with the expression of DEFA1/A3 in peripheral 
leukocytes. Several SNPs (single nucleotide polymorphisms) have been characterized of 
human DEFB1 (human defensin β-1) gene in  previous studies (Ref 18, 19) In our complex 
study we demonstrated that elevated HNP1-3 levels in diabetes are independent of 
DEFA1/DEFA3 copy numbers, but  the GG genotype of C-44G SNP in DEFB1 gene may 
result in decreased β1-defensin production. 
 
Applications 
Our data support the view, that both alpha and beta-defensins may have an important role in 
the pathogenesis of diabetes and diabetic complications The results may contribute to a better 
understanding of  the roles of defensins in the pathomechanism of  diabetes and may represent 
a future possibility toward broadening  of  the prognostic laboratory  markers. 
 
Terminology 
HNP 1-3 are Human Neutrophil Peptides, members of the  human α-defensin family. Human 
defensin β-1 (HBD1) is the member of  another family of antimicrobial peptides. Two types 
of genetic polymorphisms have been identified in genes encoding defensins: copy number 
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polymorphisms and single nucleotide poymorphisms (SNPs). Several copy number 
polymorphisms form the major source of genetic polymorphism of α-defensin genes DEFA1 
and DEFA3, encoding human neutrophil peptides Human defensin beta-1 (HBD-1) is encoded 
by the gene DEFB1.  Three frequent SNPs at positions G-20A (rs11362), C-44G (rs 1800972) 
and G-52A (rs1799946) in the 5’-untranslated region (UTR) of DEFB1 were described.  The 




DEFB1 G-20A GG GA AA χ2 test* 
Patients with diabetes  
n = 257 
82 (32%) 131 (51%) 44 (17%) 0.568 
Type 1 diabetes 
n = 117 
36 (31%) 60 (51%) 21 (18%) 0.775 
Type 2 diabetes 
n = 140 
46 (33%) 71 (51%) 23 (16%) 0.573 
Controls 
n = 200 
62 (31%) 96 (48%) 42 (21%)  
DEFB1 G-52A GG GA AA χ2 test* 
Patients with diabetes 
n = 257 
114 (44%) 104 (40%) 39 (15%) 0.572 
Type 1 diabetes 
n = 117 
52 (44%) 47 (40%) 18 (17%) 0.702 
Type 2 diabetes 
n = 140 
62 (44%) 57 (41%) 21 (15%) 0.658 
Controls 
n = 200 
80 (40%) 84 (42%) 36 (18%)  
DEFB1 C-44G CC CG GG χ2 test* 
Patients with diabetes 
n = 257 
156 (61%) + 95 (37%) 6 (2%)** 0.002 
Type 1 diabetes 
n = 117 
70 (60%) 44 (37 %) 3 (2.5%) 0.01 
Type 2 diabetes 
n = 140 
86 (61%) 51 (36%) 3 (2%) 0.003 
Controls 
n = 200 
90 (45%) 92 (46%) 18 (9%)  
 
 
Table 1. Genotypes of  DEFB1 G-20A,  DEFB1 G-52A , and DEFB1 C-44G 
polymorphisms in patients with diabetes  
*
 chi square test vs. controls 
**
 Fisher test vs. controls, p = 0.001, OR = 9.136, 95% CI: 3.512–23.82 




Fig.1. Plasma levels of human neutrophil peptides (HNP1-3) in patients with type 1 and type 
2 diabetes (DM1 and DM2) and healthy controls. The line represents the mean plasma levels 
of  HNP1-3. Significant differences as determined by Mann–Whitney test are indicated. 
Fig.2. Plasma levels of human neutrophil peptides (HNP1-3) in diabetic patients with 
different complications relative to those without complications, and to healthy controls. Mean 
and SE are indicated; significant differences between groups were determined by unpaired t 
test. 
Fig.3. Genomic copy number of DEFA1/DEFA3 in patients with diabetes and in healthy 
blood donors. Quantitative box-plot analysis (median, minimum, maximum value, 25% and 
75% percentiles) of DEFA1/A3 copy numbers determined in  DNA samples  from  133 
controls, 100 patients with type 1 diabetes (DM1), and 100 patients with type 2 diabetes 
(DM2). 
Fig.4. Plasma levels of human neutrophil peptides (HNP1-3) in diabetic patients vs. copy 
numbers of DEFA1/DEFA3. The DEFA1/A3 copy numbers were determined by quantitative 
PCR analysis and compared to the HNP1-3 plasma level of the same patient (50 with type 1 
and 50 with type 2 diabetes). 
Fig.5. Relative mRNA expression levels of DEFA1/DEFA3 in diabetic patients vs. copy 
numbers of DEFA1/DEFA3. The DEFA1/A3 copy numbers were determined by quantitative 
PCR analysis and compared to the DEFA1/DEFA3 mRNA measured by RT-PCR of the same 
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Németh BC, Sahin-Tóth M. Human cationic trypsinogen (PRSS1) variants and
chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 306: G466–G473,
2014. First published January 23, 2014; doi:10.1152/ajpgi.00419.2013.—Varia-
tions in the serine protease 1 (PRSS1) gene encoding human cationic trypsinogen
have been conclusively associated with autosomal dominant hereditary pancreatitis
and sporadic nonalcoholic chronic pancreatitis. Most high-penetrance PRSS1 vari-
ants increase intrapancreatic trypsin activity by stimulating trypsinogen autoacti-
vation and/or by inhibiting chymotrypsin C-dependent trypsinogen degradation.
Alternatively, some PRSS1 variants can cause trypsinogen misfolding, which
results in intracellular retention and degradation with consequent endoplasmic
reticulum stress. However, not all PRSS1 variants are pathogenic, and clinical
relevance of rare variants is often difficult to ascertain. Here we review the PRSS1
variants published since 1996 and discuss their functional properties and role in
chronic pancreatitis.
The PRSS1 Gene
The serine protease 1 (PRSS1, PRoteaSe Serine 1) gene in
humans is located on chromosome 7q35, within the T cell
receptor beta locus (43). The association of trypsinogen genes
with this locus is important historically, because DNA se-
quencing of this region in 1996 and the fortuitous finding of
eight trypsinogen genes intercalated here greatly facilitated the
discovery of the susceptibility gene for hereditary pancreatitis.
PRSS1 codes for human cationic trypsinogen, the precursor for
the most abundant digestive enzyme secreted by the human
pancreas (45). Besides PRSS1, the locus also contains five
trypsinogen pseudogenes, a relic gene, and PRSS2, that en-
codes anionic trypsinogen, the other major human trypsinogen
isoform. The PRSS3 gene coding for mesotrypsinogen, the
relatively minor third human isoform, is found on chromosome
9p13.
Copy Number Mutations in PRSS1
Heterozygous triplication and duplication of a 605-kb seg-
ment containing the trypsinogen genes on chromosome 7 was
found in French patients with hereditary and sporadic idio-
pathic chronic pancreatitis (5, 29, 33). Presumably similar
heterozygous duplications of PRSS1 were reported in two U.S.
families with hereditary pancreatitis (26). Such copy number
mutations should result in higher trypsinogen expression
through a gene-dosage effect, although this has not been
demonstrated directly. Higher trypsinogen concentrations, in
turn, would increase the likelihood of autoactivation and de-
velopment of intrapancreatic trypsin activity. A unique dupli-
cation event that resulted in an extra copy of a hybrid PRSS2/
PRSS1 trypsinogen gene was also described in a French family
with hereditary pancreatitis (34).
Gene Conversions Within Trypsinogen Genes
Human trypsinogen genes exhibit a high level of sequence
identity, which may facilitate gene conversion events. In fact,
gene conversion was suggested as a mechanism for the evolu-
tionary origin of the most common hereditary pancreatitis-
associated mutations (6). A gene conversion event was identi-
fied in a 6-yr-old German girl with sporadic chronic pancre-
atitis, which replaced exon 2 in PRSS1 with that from PRSS2
(60). A gene duplication event in a French family with hered-
itary pancreatitis resulted in a similar hybrid gene, containing
exons 1–2 from PRSS2 and exons 3–4–5 from PRSS1 (34).
Since exon 1 codes for part of the signal peptide which is
removed in the endoplasmic reticulum, only changes in exon 2
affect the mature trypsinogen protein. The amino acids en-
coded by exon 2 are nearly identical between the two isoforms,
with the exception of Ile29 and Ser54 found in anionic
trypsinogen (PRSS2). Consequently, the hybrid genes de-
scribed in the German and French studies encode cationic
trypsinogen with mutations p.N29I and p.N54S. Whereas the
p.N54S variation is functionally innocuous (60), the p.N29I
mutation causes hereditary pancreatitis.
Common Polymorphisms in PRSS1
Polymorphic variations with a population frequency 5%
are relatively rare in PRSS1. Variant c.486CT (p.D162 or
p.D162D; dbSNP rs6666) in exon 4 and variant c.738CT
(p.N246 or p.N246N, dbSNP rs6667) in exon 5 are the only
two variations within the coding region. The two variants are
typically found in linkage disequilibrium and the C allele has
a slightly higher frequency in Europeans (0.6), whereas it is
less frequent (0.25) in subjects of Asian origin or subjects from
India (0.1). No disease association has been demonstrated for
either variant. Two additional common variants can be found
in the 5= region upstream of the ATG start codon: c.204CA
(dbSNP rs4726576; C allele frequency is 0.7 in Europeans
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and 0.4 in Asians) and c.408CT (dbSNP rs10273639; C
allele frequency is 0.6 in Europeans and 0.3 in Asians). In
a recent genomewide association study, variant c.–408CT
(i.e., the T allele) was demonstrated to have a small protective
effect against chronic pancreatitis presumably by lowering
trypsinogen expression (64). The C allele of the same variation
(erroneously reported as 409C/T) was previously claimed to
offer protection against pancreatic cancer in a Chinese popu-
lation; however, independent confirmation is lacking (31).
PRSS1 Variants in the General Population
Published accounts indicate that sequencing the PRSS1 gene
of 200 French (7), 82 German (58), 420 Chinese (4, 68), 28
Korean (30), and 150 Brazilian (3) control subjects revealed
only the p.E79K exon 3 variant in a French and a Brazilian
individual. More recently, exon 3 of 1,000 healthy controls of
German origin was sequenced and only the p.V123L variation
was identified in a single subject (46). These observations
indicate that PRSS1 variants, other than the common polymor-
phisms, are exceedingly rare in the general population.
PRSS1 Mutations in Hereditary Pancreatitis
Autosomal dominant hereditary pancreatitis was first re-
ported by Comfort and Steinberg in 1952 (10). Using genetic
linkage analysis, three independent research groups localized
the susceptibility gene to chromosome 7 in 1996 (27, 39, 62).
In the same year, Whitcomb et al. (63) used candidate gene
sequencing to identify the most common causative mutation
p.R122H in PRSS1. Genetic heterogeneity underlying heredi-
tary pancreatitis was soon recognized when the second most
common PRSS1 mutation, p.N29I, was described by two
groups in 1997–1998 (16, 56). These two heterozygous muta-
tions are found in 90% of hereditary pancreatitis families
worldwide, with p.R122H accounting for 65% and p.N29I for
25% of the cases. In the remaining 10% of the cases, PRSS1
mutations p.A16V, p.D21A, p.D22G, p.K23R, p.K23_I24insIDK,
p.N29T, p.V39A, p.R116C, and p.R122C were identified, always
in the heterozygous state (2, 12, 22, 28, 40, 48, 55, 57, 65, 67).
Mutations p.D21A, p.D22G, p.K23R, p.K23_I24insIDK, and
p.V39A were found only in a single family each. Penetrance of
PRSS1 mutations in hereditary pancreatitis families is incomplete;
it is estimated between 80 and 90% for carriers of p.R122H,
although smaller pedigrees may exhibit lower apparent penetrance
(21, 62, 41, 49). Note that mutations p.A16V and p.R116C exhibit
variable penetrance and were also found in sporadic cases with no
family history.
Hereditary pancreatitis-associated PRSS1 mutations exert
their effect via a so-called trypsin-dependent pathological path-
way, which involves increased autoactivation of mutant
trypsinogens resulting in elevated intrapancreatic trypsin ac-
tivity. Rare mutations in the activation peptide of trypsinogen
(p.D21A, p.D22G, p.K23R, and p.K23_I24insIDK) directly
stimulate autoactivation (8, 15, 22, 37). In contrast, the more
common hereditary pancreatitis-associated PRSS1 mutations
alter the regulation of activation and degradation of cationic
trypsinogen by chymotrypsin C (CTRC), a digestive enzyme
that controls trypsin levels generated through autoactivation of
human trypsinogens (51) (Fig. 1). CTRC promotes degradation
of trypsinogen by cleaving the Leu81-Glu82 peptide bond in
the calcium binding loop and thereby attenuates trypsin levels
during autoactivation (51, 52, 53). Importantly, trypsin-medi-
ated autolytic cleavage of the Arg122-Val123 peptide bond is
also required for CTRC-dependent degradation and inactiva-
tion of trypsinogen (51, 53). Paradoxically, CTRC also stim-
ulates trypsinogen activation by processing the activation pep-
tide at the Phe18-Asp19 peptide bond to a shorter form, which
is cleaved by trypsin at a higher rate, resulting in increased
autoactivation (38, 51).
PRSS1 mutations interfere with the CTRC-mediated cleav-
ages described above and render trypsinogen resistant to deg-
radation and/or increase processing of the activation peptide
(Fig. 1). Typically, a combination of two or more effects
results in the common phenotype of increased activation (51).
Thus mutations p.R122H and p.R122C completely block
cleavage at Arg122 by trypsin but also decrease cleavage at
Leu81 by CTRC. Mutation p.N29I increases cleavage of the
activation peptide and reduces cleavage both at Leu81 and
Arg122. Mutations p.V39A and p.N29T decrease cleavage at
Leu81 and Arg122, whereas mutation p.A16V increases pro-
cessing of the activation peptide by CTRC (38, 51). Regardless
of mechanistic details, the unifying biochemical phenotype of
all hereditary pancreatitis-associated mutants is increased rates
of autoactivation, with markedly elevated final trypsin activity
levels, relative to wild-type cationic trypsinogen.
The only exception to the unifying pathological mechanism
described above is mutation p.R116C, which does not change
trypsinogen activation but causes misfolding, which results in
intracellular aggregation and degradation and consequently
reduced secretion (25). Mutation-induced misfolding can elicit
endoplasmic reticulum stress, which is probably responsible
for the increased disease risk in carriers of p.R116C, although
the exact mechanism is unknown. Mutation p.R116C exhibits
variable penetrance and is often found in sporadic cases,
suggesting that the misfolding-dependent pathological path-
way may confer relatively smaller risk.
PRSS1 Variants in Sporadic Nonalcoholic Chronic
Pancreatitis
The first indication that PRSS1 variants can cause chronic
pancreatitis with lower penetrance came from the identification
of the p.A16V variant by Witt et al. (65) in four children with
chronic pancreatitis. Only one child had a positive family
history consistent with hereditary pancreatitis, whereas in three
children the disease was sporadic with no family history, even
though inheritance from unaffected parents was demonstrated.
Subsequent studies based on the EUROPAC database (18)
confirmed the variable penetrance of this variant, demonstrat-
ing that p.A16V was found in six families with hereditary
pancreatitis, in one family with familial (single-generation)
chronic pancreatitis, and in three cases of chronic pancreatitis
with no family history. The biochemical phenotype of the
p.A16V explains its genetic properties: the mutation causes
increased autoactivation in the presence of CTRC; however,
the rate of autoactivation and the final trypsin levels attained
are much lower than those observed with the highly penetrant
PRSS1 mutations such as p.R122H (51). Increased autoactiva-
tion is due to faster processing of the mutant trypsinogen
activation peptide by CTRC (38, 51). As noted above, mutation
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p.R116C is another example of a hereditary pancreatitis-asso-
ciated mutation with variable penetrance. A recent study dem-
onstrated that variant p.G208A was associated with 4% of
idiopathic and alcoholic chronic pancreatitis patients of Japa-
nese origin, and increased disease risk by15- to 20-fold (32).
This variant has no effect on trypsinogen activation but causes
a moderate (60%) reduction in trypsinogen secretion from
transfected cells (46). Thus, as seen with variant p.R116C,
mutation-induced misfolding and endoplasmic reticulum stress
may be the pathologically relevant mechanism for variant
p.G208A as well. It is also noteworthy that p.G208A is the first
PRSS1 variant for which an association with alcoholic pancre-
atitis has been demonstrated.
Screening of various patient populations with sporadic idio-
pathic chronic pancreatitis has led to the identification of a
large number of rare missense variants (4, 7, 14, 23, 30, 35, 42,
55, 58). The clinical significance of such variants has been
unclear because their low frequency did not allow statistical
determination of genetic association with pancreatitis. Never-
theless, authors often described these as causative or pancre-
atitis-associated simply by analogy with well-characterized
disease-relevant PRSS1 mutations. Characterization of the
functional phenotype of these variants revealed that only the
activation peptide variant p.D19A increased autoactivation in a
manner similar to the hereditary pancreatitis-associated activa-
tion-peptide mutations (8, 15, 37). A handful of mutants
showed a marked (p.D100H, p.C139F, and p.C139S) or mod-
erate (p.K92N and p.S124F) secretion defect, which suggested
that these mutations exerted their pathogenic effect through a
mechanism that involves mutation-induced misfolding and
endoplasmic reticulum stress, as described above for mutations
p.R116C and p.G208A (25, 46). Another subset of mutants
showed no phenotypic alterations compared with wild-type
trypsinogen (p.L81M, p.Q98K, p.A121T, p.T137M, and
p.S181G) or suffered increased degradation by CTRC (p.P36R,
p.G83E, p.I88N, and p.V123M) (46, 52, 54). These variants are
likely harmless and their identification in patients with chronic
pancreatitis may be accidental. One variant (p.K170E) caused
slightly increased trypsinogen secretion, which, similarly to the
copy number mutations, may translate to increased risk for
pancreatitis (46).
Variant p.E79K should be highlighted because this is the
only rare PRSS1 variant that was found not only in patients but
also in unrelated controls (3, 7, 20, 23, 41, 50, 59). Early
biochemical studies demonstrated an increased propensity of
this mutant to transactivate anionic trypsinogen; however, this
small phenotypic change is unlikely to be of pathological
consequence (59). More recent studies indicated that the rate of
Fig. 1. Effect of pancreatitis-associated PRSS1 mutations on the chymotrypsin C (CTRC)-dependent activation and degradation of human cationic trypsinogen.
CTRC cleaves the Leu81-Glu82 peptide bond and trypsin cleaves the Arg122-Val123 peptide bond; these 2 cleavages result in the eventual degradation of
trypsinogen. CTRC also stimulates autoactivation of cationic trypsinogen by cleaving the Phe18-Asp19 peptide bond in the activation peptide. The shortened
activation peptide is more susceptible to trypsin-mediated activation at the Lys23-Ile24 peptide bond. The dominant effect of CTRC is degradation. A: PRSS1
mutations can increase conversion of trypsinogen to trypsin by inhibition of CTRC-dependent trypsinogen degradation (red arrow) or by increasing
CTRC-dependent stimulation of autoactivation (green arrow). See text for further details. B: proteolytic cleavage of human cationic trypsinogen by CTRC and
trypsin. Primary structure of trypsinogen with disulfide bonds is shown. CTRC cleavage sites are highlighted in orange and trypsin cleavage sites are shown in
blue. The activation peptide is in green. Note the yellow peptide segment not stabilized by disulfide bonds between the Leu81 and Arg122 cleavage sites. B is
modified from Ref. 53, copyright by the National Academy of Sciences of the United States of America.
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Table 1. Variants in the PRSS1 gene encoding human cationic trypsinogen
Region Nucleotide Change Amino Acid Change
Number of CP Carriers
Reported
Number of Non-CP
Carriers Reported Clinical Significance
PRSS1 duplication 7 Pathogenic
PRSS1 triplication 26 2 Pathogenic
5 prime c.408CT common polymorphism common polymorphism Protective
5 prime c.204CA common polymorphism common polymorphism Nonpathogenic
5 prime c.36GA 1 Unknown
5 prime c.30_28delTCC 1 Unknown
intron 1 c.401GA 1 Protective
intron 1 c.4040delC 1 Unknown
intron 1 c.41–49CT 1 Unknown
exon 2 c.47CT p.A16V 39 24 Pathogenic
exon 2 c.56AC p.D19A 1 Pathogenic
exon 2 c.62AC p.D21A 3 Pathogenic
exon 2 c.65AG p.D22G 2 1 Pathogenic
exon 2 c.68AG p.K23R 2 Pathogenic
exon 2 c.63_71dup p.K23_I24insIDK 3 Pathogenic
exon 2 c.86AT p.N29I 285 18 Pathogenic
exon 2 PRSS1-PRSS2 hybrid p.N29I  p.N54S 7 1 Pathogenic
exon 2 c.86AC p.N29T 5 Pathogenic
exon 2 c.107CG p.P36R 2 Nonpathogenic
exon 2 c.111CA p.Y37X 1 Protective
exon 2 c.116TC p.V39A 7 Pathogenic
intron 2 c.2001GA 1 Protective
exon 3 c.235GA p.E79K 13 6 Pathogenic?
exon 3 c.241CA p.L81M 4 Unknown
exon 3 c.248GA p.G83E 1 Nonpathogenic
exon 3 c.263TA p.I88N 1 Nonpathogenic
exon 3 c.273CA p.A91 1 Unknown
exon 3 c.276GT p.K92N 1 Pathogenic
exon 3 c.292CA p.Q98K 1 Nonpathogenic
exon 3 c.298GC p.D100H 2 3 Pathogenic
exon 3 c.310CG p.L104V 4 Unknown
exon 3 c.311TC p.L104P 1 3 Pathogenic
exon 3 c.346CT p.R116C 16 4 Pathogenic
exon 3 c.361GA p.A121T 14 6 Nonpathogenic
exon 3 c.364CT p.R122C 35 23 Pathogenic
exon 3 c.365GA p.R122H 793 69 Pathogenic
exon 3 c.365_366GCAT p.R122H 3 Pathogenic
exon 3 c.367GA p.V123M 1 Nonpathogenic
exon 3 c.367GT p.V123L 1 Nonpathogenic
exon 3 c.371CT p.S124F 1 Pathogenic
exon 3 c.403AG p.T135A 1 Unknown
exon 3 c.410CT p.T137M 2 1 Nonpathogenic
exon 3 c.415TA p.C139S 11 Pathogenic
exon 3 c.416GT p.C139F 2 1 Pathogenic
exon 3 c.417CT p.C139 1 Unknown
exon 3 c.443CT p.A148V 1 Unknown
intron 3 c.45410AC 5 Unknown
intron 3 c.45436TC 1 Unknown
intron 3 c.45475AG 24 4 Unknown
intron 3 c.454127AT 1 Unknown
intron 3 c.454157CA 1 Unknown
intron 3 c.454157CG 1 2 Unknown
intron 3 c.454172CT 4 Unknown
intron 3 c.455–192TA 1 Unknown
exon 4 c.486CT p.D162 common polymorphism common polymorphism Nonpathogenic
exon 4 c.508AG p.K170E 2 Pathogenic?
exon 4 c.541AG p.S181G 1 1 Nonpathogenic
intron 4 c.592–79GA 1 Unknown
intron 4 c.592–78GA 1 Unknown
intron 4 c.592–24CT 1 Unknown
intron 4 c.592–11CT 1 Unknown
intron 4 c.592–8CT 1 Unknown
Continued
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autoactivation of mutant p.E79K is suppressed in the presence
of CTRC; however, the mutant reaches higher final trypsin
levels than wild-type trypsinogen, because of its resistance to
CTRC-mediated degradation (A. Szabó and M. Sahin-Tóth,
unpublished observations). Thus the biochemical phenotype is
inconclusive but, together with the genetic data, may be cau-
tiously interpreted as p.E79K being a mild pathogenic variant
with low penetrance.
PRSS1 Variants in Conditions Unrelated to Pancreatitis
Chen et al. (9) reported two loss-of-function PRSS1 variants,
a nonsense variant p.Y37X and a splice-site mutation
c.2001GA in intron 2 found in chronic alcoholics without
pancreatic disease. The authors suggested that the variants
should be protective against chronic pancreatitis. Gullo et al.
(19) investigated PRSS1 variants in benign pancreatic hyper-
enzymemia and found variant p.A148V and the splice-site
mutation c.401GA in intron 1. Variant p.A148V has no
functional consequences (A. Schnúr and M. Sahin-Tóth, un-
published observations), whereas variant c.401GA should
result in decreased trypsinogen expression, which might be
protective against chronic pancreatitis. Two studies described
PRSS1 variants in Chinese patients with pancreatic cancer
(p.T135A, p.T137M, c.45436TC, and c.454157CG in
intron 3), which are in all likelihood incidental findings unre-
lated to pathology (13, 68). The same group proposed a strong
protective effect for the C allele of the common polymorphic
variant c.408CT (erroneously reported as 409C/T)
against pancreatic cancer (31). Variant p.L104V was re-
ported in two female members of a Chinese family with
familial solid pseudopapillary tumor of the pancreas and in
two healthy male relatives (17). Finally, patients with
Table 2. Mechanism of action of pathogenic PRSS1 variants
Region Nucleotide change Amino acid change Pathogenic mechanism Notes Citations
PRSS1 duplication increased secretion no direct evidence
PRSS1 triplication increased secretion no direct evidence
exon 2 c.47CT p.A16V increased activation CTRC dependent 38, 51
exon 2 c.56AC p.D19A increased activation 8, 15, 24, 37
exon 2 c.62AC p.D21A increased activation 37
exon 2 c.65AG p.D22G increased activation 8, 15, 22, 24, 57
exon 2 c.68AG p.K23R increased activation 8, 15, 24, 57
exon 2 c.63_71dup p.K23_I24insIDK increased activation 15, 22
exon 2 c.86AT p.N29I increased activation CTRC dependent 51
exon 2 PRSS1-PRSS2 hybrid p.N29I p.N54S increased activation CTRC dependent 51, 60
exon 2 c.86AC p.N29T increased activation CTRC dependent 51
exon 2 c.116TC p.V39A increased activation CTRC dependent 51
exon 3 c.235GA p.E79K increased activation* CTRC dependent unpublished
exon 3 c.276GT p.K92N misfolding 46
exon 3 c.298GC p.D100H misfolding 46
exon 3 c.311TC p.L104P misfolding unpublished
exon 3 c.346CT p.R116C misfolding 25
exon 3 c.364CT p.R122C increased activation CTRC dependent 51
exon 3 c.365GA p.R122H increased activation CTRC dependent 51
exon 3 c.365_366GCAT p.R122H increased activation CTRC dependent 51
exon 3 c.371CT p.S124F misfolding 46
exon 3 c.415TA p.C139S misfolding 25
exon 3 c.416GT p.C139F misfolding 46
exon 4 c.508AG p.K170E increased secretion 46
exon 5 c.623GC p.G208A misfolding 46
See Table 1 for inclusion criteria. Mutations in PRSS1 can increase activation of cationic trypsinogen via 4 independent but mutually nonexclusive
mechanisms: 1) inhibition of CTRC-dependent trypsinogen degradation, 2) increasing CTRC-dependent stimulation of autoactivation; 3) direct stimulation of
autoactivation; and 4) increased trypsinogen secretion. Alternatively, PRSS1 mutations can cause misfolding and endoplasmic reticulum stress. See Fig. 1 for
CTRC-dependent mechanisms of trypsinogen activation and degradation. *Note that the biochemical phenotype of p.E79K is ambiguous; see text for details.





Number of CP Carriers
Reported
Number of Non-CP
Carriers Reported Clinical Significance
exon 5 c.623GC p.G208A 22 3 Pathogenic
exon 5 c.738CT p.N246 common polymorphism common polymorphism Nonpathogenic
Adapted from www.pancreasgenetics.org, February 2, 2014. For a complete list of citations please visit the database website. The number of reported chronic
pancreatitis (CP) carriers is an approximation for the most frequent variants, because authors often published the same patients in multiple publications without
indicating the repetitive entries. Non-CP carriers include nonpenetrant family members, unrelated healthy control subjects or individuals with conditions other
than pancreatitis. The clinical significance field indicates our interpretation of the available genetic and functional data with respect to the pathogenic potential
of PRSS1 variants. The following genetic evidence was considered as indicative of pathogenic nature: segregation with disease, multiple reports worldwide of
affected carriers, and absence in unrelated controls. In case of rare variants, phenotypic similarity to well-characterized, hereditary pancreatitis-associated
mutations served as the basis for classification. Thus variants were considered pathogenic if they caused 1) increased autoactivation in the absence or presence
of chymotrypsin C (CTRC), 2) reduced secretion, indicative of potential misfolding, or 3) increased trypsinogen expression or secretion. Conversely, variants
that are expected to reduce trypsinogen expression were designated protective.
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PRSS1-related hereditary pancreatitis have a 40 –55% life-
time risk of developing pancreatic cancer (Ref. 66 and
references therein).
The PRSS1 Database
The first database for PRSS1 variants associated with
chronic pancreatitis was created by Dr. Niels Teich at the
University of Leipzig, Germany (61). Although the link is still
active (http://www.uni-leipzig.de/pancreasmutation/db.html),
the website has not been updated since 2006. To track the
increasing number of PRSS1 variants in the literature and to
help with classification of their clinical relevance, in 2012 we
created a new online database. Currently, the database lists 64
PRSS1 variants: 2 copy number mutations, 34 missense vari-
ants, 4 synonymous variants, 1 nonsense variant, 1 micro-
insertion, 1 hybrid gene, and 21 variants in noncoding
regions (Table 1). With respect to clinical significance, 25
variants are pathogenic (Table 2), 14 are nonpathogenic, 4
variants are protective, and 21 (mostly intronic) variants
have unknown significance. The database can be accessed at
www.pancreasgenetics.org.
Animal Models of PRSS1 Related Pancreatitis
Although considerable progress has been made in clarifying
the mechanism of PRSS1 mutations at the biochemical level,
animal models that recapitulate salient features of human
hereditary pancreatitis are still lacking. At the time of writing
this review, only two publications documented attempts to
generate such models. Selig et al. (47) created transgenic mice
with the coding DNA of human PRSS1 containing the
p.R122H mutation. The animals did not develop spontaneous
pancreatitis, and cerulein caused only slightly more severe
pancreatitis in transgenic mice relative to controls. Archer et al.
(1) described the spontaneous development of acute and
chronic pancreatitis in a transgenic line with the p.R122H
mutation introduced into the coding DNA of mouse trypsino-
gen isoform T8. Unfortunately, independent replications or
additional studies on this promising model have not been
published since 2006. It is also unclear whether the observed
phenotype was related to the expression of the mutant trypsino-
gen. Nevertheless, this study focused attention to the question
whether the biochemical effects human PRSS1 mutations
would be similar in the context of mouse and human trypsino-
gens and whether we can make use of mouse trypsinogens to
model the human disease. Recently, we demonstrated that the
mouse pancreas expresses four trypsinogen isoforms to high
levels (T7, T8, T9, and T20), and mouse Ctrc strongly inhibits
autoactivation of isoforms T8 and T9 through cleavage of the
autolysis loop (36). In sharp contrast to the human situation
(see Ref. 51 and Fig. 1), mutation p.R122H had no appreciable
effect on the autoactivation of T8 trypsinogen in the presence
of mouse Ctrc (36). These observations argue that human
pancreatitis-associated mutations may not recapitulate the
pathogenic biochemical phenotype in the context of mouse
trypsinogens.
Genetic deletion of mouse T7 was recently shown to abolish
intra-acinar trypsinogen activation in response to hyperstimu-
lation with cerulein, whereas severity of acute pancreatitis was
somewhat decreased but not diminished (11). Furthermore,
development of cerulein-induced chronic pancreatitis was un-
affected by the absence of T7 (44). These observations seem to
call into question the direct role of trypsinogen in the devel-
opment of pancreatitis and seem to be at odds with the
preponderance of human genetic and biochemical data dis-
cussed in this review. However, a more likely explanation for
the apparent contradiction is that the hyperstimulation model
employed in these studies does not mimic the pathological
pathway associated with human hereditary pancreatitis. Future
studies will be needed to shed more light on this intriguing
problem.
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Quantitation of DEFA1A3 gene copy number polymorphism 
by allele specific amplification and real-time PCR
Balázs Csaba Németh, Ádám Horváth, Márta Szekeres, Yvette Mándi, Ferenc Somogyvári*
ABSTRACT                        Some of the PCR based genotyping methods are faster and less expensive than 
sequencing in population-wide studies. One of the cost effective solutions is the allele specific 
amplification (ASA). We applied this method for quantitative analysis of defensin ?1 (DEFA1) and 
defensin ?3 (DEFA3) genes which are known to have copy number polymorphism in the human 
genome. The proteins encoded by these genes are human alpha defensins / human neutrophil 
peptides 1 and 3. Their antimicrobial mechanisms have an important role in the function of 
innate immune system. Our aim was to improve the reproducibility of ASA using 14 different 
mastermixes (MMX). Unfortunately, not all MMX-s are suitable for ASA investigations due to 
their different characteristics of polymerase activity. Here we investigated 14 commercial MMX-s 









































































































Figure 1. Principle of the allele specific amplification (ASA). The reaction takes place in two tubes. Each tube has one kind of forward extension 
primer which 3’ end perfectly complement to one of the target sequence. The reverse primer is common. The amplicon indicates the presence of 









???????? ??? ?????????? ??????????????????????????????










































































Figure 2. Test of the different mastermixes (MMX).MMX 1, 2 and 3 
could not differentiate between the DEFA1 and DEFA3 genes because 
of the proof reading activity of the Taq polymerase. MMX 4 produced 
aspecific bands as a side effect due to the presence of dsDNA binding 
protein which stabilizes the polymerase-template complex and able to 
amplify the target DNA in the presence of inhibitors (BioRad SsoFast 
EvaGreen Supermix). MMX 5 is suitable for ASA (Fermentas Maxima 
SybrGreen qPCR Mastermix and BioRad iTaq SybrGreen Supermix). 
Followed by annealing temperature optimisation MMX 6 also could 
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Background: Hereditary pancreatitis-associated mutations alter regulation of trypsinogen activation by chymotrypsin C.
Results: Activation of mouse trypsinogens T8 and T9 is inhibited by chymotrypsin C-mediated cleavage of the autolysis loop.
Conclusion: Chymotrypsin C regulates activation of human and mouse trypsinogens by different mechanisms.
Significance: Introduction of human pancreatitis-associated mutations into mouse trypsinogens will not recapitulate the
pathogenic biochemical effects.
Chymotrypsin C (CTRC) is a proteolytic regulator of tryp-
sinogen autoactivation in humans. CTRC cleavage of the
trypsinogen activation peptide stimulates autoactivation,
whereas cleavage of the calcium binding loop promotes trypsin-
ogen degradation. Trypsinogenmutations that alter these regu-
latory cleavages lead to increased intrapancreatic trypsinogen
activation and cause hereditary pancreatitis. The aim of this
study was to characterize the regulation of autoactivation of
mouse trypsinogens by mouse Ctrc. We found that the mouse
pancreas expresses four trypsinogen isoforms to high levels, T7,
T8, T9, and T20. Only the T7 activation peptide was cleaved by
mouse Ctrc, causing negligible stimulation of autoactivation.
Surprisingly, mouse Ctrc poorly cleaved the calcium binding
loop in all mouse trypsinogens. In contrast, mouse Ctrc readily
cleaved thePhe-150–Gly-151peptide bond in the autolysis loop
ofT8 andT9 and inhibited autoactivation.Mouse chymotrypsin
B also cleaved the same peptide bond but was 7-fold slower. T7
was less sensitive to chymotryptic regulation, which involved
slow cleavage of the Leu-149–Ser-150 peptide bond in the
autolysis loop.Modeling indicated steric proximity of the autol-
ysis loop and the activation peptide in trypsinogen, suggesting
the cleaved autolysis loopmay directly interfere with activation.
Weconclude that autoactivationofmouse trypsinogens is under
the control of mouse Ctrc with some notable differences from
the human situation. Thus, cleavage of the trypsinogen activa-
tion peptide or the calciumbinding loop byCtrc is unimportant.
Instead, inhibition of autoactivation via cleavage of the autolysis
loop is the dominant mechanism that canmitigate intrapancre-
atic trypsinogen activation.
Hereditary chronic pancreatitis is a human genetic disorder
caused by heterozygous mutations in the serine protease 1
(PRSS1) gene, which codes for the digestive proenzyme cationic
trypsinogen (1). High penetrance trypsinogen mutations such
as p.N29I and p.R122H are associated with an autosomal dom-
inant inheritance pattern, whereas mutations with lower pen-
etrance, exemplified by p.A16V, may be found not only in
hereditary but also in sporadic cases with no family history (2).
The disease mechanism involves increased autoactivation of
mutant trypsinogens within the pancreas due to altered regula-
tion by chymotrypsin C (CTRC)2 (3). Autoactivation of human
trypsinogens is proteolytically regulated by CTRC that cleaves
cationic trypsinogen at twodistinct regulatory sites. Cleavage of
the Phe-18–Asp-19 peptide bond in the activation peptide
results in a shorter activation peptide and increased autoacti-
vation (4). This cleavage is stimulated by pancreatitis-associ-
ated mutations p.N29I and p.A16V (3, 4). Cleavage of the Leu-
81–Glu-82 peptide bond in the calcium binding loop, together
with the trypsin-mediated autolytic cleavage of the Arg-122–
Val-123 peptide bond, results in rapid degradation and inacti-
vation of cationic trypsinogen (5). Mutations p.N29I and
p.R122H hamper CTRC-mediated degradation and thereby
increase trypsinogen autoactivation (3).
Despite the significant progress in understanding the mech-
anism of trypsinogen mutations at the biochemical level, ani-
mal models that recapitulate the human disease both pheno-
typically and mechanistically remain unavailable. Transgenic
mice carrying the coding DNA for human cationic trypsinogen
with the p.R122H mutation did not develop spontaneous pan-
creatitis, although small differences in the pathological
responseswere notedwhen pancreatitis was artificially induced
(6). In contrast, when mice were made transgenic with the
p.R122Hmutation introduced intomouse trypsinogen isoform
T8 (see Table 1), the resulting animals developed acute and
eventually chronic pancreatitis (7). Unfortunately, this remark-
able model has never been made available to the pancreas
research community for independent replication nor have
there been any follow-up studies published by the original
authors since 2006. It thus remains unclear whether the
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observed phenotypewas related to the expression of themutant
trypsinogen. Nonetheless, this study raises the question
whether the biochemical effects of the p.R122H mutation are
similar in the context of mouse and human trypsinogens and
whether we can utilize mouse trypsinogens to model the
human condition.
Considering the widespread use of mice in experimental
studies of the pancreas, it is surprising how little is known about
mouse trypsinogens. Watanabe and Ogasawara (8) reported
the purification of three trypsinogen isoforms from the mouse
pancreas. Stevenson et al. (9) cloned a trypsinogen cDNA, cor-
responding to isoform T20, from the pancreas and demon-
strated that the mouse genome contained multiple different
trypsinogen genes. This was later confirmed by Hood and co-
workers in 1997 (10) who sequenced the mouse T cell receptor
 locus on chromosome 6 and identified 20 trypsinogen genes
organized in two groups, one containing genes T1–T7 and the
other containing genes T8–T20 (Table 1). Eleven of the 20
genes are potentially functional (Table 1 and Fig. 1), whereas
the other nine genes are pseudogenes or relic genes. Ohmura et
al. (11) cloned the cDNA for isoformT9 from sperm acrosome.
It remains unknown, however, which isoforms of the 11 poten-
tially functional trypsinogen genes are expressed at the protein
level in the mouse pancreas. More recently, genetic deletion of
T7 indicated that this isoform may contribute as much as 60%
of pancreatic trypsinogens (12, 13). The authors also found that
despite the presence of other trypsinogen isoforms, mice defi-
cient in T7 did not respond to secretagogue hyperstimulation
with the characteristic intra-acinar cell trypsinogen activation,
an early event in acute pancreatitis. These new findings suggest
that the differentmouse trypsinogen isoforms vary in their acti-
vation kinetics and highlight the need for their comparative
biochemical characterization. Therefore, in this study, we iden-
tified the major trypsinogen isoforms in the mouse pancreas,
expressed these recombinantly, and studied their autoactiva-
tion and regulation by mouse Ctrc.
EXPERIMENTAL PROCEDURES
Nomenclature—Amino acid residues are numbered start-
ing with the initiator methionine of the primary translation
product, according to the recommendations of the Human
GenomeVariation Society. Note that because of an extra Asp
residue (Asp-23) in the activation peptide of T7, amino acid
numbering in this isoform is shifted by one relative to human
and other mouse trypsinogens. Autolysis loop refers to the
flexible region between residues 146 and 154 in trypsinogen
(Fig. 1).
Plasmid Construction and Mutagenesis—Construction of
the pTrapT7-intein-Hu1 and pcDNA3.1()-CTRB2 expres-
sion plasmids harboring the coding sequence for human cat-
ionic trypsinogen (Hu1) and human chymotrypsinogen B2
(CTRB2)was reported previously (5, 14).Mutation p.S150Fwas
introduced into human cationic trypsinogen using overlap-ex-
tension PCR mutagenesis. Expression plasmids for mouse
trypsinogens were created in the pTrapT7 plasmid previously
designed for bacterial expression of human trypsinogens (15,
16). The coding DNA was PCR-amplified from commercial
IMAGE clones and cloned into pTrapT7 using NcoI and SalI
restriction sites. In all constructs, the N-terminal secretory sig-
nal peptide was replaced with a Met-Ala sequence. In T20, the
stop codonwas changed fromamber (TAG) to ochre (TAA). T7
was amplified from IMAGE clone 30306963 (GenBankTM
accession BC061093.1) using T7 NcoI sense (5-AAA TTT
CCA TGG CTC TCC CCC TGG ATG ATG ATG ATG-3,
where the NcoI site is underlined) and T7 SalI antisense
(5-AAA TTT GTC GAC TTA GTT GGC AGC GAT GGT
CTGCTG-3, where the SalI site is underlined) primers. T8was
amplified from IMAGEclone 30306436 (GenBankTMaccession
BC061135.1) using T8 NcoI sense (5-AAA TTT CCA TGG
CTTTCCCTGTGGATGATGATGACA-3, where theNcoI
site is underlined) and T8 SalI antisense (5-AAA TTT GTC
GACTTAGTTTGCAGCAATGGTGTTTTG-3, where the
TABLE 1
Trypsinogen genes in the mouse genome
Table is based on the 1997 GenBankTM submissions AE000663.1, AE000664.1, and AE000665.1, which first reported the genomic sequence of the mouse T cell receptor 
locus. The original annotation described genes T2 and T14 as relic genes based on the absence of exon 1. The more recent annotation to the mouse genome identified the
first exons for both genes, and we re-classified these as pseudogenes.
Gene Function Notes
T1 Pseudogene Exons give in-frame translation; product may serve unknown function
Also known as protease, serine 58 (Prss58), GenBankTM NM_175020.3
T2 Pseudogene Exons give in-frame translation; product may serve unknown function
T3 Pseudogene A single nucleotide deletion in exon 2 leads to a frameshift
T4 Functional
T5 Functional
T6 Relic This gene has only exons 2 and 3
T7 Functional
T8 Functional Also known as trypsin4 (Try 4), GenBankTM NM_011646.5
T9 Functional Also known as trypsin5 (Try 5) GenBankTM NM_001003405.4
Also known as TESP4, GenBankTM AB017031.1
T10 Functional
T11 Functional Also known as protease, serine,3 (Prss3), GenBankTM NM_011645.2
T12 Functional
T13 Relic This gene has only exons 3 and 5
T14 Pseudogene This gene has a defective splice site after exon 2
T15 Functional
T16 Functional Also known as protease, serine,1 (Prss1), GenBankTM NM_053243.2
T17 Relic This gene is missing exons 1 and 2
T18 Relic This gene is missing exons 1 and 2
T19 Relic This gene has only exon 3
T20 Functional Also known as protease, serine,2 (Prss2), GenBankTM NM_009430.2
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SalI site is underlined) primers. T9 was amplified from IMAGE
clone 6433372 (GenBankTM accession CF581321.1) using T8
NcoI sense and T9 SalI antisense (5-AAA TTT GTC GAC
TTAGTT TGCGGCAATGGTGTC CTG-3, where the SalI
site is underlined) primers. T20 was amplified from IMAGE
clone 6433384 (GenBankTM accession CF581305.1) using T20
NcoI sense (5-AAA TTT CCA TGG CTT TCC CTG TGG
ATG ATG ATG ACA-3, where the NcoI site is underlined)
and T20 SalI antisense (5-AAA TTT GTC GAC TTA GTT
GTC AGC AAT TGT GTT CTG-3, where the SalI site is
underlined) primers. Mutations p.L82A, p.R123H, and
p.L149A in T7 and p.R122H in T8 were created by overlap
extension PCR and cloned into the pTrapT7 plasmid.
Expression plasmids for mouse chymotrypsinogens carrying
a His10 affinity tag were created in the pcDNA3.1() plasmid.
The coding DNA for mouse chymotrypsinogen C (Ctrc) was
PCR-amplified from a cDNA preparation from CD-1 mouse
pancreas, using mouse CTRC XhoI sense (5-AAA TTT CTC
GAG ACC TGA ACC ATG TTG GGA ATT ACA GTC-3,
where the XhoI site is underlined) and mouse CTRC EcoRI
antisense (5-AAATTTGAATTCGGCGTCGAGACTTCT
GGA ACC GTC TCT-3, where the EcoRI site is underlined)
primers and cloned into pcDNA3.1() using XhoI and EcoRI.
A His10 affinity tag was added to the C terminus using gene
synthesis (GenScript, Piscataway, NJ) and the XcmI and
EcoRI sites. In this synthetic construct Leu-268 was deleted
to prevent autolytic cleavage of the His tag. The coding DNA
for mouse chymotrypsinogen B (Ctrb, GenBankTM accession
NM_025583.2) with a C-terminal His10 tag was custom-syn-
thesized (GenScript) and cloned into pcDNA3.1() using
XhoI and BamHI.
Purification and Identification of Trypsinogens from CD-1
Mouse Pancreas—Pancreata (2 to 3) were homogenized in 10
ml of 20 mM Na-HEPES (pH 7.4) buffer, briefly sonicated, and
centrifuged at 13,500 rpm for 10min, and4ml of supernatant
was loaded onto a 2-ml ecotin column. Ecotin is a pan-serine
protease inhibitor from Escherichia coli, which can bind the
inactive zymogen forms of pancreatic serine proteases (17, 18).
The ecotin column was washed with 20 mM Tris-HCl (pH 8.0),
0.2 MNaCl, and trypsinogens were eluted with 50mMHCl. The
flow-through contained no trypsinogen, as judged by the
lack of trypsin activity after incubation with enteropepti-
dase. The ecotin-eluate contained all trypsinogen isoforms
and low levels of chymotrypsinogen and proelastase. Four ml
of eluate was loaded onto a 2-ml Mono S column equili-
brated with 20 mM sodium acetate (pH 5.0), and trypsino-
gens were eluted with a 0–0.5MMNaCl gradient at 1 ml/min
flow rate (Fig. 2A). The eluted proteins were separated by
SDS-PAGE and transferred to a PVDF membrane, and indi-
vidual bands were subjected to N-terminal protein sequenc-
ing by Edman degradation (Midwest Analytical, St. Louis,
MO). Peaks corresponding to T8, T9, and T20 were also
subjected to in-gel digestion followed by LC-MS/MS mass
spectrometry (ProtTech, Phoenixville, PA). Relative abun-
dance of trypsinogen isoforms was calculated from the peak
areas corrected for the ultraviolet extinction coefficient dif-
ferences. The T9-T8 peaks were also corrected for Ctrb con-
tamination, which was determined from the relative trypsin
and chymotrypsin activities after activation with enteropep-
tidase. Because of the poor separation of T8 and T9, these
two isoforms were calculated as one.
Identification of Trypsinogens fromNMRIMouse Pancreas by
Two-dimensional PAGE and Mass Spectrometry—Pancreata
were homogenized in a Potter homogenizer at 2,500 rpm in
ice-cold homogenization buffer (HS buffer, 250mM sucrose, 10
mM citric acid (pH 6.0), 0.5 mM EGTA, 0.1 mM MgSO4) with
Complete mini protease inhibitor mixture (Roche Applied Sci-
ence). The homogenate was centrifuged for 5 min at 500  g,
and the post-nuclear supernatant was centrifuged at 1,300 g
for 15 min at 4 °C. This zymogen granule-enriched pellet was
washedwithHS buffer and dissolved in sample buffer (5 M urea,
2 M thiourea, 2 M CHAPS, 2% ASB-14, 0.05% SB3–10) with
Complete mini protease inhibitor mixture and stored in ali-
quots at80 °C.
Immobilized pH gradient (IPG) strips (pH 3–10, 13 cm)were
rehydrated overnight in sample buffer containing 65 mM (10
mg/ml) dithiothreitol (DTT), 2% IPG buffer, and 0.01% Serva
blue. The zymogen granule-enriched pancreatic extract dis-
solved in sample buffer (50–100g) was supplementedwith 65
mM (10 mg/ml) DTT, 2% IPG buffer, 0.01% Serva blue and
cup-loaded at the anode end of the strips. Isoelectric focusing
was performed undermineral oil at 3,500 Vwith a current limit
of 50Aper strip up to 8,000 total volt hours using an IPGphor
unit (Amersham Biosciences). Strips were subsequently incu-
bated in equilibration buffer (0.5 M Tris-HCl (pH 8.8), 6 M urea,
2%SDS, 30%glycerol) containing 50mMDTT followed by incu-
bation in 0.3 M acrylamide, for 15min each. For electrophoresis
in the second dimension, the IPG strips were applied onto a
10.5% SDS-polyacrylamide gel, and proteins were separated
according to Schaegger and van Jagow (19). Gels were stained
with silver nitrate by a modified method of Blum et al. (20). For
estimation of relative protein content of trypsinogen spots, gels
were further stainedwith Serva blue, according toNeuhoff et al.
(21). Gel images were analyzed, and spot intensities were quan-
titated with the ImageMaster 2D Elute version 3.10 software
(Amersham Biosciences). Protein spots of interest were
excised, de-stained, and digested in-gel with sequencing grade
bovine trypsin (RocheApplied Science, 12.5 ng/l) overnight at
37 °C. Peptides were extracted from gel slices, andmass spectra
were analyzed usingMALDI-TOFReflex IIImass spectrometer
machine (Bruker Daltonics, Germany) in linear mode with
external calibration. Peptide fingerprint data analysis was per-
formed using the web-based ProFound database with a mass
tolerance of 250 ppm.
Expression and Purification of Trypsinogens—Human cati-
onic trypsinogen was expressed in the aminopeptidase P-defi-
cient LG-3 E. coli strain as fusions with a self-splicing mini-
intein, as described previously (14, 22). Mouse trypsinogens
were expressed in E. coli BL21(DE3), as described for human
trypsinogens previously (15, 16). Isolation of cytoplasmic
inclusion bodies, in vitro refolding, and purification with
ecotin affinity chromatography were performed according
to published protocols (14–16, 18, 22). The preparations
were more than 90% pure, as judged by SDS-PAGE and Coo-
massie Blue staining. Concentrations of trypsinogen solu-
tions were calculated from their UV absorbance at 280 nm
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using the following extinction coefficients: 37,525 M1cm1
(human cationic trypsinogen), 39,140 M1cm1 (mouse T7),
34,670 M1cm1 (mouse T8 and T9), and 43,150 M1cm1
(mouse T20).
Expression and Purification of Chymotrypsinogens—Human
CTRB2 and mouse Ctrb and Ctrc carrying His10 affinity tags
were expressed in transiently transfected HEK 293T cells and
purified from 450ml of conditionedmediumusing nickel affin-
ity chromatography as reported previously (3, 23). Aliquots (75
l) of the eluted 5-ml fractions were analyzed by 15% SDS-
PAGE and Coomassie Blue staining, and peak fractions with
90% purity were pooled and dialyzed for 72 h against three
changes of 1 liter of 0.1 M Tris-HCl (pH 8.0) buffer containing
150 mM NaCl. The dialyzed chymotrypsinogen solutions were
concentrated using a Vivaspin 20 concentrator (10-kDamolec-
ular mass cutoff). Chymotrypsinogens were activated with
trypsin, and active chymotrypsin concentrations were deter-
mined by active site titration with ecotin, as described previ-
ously (24).
Trypsinogen Autoactivation—Trypsinogen at 2 M concen-
tration was incubated in the absence or presence of 25 nM chy-
motrypsin, as indicated, and 10 nM initial trypsin in 0.1 M Tris-
HCl (pH 8.0), 1 or 10 mM CaCl2, and 0.05% Tween 20 (final
concentrations) at 37 °C. At given times, 1.5-l aliquots were
withdrawn and mixed with 48.5 l of assay buffer containing
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20.
Trypsin activity was measured by adding 150 l of 200 M
N-CBZ-Gly-Pro-Arg-p-nitroanilide substrate dissolved in
assay buffer and following the release of the yellow p-nitroani-
line at 405 nm in a SpectraMax plus384 microplate reader
(Molecular Devices, Sunnyvale, CA) for 1 min. Reaction rates
were calculated from fits to the initial linear portions of the
curves.
TrypsinogenActivationwith Enteropeptidase—Todetermine
the maximal trypsin activity attainable after full activation, 2
M trypsinogen was incubated in 0.1 M Tris-HCl (pH 8.0), 10
mM CaCl2, and 0.05% Tween 20 (final concentrations) at 37 °C
with 140 ng/ml final concentration of human enteropeptidase
(R&D Systems, Minneapolis, MN) for 1 h, and trypsin activity
was measured as described above. This activity was designated
as 100%, and trypsin activity measured in autoactivation exper-
iments was expressed relative to this value. The 100% values































































Activation peptide Signal peptide Ca-binding loop 
←8
6
Hu1  MNPLLILTFVAAALA-APFDDDDKIVGGYNCEENSVPYQVSLNSGY-HFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQ 
T4   MKIITFFTFLGAAVA-LPANSDDKIVGGYTCPKHSVPYQVSLNDGISHQCGGSLISDQWVLSAAHCYKRRLQVRLGEHNIDVLEGGEQ 
T5   MKIIFFFTFLGAAVA-LPANSDDKIVGGYTCPKHSVPYQVSLNDGISHQCGGSLINDQWVLSAAHCYKRRLQVRLGEHNIDVLEGGEQ 
T7   MKTLIFLAFLGAAVALPLDDDDDKIVGGYTCQRNALPYQVSLNSGY-HFCGGSLINSQWVVSAAHCYKSRIQVRLGEHNIDALEGGEQ 
T8   MRALLFLALVGAAVA-FPVDDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNEQ 
T9   MNSLLFLALVGAAVA-FPVDDDDKIVGGYTCRENSIPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T10  MSTLLFLALVGAAVA-FPVDDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNEQ 
T11  MNALLILALVGAAVA-FPVDDDDKIVGGYTCQENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T12  MSALLFLALVGAAVA--FPVDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNIKVLEGNEQ 
T15  MNAFLILALVGAAVA-FPVDDDDKIVGGYTCQENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T16  MSALLFLALVGAAVA-FPVDDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T20  MSALLILALVGAAVA-FPVDDDDKIVGGYTCRESSVPYQVSLNAGY-HFCGGSLINDQWVVSAAHCYKYRIQVRLGEHNINVLEGNEQ 
Hu1  FINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEAS 
T4   FIDAEKIIRHPDYNKDTVDNDIMLIKLKSPAILNSQVSTVSLPRSCASTNAQCLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKS 
T5   FIDAEKIIRHPDYNKDTVDNDIMLIKLKSPAILNSQVSTVSLPRSCASTNAQCLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKS 
T7   FIDAAKIIRHPNYNANTYNNDIMLIKLKTAATLNSRVSTVALPRSCPSAGTRCLVSGWGNTLSSGTNYPSLLQCLDAPVLSDSSCTSS 
T8   FVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEAS 
T9   FVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEAS 
T10  FIDAANIIKHPKFKKKTLDNDIMLIKLSSPVTLNARVATVALPSSCAAAGTQCLISGWGNTLSSGVNNPDLLQCLDAPLLPQADCEAS 
T11  FVNAAKIIKHPNFNRKTLNNDIMLLKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T12  FVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T15  FVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T16  FIDAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T20  FVDSAKIIRHPNYNSWTLDNDIMLIKLASPVTLNARVASVPLPSSCAPAGTQCLISGWVTLNARVASVPDLLQCVDAPVLPQADCEAS 
Hu1  YPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS 
T4   YPGQITSNMFCLGFLEGGKDSCDGDSGGPVVCNGEIQGIVSWGSVCAMRGKPGVYTKVCNYLSWIQETMANN- 
T5   YPGQITSNMFCLGFLEGGKDSCDGDSGGPVVCNGEIQGIVSWGSVCAMRGKPGVYTKVCNYLSWIQETMANN- 
T7   YPGKITSNMFCLGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGYGCAQRGKPGVYTKVCKYVNWIQQTIAAN- 
T8   YPGKITNNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCALKDNPGVYTKVCNYVDWIQNTIAAN- 
T9   YPGKITNNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCALKDNPGVYTKVCNYVDWIQDTIAAN- 
T10  YPGKITKNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCAQKDNPGVYTKVCNYVDWIQNTIAAN- 
T11  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNRELQGIVSWGYGCALPDNPGVYTKVCNYVDWIQDTIAAN- 
T12  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCALADNPGVYTKVCNYVDWIQDTIAAN- 
T15  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCALPDNPGVYTKVCNYVDWIQDTIAAN- 
T16  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCALPDNPGVYTKVCNYVDWIQDTIAAN- 





FIGURE1.Primary sequencealignmentofhumancationic trypsinogen (Hu1) and11potentially functionalmouse trypsinogens.Numbering startswith
the initiatormethionine.Note that due to insertions in T4, T5, andT7, thenumbering is shiftedbyoneafter the insertion sites, relative to the indicatednumbers.
Similarly, a deletion in T12 shifts numbering. Trypsin cleavage sites are highlighted in blue and chymotrypsin C cleavage sites in red. Cys residues are indicated
in green and the catalytic triad inmagenta. The original annotation predicted deletion of Arg-69 (red letter) in T4 and T5, but more recent annotations include
this residue. See text for details.
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Gel Electrophoresis—Trypsinogen samples (75l,3.8g of
protein) were precipitated with trichloroacetic acid (10% final
concentration), and the precipitate was recovered by centrifu-
gation, dissolved in 15 l of Laemmli sample buffer containing
100 mM DTT (final concentration), and heat-denatured at
95 °C for 5 min. Electrophoretic separation was performed on
15% SDS-PAGE mini gels in standard Tris-glycine buffer. Gels
were stained with Brilliant Blue R-250 and destained as
described earlier (25). Quantitation of bands was carried out
with the GelDoc XR gel documentation system and Image
Lab 3.0 software (Bio-Rad).
RESULTS
Identification of Major Trypsinogen Isoforms in the Mouse
Pancreas—To identify trypsinogen isoforms expressed at high
levels in the mouse pancreas, we used ecotin-affinity chroma-
tography to purify trypsinogens en bloc from pancreas tissue
extracts of the outbred CD-1 mouse strain. Trypsinogens were
eluted under acidic conditions from the ecotin column and
immediately loaded onto a Mono S cation exchange column
equilibrated with 20 mM sodium acetate (pH 5.0). The Mono S
column was developed with a NaCl gradient, resulting in five
FIGURE 2. Identification of major trypsinogen isoforms expressed in the
mouse pancreas. A, chromatographic separation of trypsinogen isoforms.
Trypsinogens were purified from pancreas tissue extracts of CD-1mice using
ecotin affinity chromatography, and the ecotin eluate was loaded onto a
MonoS columnequilibratedwith 20mMsodiumacetate (pH5.0). The column
wasdevelopedwith a linear gradient of 0–0.5MNaCl. Peakswere analyzedby
SDS-PAGE, N-terminal sequencing, and mass spectrometry, as described
under “Experimental Procedures” and “Results.” B, two-dimensional PAGE of
a zymogen granule-enriched fraction of pancreas tissue from NMRI mice. Sil-
ver-stained spots were digested with trypsin and analyzed by peptide mass
fingerprinting, as described under “Experimental Procedures.” Spots for tryp-
sinogen isoforms T7, T8, T9, and T20, proelastase 3 (Ela3); chymotrypsinogen
B (Ctrb), and proelastase 1 (Ela1) are indicated.
FIGURE 3.Autoactivationofmouse trypsinogens. Trypsinogenswere incu-
bated at 2Mconcentrationwith 10nM initial trypsin in 0.1 M Tris-HCl (pH8.0),
1 mM CaCl2 (A) or 10 mM CaCl2 (B) and 0.05% Tween 20 at 37 °C. Aliquots (1.5
l) were withdrawn at the indicated times, and trypsin activity was deter-
mined as described under “Experimental Procedures.” Trypsin activity was
expressedaspercentageof themaximal activity determinedby full activation
with enteropeptidase. Representative experiments from four replicates are
shown.
TABLE 2
Relative expression levels ofmajor trypsinogen isoforms in themouse
pancreas determined by ion exchange chromatography (CD-1) or
two-dimensional gel electrophoresis (NMRI)
The averages from four experiments S.D. are indicated. See text for details.
Mouse strain
Relative expression levels (% of total)
T7 T8 T9 T20
CD-1 41 1 47 3 12 2
NMRI 25 1 33 1 27 1 15 2
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peaks (Fig. 2A). Edman degradation unambiguously identified
the small fourth peak as proelastase 3 (N terminus is CGQPS)
and the large fifth peak as the cationic T7 trypsinogen isoform,
which has a unique N-terminal sequence, LPLDD (Fig. 1). The
other three peaks proved to be trypsinogens but had the sameN
termini, FPVDD; therefore, these were subjected to in-gel tryp-
tic digestion followed by mass spectrometric nanosequencing,
which revealed the identity of the first peak as isoform T20 and
the second and third peaks as isoformsT9 andT8 (Fig. 2A). The
latter two isoforms are nearly identical in their amino acid
sequence (99% identity, Fig. 1) and MS/MS peptide coverage
did not include any regions thatwere distinctive.On the basis of
a slight difference in their ionic character, T9 was assigned to
the second peak and T8 to the third peak. N-terminal sequenc-
ing of the combined second/third peaks after activation of tryp-
sinogen to trypsin indicated a mixture of Val/Ile amino acids at
position 35 (IVGGYTCRENS(V/I)P), with a preponderance of
Val, confirming that the smaller second peak is T9 (containing
FIGURE 4. Effect of mouse Ctrc onmouse trypsinogen T7. A, autoactivation was measured in 1 and 10 mM CaCl2 in the absence (solid symbols) or presence
(open symbols) of 25 nMmouse Ctrc, as described under “Experimental Procedures.” B, SDS-PAGE analysis of the autoactivation reaction in 1mMCaCl2. Samples
were withdrawn at the indicated time points, precipitated with trichloroacetic acid, electrophoresed, and stained as described under “Experimental Proce-
dures.” C, cleavage of T7 trypsinogen by 25 nM mouse Ctrc. Incubations were performed with 2 M trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence or
presence of 10 mM CaCl2. Samples were precipitated with trichloroacetic acid and analyzed by SDS-PAGE and Coomassie Blue staining. Representative
experiments from three replicates are shown. D, cleavage of the activation peptide of trypsinogen T7 by mouse Ctrc. Primary structure of the native T7
activation peptidewith proteolytic cleavage sites for Ctrc and trypsin is also indicated. Note that theN-terminal amino acid ofmature trypsinogen is Leu-16, as
the 15-amino acid-long secretory signal peptide is removed in the endoplasmic reticulum. Trypsinogen was incubated at 2M concentration with 25 nM Ctrc
in 0.1 M Tris-HCl (pH 8.0) and 0 or 10mMCaCl2 (final concentrations) at 37 °C. To prevent autoactivation, 25 nM human SPINK1 trypsin inhibitor was included. At
the indicated times, reactionswere terminated by precipitationwith trichloroacetic acid, and sampleswere analyzed by nonreducing SDS-PAGE and Coomas-
sie Blue staining. Relevant segments of representative gels (from two replicates) demonstrate the small mobility shift of the trypsinogen band caused by
Ctrc-mediated cleavageof the Leu-18–Asp-19peptidebond.Note that the rapid rateof cleavage is partly due to theaddedMet-Ala sequenceat theN terminus
of recombinant T7.
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Ile-35) and the larger third peak is T8 (containing Val-35) (see
Fig. 1). Both N-terminal sequencing (CGVPA) and MS/MS
indicated that the T9/T8 peaks were contaminated with some
Ctrb. Quantitative evaluation of trypsinogen peaks was per-
formed as described under “Experimental Procedures,” and the
following relative expression levels were obtained (mean 
S.D., n 4): 41 1% for T7; 47 3% for T8 and T9 combined,
and 12 2% for T20 (Table 2).
To confirm our findings with an independent method and in
a different mouse strain, we used a proteomic approach based
on two-dimensional PAGE, followed by in gel-digestion of sil-
ver-stained protein spots and peptide mass fingerprinting after
MALDI-TOF mass spectrometry. Fig. 2B demonstrates two-
dimensional PAGE protein patterns of a granule-enriched pan-
creas homogenate from the outbredNMRImouse strain. In the
20–37-kDa molecular mass range, the same four trypsinogen
isoforms were identified as with the chromatographic
approach. The relative proportions of spot intensities (mean
S.D., n 4) were 25 1% for T7, 33 1% for T8, 27 1% for
T9, and 15 2% for T20 (Table 2). These values compare fairly
well, within experimental error, with those obtained for CD-1
mice.
Autoactivation ofMouse Trypsinogens—Large scale purifica-
tion of different trypsinogen isoforms from themouse pancreas
is impractical, and preparations may be contaminated with low
levels of other pancreatic proteases. In contrast, recombinant
expression should provide highly purified homogeneous
enzyme preparations. We previously established methodology
for the expression and purification of human trypsinogens (15,
16), and here we used the same approach to obtain functionally
competent mouse trypsinogen preparations. Trypsinogens
were expressed in E. coli as inclusion bodies, renatured in vitro
and purified by ecotin-affinity chromatography. When mouse
trypsinogens were incubated in 1mMCaCl2 at pH 8.0, isoforms
T7, T8, and T9 autoactivated and reached about 40–60% of
potentially attainable trypsin levels, indicating that some
autocatalytic (trypsin-mediated) degradation occurred (Fig.
3A) during autoactivation. In contrast, T20 did not autoac-
tivate under these conditions. As expected, high concentra-
tions of calcium (10 mM) increased the rate of autoactivation
and stabilized trypsinogens against degradation, yielding
80–100% of attainable trypsin levels. The stimulatory effect
of calcium on the autoactivation of T20 was particularly
striking (Fig. 3B).
FIGURE 5. Effect of mutations p.L82A and p.L149A onmouse trypsinogen T7. A, autoactivation was measured in 1 mM CaCl2 as described under “Experi-
mental Procedures.” Trypsin activity was expressed as percentage of the maximal activity determined by full activation with enteropeptidase. B, cleavage of
wild-type and p.L82A T7 trypsinogen by 25 nM mouse Ctrc. C, cleavage of wild-type and p.L149A T7 trypsinogen by 25 nM mouse Ctrc. Incubations were
performed with 2 M trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence of calcium. Trypsinogen samples were precipitated with trichloroacetic acid and
analyzed by SDS-PAGE and Coomassie Blue staining. Representative experiments from two replicates are shown.
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Effect of Mouse Ctrc on T7 Trypsinogen—Addition of 25 nM
mouse Ctrc to the autoactivation assays of isoform T7 moder-
ately (by 35%) reduced trypsin levels in 1 mM calcium and
slightly stimulated the rate of autoactivation in 10 mM calcium
(Fig. 4A). SDS-PAGE analysis of the autoactivation reaction in 1
mM calcium, in the absence of Ctrc, confirmed conversion of
the T7 trypsinogen band to trypsin and also indicated degrada-
tion fragments generated by cleavages of trypsin-sensitive pep-
tide bonds Arg-123–Val-124 and Lys-194–Asp-195 (Fig. 4B,
left panel, see also Fig. 1). These were identified by N-terminal
sequencing, similarity to the published degradation fragments
of rat anionic trypsinogen-2 (26), and comparison of the band-
ing pattern with that of the T7 p.R123H mutant (see below).
Note that because of an extra amino acid in the activation pep-
tide of T7, amino acid numbering is shifted by one relative to
human and other mouse trypsinogens (see Fig. 1). Cleavage
after Arg-123 should result in a fully active two-chain trypsin
(27, 28), whereas cleavage after Lys-194 causes inactivation (26,
29). Ctrc caused a small shift of the T7 trypsinogen band, sug-
gesting cleavage of the activation peptide (Fig. 4B, right panel).
In addition, the banding pattern of degradation fragments
becamemore complex, which is consistent with the lower tryp-
sin activity attained during autoactivation in 1 mM calcium in
the presence of Ctrc.
To identify Ctrc-mediated cleavages of trypsinogen, we per-
formed digestion experiments with short incubation times
when no trypsinogen activation took place and no trypsin activ-
ity was present. Under these conditions, slow cleavage of the
Leu-149–Ser-150 peptide bond in the autolysis loop was
observed in the absence of calcium (Fig. 4C, left panel), and this
was completely inhibited by 10 mM calcium (Fig. 4C, right
panel, see also Fig. 1). The Leu-82–Glu-83 peptide bond (cor-
responding to Leu-81–Glu-82 in human trypsinogens and
other studied mouse isoforms) in the calcium binding loop was
not cleaved to a detectable extent. This finding suggested that
in T7 the moderate degradation observed during autoactiva-
tion in 1 mM calcium in the presence of Ctrc is mediated by
cleavage of the Leu-149–Ser-150 peptide bond. To confirm this
assumption, we compared autoactivation of the T7 p.L82A and
p.L149A mutants in 1 mM calcium and found that only muta-
tion of p.L149A protected against degradation in the presence
of Ctrc (Fig. 5). Interestingly, mutant p.L82A suffered Ctrc-de-
pendent degradation during autoactivation to an even larger
extent than wild-type T7.
N-terminal Processing of T7 Trypsinogen by Mouse Ctrc—
Among the activation peptide sequences of mouse trypsino-
gens, only T7 contains a potentially Ctrc-sensitive peptide
bond, Leu-18–Asp-19 (Fig. 1). Inspection of Fig. 4B revealed
that the T7 trypsinogen band became slightly shifted as a result
of treatment with Ctrc, suggesting that the activation peptide
might be cleaved at Leu-18–Asp-19. When samples were run
under nonreducing conditions, the mobility shift caused by
N-terminal processing of the T7 activation peptide became
more apparent (Fig. 4D), andN-terminal sequencing confirmed
the predicted cleavage site. However, in contrast to human cat-
ionic trypsinogen, the rate of autoactivation of N-terminally
processed T7 was only negligibly stimulated (see Fig. 4A, right
panel), indicating that Ctrc does not regulate activation of
mouse trypsinogens through cleavage of the activation peptide.
Effect of the p.R123H Mutation on T7 Trypsinogen—Muta-
tion p.R123H protected T7 trypsinogen against degradation
during autoactivation in 1 mM calcium in the presence of Ctrc
(Fig. 6); however, it had no effect on the cleavage of the Leu-
149–Ser-150 peptide bond per se. This observation indicates
thatmoderate degradation ofT7 during autoactivation is due to
the combined effects of Ctrc-mediated and tryptic cleavages
after Leu-149 and Arg-123, respectively (see Fig. 1).
Effect of Mouse Ctrc on T8 and T9 Trypsinogen—Mouse Ctrc
almost completely inhibited autoactivation of T8 and T9 tryp-
sinogen in 1 mM calcium and markedly reduced it in 10 mM
calcium (Figs. 7 and 8). This inhibitory effect was not due to
degradation, as addition of enteropeptidase to the Ctrc-treated
samples resulted in the appearance of highly significant trypsin
activity. SDS-PAGE analysis of autoactivation in 1mM calcium,
FIGURE 6. Effect of mutation p.R123H on mouse trypsinogen T7. A, auto-
activation was measured in 1 mM CaCl2 as described under “Experimental
Procedures.” Trypsin activity was expressed as percentage of the maximal
activity determined by full activation with enteropeptidase. B, SDS-PAGE
analysis of the autoactivation reaction. Sampleswerewithdrawn at indicated
times, precipitated with trichloroacetic acid, electrophoresed, and stained as
described under “Experimental Procedures.” C, cleavage of wild-type and
p.R123H T7 trypsinogen by 25 nM mouse Ctrc. Incubations were performed
with 2 M trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence of calcium.
Samples were precipitated with trichloroacetic acid and analyzed by SDS-
PAGE and Coomassie Blue staining. Cleavage products were identified with
N-terminal sequencing. Representative experiments from two replicates are
shown.
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in the absence of Ctrc, demonstrated conversion of trypsinogen
to trypsin with the characteristic degradation fragments gener-
ated by tryptic cleavage of the Arg-122–Val-123 and Lys-193–
Asp-194 peptide bonds (Figs. 7B and 8B, left panel, see also Fig.
1). In dramatic contrast, when autoactivation was followed in
the presence of Ctrc, no trypsin band nor any of the tryptic
degradation bands were observed. Instead, Ctrc rapidly and
completely cleaved T8 and T9 trypsinogen at a single site,
which N-terminal sequencing revealed as the Phe-150–Gly-
151 peptide bond (Figs. 7B and 8B, right panel). This peptide
bond lies within the so-called autolysis loop, a flexible segment
between residues 146 and 154 (Fig. 1).When cleavage of T8 and
T9 trypsinogen byCtrcwas studiedwith short incubation times
(i.e. before autoactivation occurred), both isoforms were pri-
marily cleaved at the Phe-150–Gly-151 peptide bond, with
minimal cleavage observed at the Leu-81–Glu-82 peptide bond
in the absence of calcium (Figs. 7C and 8C). Cleavage of the
Phe-150–Gly-151 peptide bond was slower but still readily
detectable in 10 mM calcium.
Cleavage of the Phe-150–Gly-151 Peptide Bond by Mouse
ChymotrypsinB (Ctrb)—Regulation of autoactivation of human
cationic trypsinogen by human CTRC is highly specific, and
other chymotrypsins and elastases do not cleave the CTRC
cleavage sites. To test whether the same Ctrc specificity exists
in the mouse, we compared the effect of mouse Ctrb and Ctrc
on T8 trypsinogen. As shown in Fig. 9A, autoactivation of T8
was much less effectively inhibited by 25 nM Ctrb than by an
equimolar concentration of Ctrc. In degradation experiments,
Ctrb cleaved the Phe-150–Gly-151 peptide bond at a more
than 7-fold slower rate than Ctrc (Fig. 9, B and C).
Effect of the p.R122H Mutation on T8 Trypsinogen—Muta-
tion p.R122H slightly stimulated autoactivation of T8 trypsin-
ogen in 1 mM calcium, in the absence of Ctrc (Fig. 10A). In the
presence of Ctrc, however, autoactivation was strongly inhib-
ited by Ctrc, approximately to the same extent as seen with
wild-type T8 (Fig. 10B, cf. Fig. 7A). Consistent with the robust
inhibitory effect, the Phe-150–Gly-151 peptide bond was
cleaved by Ctrc almost as well in T8 p.R122H trypsinogen as in
wild-type T8 (Fig. 10C).
Cleavage of the Autolysis Loop in the p.S150F Human Cati-
onic TrypsinogenMutant Inhibits Autoactivation—Themajor-
ity of mammalian trypsinogens do not contain Phe-150 in their
autolysis loop. To test whether introduction of Phe-150 would
reconstitute the chymotrypsin-dependent autoactivation inhi-
FIGURE 7. Effect of mouse Ctrc onmouse trypsinogen T8. A, autoactivation was measured in 1 and 10mM CaCl2, in the absence (solid symbols) or presence
(open symbols) of 25nMmouseCtrc, as describedunder “Experimental Procedures.”Where indicated, 2l of 1.4g/ml humanenteropeptidase (EP)was added.
B, SDS-PAGE analysis of the autoactivation reaction in 1mM CaCl2. Samples were withdrawn at indicated times, precipitated with trichloroacetic acid, electro-
phoresed, and stained as described under “Experimental Procedures.” C, cleavage of trypsinogen by 25 nMmouse Ctrc. Incubationswere performedwith 2M
trypsinogen in 0.1MTris-HCl (pH8.0) in the absenceor presenceof 10mMCaCl2. Sampleswereprecipitatedwith trichloroacetic acid andanalyzedbySDS-PAGE
and Coomassie Blue staining. Cleavage products were identified with N-terminal sequencing. In the absence of calcium (left panel), the faint bands above and
below themajor cleavageproducts correspond to fragments of trypsinogen cleaved at the Leu-81–Glu-82peptidebond. The faint band visible in thepresence
of 10 mM calcium (right panel) could not be identified. Representative experiments from three replicates are shown.
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bition in anothermammalian trypsinogen, wemutated Ser-150
in human cationic trypsinogen to Phe. Because human CTRC
cleaves the Leu-81–Glu-82 peptide bond and causes trypsino-
gen degradation, we used human CTRB2 to selectively cleave
the newly created Phe-150–Gly-151 peptide bond. CTRB2 at
25 nM concentration had no effect on the autoactivation of
wild-type cationic trypsinogen (Fig. 11A), but it inhibited acti-
vation of the p.S150F mutant (Fig. 11B), via cleavage at the
Phe-150–Gly-151 peptide bond (Fig. 11C).
Effect of Mouse Ctrc on T20 Trypsinogen—Finally, mouse
Ctrc had essentially no effect on trypsinogen T20, except for a
slight stimulation of the activation rate in 10 mM calcium (Fig.
12A). On SDS-PAGE, no trypsinogen to trypsin conversionwas
evident in 1mMcalcium, in the absence or presence ofCtrc (Fig.
12B). Note that T20 trypsinogen ran as a doublet on gels, which
seems to represent differently denatured conformers, as N-ter-
minal sequencing and mass spectrometry indicated molecular
homogeneity (data not shown). Finally, cleavage of T20 with
Ctrc resulted in very faint degradation bands even in the
absence of calcium, indicating that this isoform is resistant to
Ctrc (Fig. 12C).
DISCUSSION
The aim of this study was to identify the major trypsinogen
isoforms expressed by the mouse pancreas and characterize
their regulation of autoactivation bymouse Ctrc. These studies
were undertaken to clarify whether introduction of trypsinogen
mutations associated with human hereditary pancreatitis into
mouse trypsinogens would offer a viable approach to model
hereditary pancreatitis in mice. Previous attempts to generate
transgenicmice expressing the codingDNA for human cationic
trypsinogen with the p.R122H mutation failed to recapitulate
hereditary pancreatitis, partly because of the low transgene
expression levels (6). Introduction ofmutation p.R122H into an
endogenous mouse trypsinogen may circumvent the expres-
sion problem. However, the effect of p.R122H in human cat-
ionic trypsinogen is dependent on CTRC (3), and it has been
unknownwhether autoactivation ofmouse trypsinogens is reg-
ulated by mouse Ctrc in a manner that mimics the human
situation.
Using two independent biochemical approaches with two
commonly used outbredmouse strains, we found that only four
trypsinogen isoforms,T7,T8,T9 andT20, are expressed to high
levels (Table 2) in the mouse pancreas, even though the mouse
genome contains 20 trypsinogen genes, of which 11 are poten-
tially functional (Table 1 and Fig. 1). The cationic isoform T7
was recently deleted in the C57BL/6 strain, and judging from
the residual trypsinogen content the authors suggested that T7
contributes 60% of total mouse trypsinogens (12, 13). Here, we
obtained smaller values (41% in CD-1 and 25% in NMRI mice);
however, these differences seem to fall within experimental
error and may even represent strain-specific differences. It is
important to note that Prss1 (T16) and Prss3 (T11) (see Table
FIGURE 8. Effect of mouse Ctrc onmouse trypsinogen T9. See Fig. 7 for experimental details. EP, human enteropeptidase.
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1), the presumed orthologs of human cationic trypsinogen
(PRSS1) and mesotrypsinogen (PRSS3), are not expressed at
detectable levels, indicating that assignment of orthology by
database curators may be unreliable and even misleading to
investigators, as evidenced by a recent study where expression
ofmouse Prss1 was studied (30). Finally, we emphasize that our
data pertain to the resting, unstimulatedmouse pancreas, and it
is possible, even likely, that upon hormonal stimulation the
trypsinogen expression pattern may change, as shown previ-
ously for rat p23, the ortholog of mouse T4 and T5, which
becomes drastically up-regulated upon cerulein stimulation
(31). Marked up-regulation of T5 was observed in a knock-out
mouse strain deficient in interferon regulatory factor 2 (32).
Autoactivation of mouse trypsinogens T7, T8, and T9 was
comparable, whereas T20 autoactivated more slowly, particu-
larly in 1 mM calcium (see Fig. 3). Surprisingly, regulation of
autoactivation by mouse Ctrc was isoform-specific and mech-
anistically different from the actions of human CTRC on
human cationic trypsinogen. Whereas the human enzyme tar-
gets regulatory cleavage sites in the activation peptide and the
calcium binding loop of cationic trypsinogen, these proved to
be irrelevant in mouse trypsinogens. Thus, Ctrc-mediated
cleavage of the activation peptide was observed only with the
T7 isoform, however, this N-terminal processing had no signif-
icant effect on autoactivation. Cleavage of the Leu-81–Glu-82
peptide bond in the calcium binding loop (Leu-82–Glu-83 in
T7) was not detectable in T7 or T20, and minimal cleavage was
seen in T8 andT9. In contrast, isoformsT8 andT9were rapidly
cleaved at the Phe-150–Gly-151 peptide bond in the autolysis
loop, and this cleavage resulted in marked inhibition of autoac-
tivation. The Phe-150–Gly-151 peptide bond was also cleaved
by Ctrb at a 7-fold slower rate. However, considering that Ctrb
is the most abundant chymotrypsin in the pancreas, physiolog-
FIGURE9.EffectofmouseCtrbonmouse trypsinogenT8.A, autoactivation
wasmeasured in1mMCaCl2 asdescribedunder “Experimental Procedures” in
the absenceor presenceof 25nMmouseCtrb or Ctrc, as indicated.B, cleavage
of trypsinogen by 25 nM Ctrb and Ctrc was compared in the absence of cal-
cium, as described in Fig. 7C. Representative experiments from two replicates
are shown. C, disappearance of the intact trypsinogen band was quantitated
by densitometry, and data from two experiments were plotted. For clarity,
error barswere omitted; the error was within 10% of the mean.
FIGURE 10. Effect ofmutation p.R122Honmouse trypsinogen T8. A, auto-
activation of wild-type and p.R122Hmutant T8 trypsinogenwasmeasured in
1 mM CaCl2 as described under “Experimental Procedures.” B, effect of 25 nM
mouse Ctrc on the autoactivation of the p.R122Hmutant T8. Conditionswere
the sameas inA.C, cleavageofwild-type andp.R122Hmutant T8 trypsinogen
by 25 nMmouse Ctrc in the absence of calcium. Samples were incubated and
analyzed as described in Fig. 7C. Representative experiments from two repli-
cates are shown.
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ical regulation of activation ofT8 andT9maybe also dependent
onCtrb. IsoformT7was also cleaved in the autolysis loop, albeit
slowly and at a different peptide bond (Leu-149–Ser-150),
which resulted in moderate degradation during autoactivation.
Nevertheless, isoform T7 was clearly less sensitive to chymo-
tryptic regulation than human cationic trypsinogen or mouse
trypsinogens T8 and T9.
The lack of cleavage at the Leu-81–Glu-82 (Leu-82–Glu-83
in T7) peptide bond by Ctrc may be partly explained by differ-
ences in the amino acid sequence of the calcium binding loop
(see Fig. 1). Furthermore, as we learned from the recent crys-
tal structure of human CTRC, recognition of the calcium
binding loop is governed by long range electrostatic interac-
tions between the negatively charged substrate and positively
charged surface regions on CTRC (33). These macroscopic
electrostatic interactions are less favorable in themouse, due to
missing positively charged residues in Ctrc (Arg-80 and Arg-
240) and negatively charged residues inmouse trypsinogens T7
(Glu-32, Asp-156, and Glu-157) and T8, T9, and T20 (Glu-79
and Glu-157) (see Fig. 1).
The majority of mammalian trypsinogens do not contain
Phe-150, indicating that this novel mechanism of autoactiva-
tion regulation may be unique to rodents. Human meso-
trypsinogen contains Phe-150, and cleavage at this site by
humanCTRCwas demonstrated previously (5), suggesting that
activation ofmesotrypsinogenmay be under similar regulation.
Human anionic and cationic trypsinogens contain Ser at posi-
tion 150, but mutation S150F confers sensitivity to CTRB2-
mediated cleavage of the autolysis loop, which inhibits autoac-
tivation in a manner that is similar to the Ctrc-dependent
inhibition of T8 and T9 in the mouse. Crystal structures of
mouse trypsinogens are not available, and the autolysis loop in
structures of rat anionic trypsinogen is disordered and not vis-
ible. Therefore, we used a bovine trypsinogen structure to
model the potential effects of cleavage of the autolysis loop after
Phe-150. As shown in Fig. 13, the autolysis loopmay be in close
proximity to the trypsinogen activation peptide, at least judged
by the position of Val-25, the first visible residue of the other-
wise disorderedN-terminal segment. Cleavage of the Phe-150–
Gly-151 peptide bond should increase themobility of the autol-
ysis loop, which may directly interact with the activation
peptide thereby decreasing its accessibility. One possible inter-
action may occur between the positive charge of the newly cre-
ated N terminus in the autolysis loop and the negatively
charged tetra-Asp motif in the activation peptide.
The Ctrc-dependent inhibition of autoactivation of T8
and T9 trypsinogens may have evolved as a protective mecha-
nism to curtail unwanted trypsinogen activation in the pan-
creas. This is conceptually analogous to the regulation of
human trypsinogens by human CTRC even though mechanis-
tic details are dissimilar. Interestingly, we found that cleavage of
the Phe-150–Gly-151 peptide bond in T8 and T9 trypsinogens
also inhibits activation by enteropeptidase, the physiological
trypsinogen activator in the duodenum (data not shown).
Although inhibition of digestive enzyme activation in the gut
may seemcounterintuitive, this chymotrypsin-dependent feed-
backmechanism likely ensures that intestinal trypsinogen acti-
vation proceeds with a slower, more prolonged kinetics, which
may be favorable for food digestion.
Intra-acinar cell activation of trypsinogen in cytoplasmic
vesicles of autophagic origin is an early event in experimental
models of acute pancreatitis (34). Genetic deletion of T7 was
recently shown to abolish intra-acinar trypsinogen activation in
response to hyperstimulation with cerulein: a somewhat per-
plexing observation as other trypsinogen isoforms could have
potentially be activated (12, 13). The results presented here
offer a plausible explanation for this puzzle. When trypsinogen
activation occurs, isoforms T8 and T9 may be inhibited in a
Ctrc or Ctrb-dependent manner, whereas T7 is less sensitive to
chymotryptic regulation. Because of its lower concentration
and poor activation, isoform T20 is unlikely to contribute to
intra-acinar trypsinogen activation to a detectable extent.
Finally, our data argue that in the context of mouse trypsino-
gens, human pancreatitis-associated mutations may not reca-
pitulate the pathogenic biochemical phenotype observed with
FIGURE11.Effect of humanCTRB2on theautoactivationofwild-typeand
p.S150F mutant human cationic trypsinogen (Hu1). A and B, autoactiva-
tionwasmeasured in 1mMCaCl2, in the absence or presence of 25 nM CTRB2,
as described under “Experimental Procedures.” C, cleavage of wild-type and
p.S150F mutant human cationic trypsinogen by 25 nM CTRB2 in the absence
of calcium. Incubationswere performed, and sampleswere analyzed as given
in Fig. 7C. To prevent autoactivation, 25 nM human SPINK1 trypsin inhibitor
was included. Representative experiments from two replicates are shown.
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human cationic trypsinogen.We found thatmutation p.R122H
did not affect inhibition of autoactivation by Ctrc in T8 trypsin-
ogen, which stands in contrast to the robust negative effect of
this mutation on CTRC-dependent degradation of human
cationic trypsinogen (3). Thus, introduction of humanmuta-
tions into mouse trypsinogens may not be a practical
approach for the generation of mouse models of human
hereditary pancreatitis.
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Abstract Kynurenic acid (KynA), a broad spectrum
antagonist of excitatory amino acid receptors, may serve as a
protective agent in neurological disorders. The potential anti-
inflammatory effect of KynA in human leukocytes has not
been characterized. The aim of this study was to compare the
effects of KynA with those of a new analogue, 2-(2-N,N-
dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one
hydrochloride on tumour necrosis factor-α (TNF-α) produc-
tion and high mobility group box protein 1 (HMGB1)
secretion. The effects of KynA on granulocyte activation
were investigated via the secretion of human neutrophil
peptide 1–3 (HNP1–3). Peripheral blood mononuclear cells
and granulocytes or CD14 positive monocytes were applied
as effector cells, or whole blood cultures were used. TNF-α,
HMGB1 and HNP1–3 concentrations were determined by
ELISA, TNF-α and HNP1–3 mRNA expressions were
quantified by reverse transcription PCR. KynA attenuated
the TNF-α production of human mononuclear cells
activated by heat-inactivated Staphylococcus aureus,
inhibiting TNF-α production at the transcription level.
Furthermore, KynA diminished HMGB1 secretion by U
937 monocytic cells and by peripheral blood monocytes.
KynA inhibited the HNP1–3 secretion in whole blood and
in granulocyte cultures. The suppressive effect of the
KynA analogue was more potent than that of an equimolar
concentration KynA in TNF-α, HMGB1 and HNP1–3
inhibition. These results suggest that the new KynA
analogue has a more potent immunoregulatory effect than
KynA on human mononuclear cells, monocytes and
granulocytes and indicate the potential benefits of further
exploration of its uses in human inflammatory disease.
Keywords Kynurenic acid . TNF-α . HMGB1 .
Defensin-α . Monocytes . Granulocytes
Introduction
Kynurenic acid (KynA), an endogenous product of the
tryptophan metabolism and a broad spectrum antagonist of
excitatory amino acid receptors, may serve as a protective
agent in neurological disorders (Stone 2000; Klivenyi et al.
2004; Nemeth et al. 2005; Sas et al. 2007; Gigler et al. 2007;
Vamos et al. 2009). KynA is an N-methyl-D-aspartate
(NMDA) antagonist (Stone 1993; Vecsei et al. 1992;
Schwarcz et al. 1999; Robotka et al. 2008) and exerts a
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wide range of biologically important action in the central
nervous system, including the reduction of excitotoxic damage
(Swartz et al. 1990; Kiss and Vecsei 2005; Robotka et al.
2008; Zádori et al. 2006). Exogenous KynA has been
demonstrated to be able to inhibit leukocyte activation in a
canine model of intestinal inflammation (Kaszaki et al. 2008).
Furthermore, KynA decreases the inflammatory activa-
tion and colonic motility in the early phase of acute
experimental colitis in the rat (Varga et al. 2010)
While most biological effects associated with KynA, such
as neuroprotective activities, have been attributed to its
antagonism on NMDA receptor, a novel mechanism by which
KynA may regulate peripheral cellular responses through
activation of GPR35 has been reported (Wang et al. 2006). It
has been demonstrated that KynA acts as a ligand for
GPR35, which is one of the members of the G-protein-
coupled receptors (Lagerström and Schiöth 2008). Expres-
sion analysis has revealed prominent expression of GPR35 in
immune and gastrointestinal tissues. In humans, GPR35 has
mainly been detected in peripheral leukocytes, among
them in monocytes, T cells, dendritic cells and neutro-
phils (Wang et al. 2006). Moreover, KynA was able to
attenuate LPS-induced tumour necrosis factor-α (TNF-α)
secretion of mononuclear cells. In view of its potential
anti-inflammatory action, we considered it of interest to
investigate the effects of KynA on TNF-α production and
on the high mobility group box protein 1 (HMGB1) and
defensin-α production of human white blood cells.
TNF is an inflammatory cytokine, an early mediator of
proinflammatory reactions, orchestrating the production of the
cytokine cascade (Fiers 1991). TNF-α has been shown to
promote inflammation via the activation and induction of the
cytokines interleukin 1 (IL-1), IL-6 and IL-8 and by the
upregulation of adhesion molecules on endothelial cells,
leading to increased leukocyte extravasation (Bradley 2008).
Theoretically, the blockade of TNF should be of broad
potential in the treatment of numerous inflammatory diseases
(Mazza et al. 2010). HMGB1 functions as a proinflammatory
late cytokine, actively secreted from monocytes and macro-
phages in response to proinflammatory stimuli, i.e. cytokines
such as TNF-α, IL-1 or even lipopolysacharide (LPS; Harris
and Andersson 2004; Lotze and Tracey 2005). Extracellular
HMGB1 induces further release of proinflammatory media-
tors, thereby prolonging inflammatory processes (Andersson
et al. 2002). In the present study, therefore the effects of
KynA and a KynA analogue on the HMGB1 secretion of
human monocyte cell line U 937 were investigated. Addi-
tionally, the effects of KynA on granulocyte activation were
studied via the secretion of human neutrophil peptide 1–3
(HNP1–3), also known as defensin-α, which can be secreted
and released into the extracellular milieu following the
activation of polymorphonuclear neutrophils during inflam-
mation (Ganz 1987; Quinn et al. 2008). Conventionally, α
defensins are involved in microbial killing, but they
also have an important immunomodulative role in
inflammation (Yang et al. 2002). We further compared the
effects of KynA with those of a novel, synthetic KynA
analogue 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-
1H-quinolin-4-one hydrochloride, which is able to cross the
blood–brain barrier (Marosi et al. 2010).
Materials and methods
Reagents
The test compound KynAwas purchased from SIGMA, while
the new analogue (Fig. 1) was synthetized by Prof. Fülöp at
the Department of Pharmaceutical Chemistry, University of
Szeged. KynA and the analogue were dissolved in phosphate-
buffered saline (PBS) and added in increasing concentration in
the μ range to the cell cultures or whole blood samples.
Isolation and stimulation of human mononuclear cells
Peripheral bloodmononuclear cells were prepared fromEDTA-
anticoagulated venous blood samples obtained from healthy
volunteers by Ficoll-Hypaque (Sigma Chemicals) density
gradient centrifugation. After washing, isolated cells (mono-
cytes and lymphocytes) were resuspended in RPMI 1640
medium (GIBCO) supplemented with 10% foetal calf serum
(FCS) to achieve a final concentration of 5×106 cells/ml.
Experimental cultures were incubated for 18 h with heat-
inactivated Staphylococcus aureus 108/ml as a TNF inducer
(Wang et al. 2000). In parallel experiments, mononuclear
cells were pretreated for 30 min with KynA or with KynA
analogue 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-
1H-quinolin-4-one hydrochloride at concentrations of 500,
250, 125, 50 and 25 μM, respectively. Cell supernatants
were tested for TNF-α content by ELISA (R&D).
Isolation and stimulation of human monocytes
Peripheral blood mononuclear cells were prepared from
EDTA-anticoagulated venous blood samples from healthy
Fig. 1 The structures of kynurenic acid (KynA) and of the new
KYNA analogue 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-
quinolin-4-one hydrochloride (Marosi et al. 2010)
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volunteers by Ficoll-Hypaque (Sigma Chemicals) density
gradient centrifugation. Cells were washed with PBS and
resuspended in 80 μl of buffer consisting of PBS with 0.5%
of bovine serum albumin and 2 mM EDTA per 107 total
cells and 20 μl of magnetic MACS anti-CD14 MicroBeads
(Miltenyi Biotec, Germany) per total 107 total cells and
incubated for 15 min at 6–8°C. After washing, the cells
were resuspended in 500 μl of buffer and run through a
column (LS) placed in a magnetic field according to the
instructions of the manufacturer. The magnetic anti-CD14
cell separation (positive selection) yielded a cell popula-
tion consisting of 98% monocytes, as checked by flow
cytometric analysis (FACstar, Becton Dickinson). Cells
were cultured in RPMI 1640 medium (GIBCO) supple-
mented with 10% FCS to achieve final concentration of
2×106 cells/ml. The cells were stimulated for 24 h with
5 ng/ml phorbol-12-myristate-13-acetate (PMA; SIGMA),
with or without heat-inactivated S. aureus at 108/ml. In
parallel experiments, cultures were pretreated for 30 min
with KynA or with KynA analogue at concentrations of
500, 250, 125 and 50 μM. Supernatants were tested for
HMGB1 content by ELISA.
Isolation and stimulation of human polymorphonuclear
neutrophilic granulocytes
Polymorphonuclear neutrophilic granulocytes were isolated
from EDTA-anticoagulated blood by Ficoll-Hypaque den-
sity gradient centrifugation followed by brief hypotonic
lysis of red blood cells. Thereafter, cells were resuspended
in RPMI 1640 medium supplemented with 10% FCS. This
technique yielded 90–95% neutrophils as assessed by
Giemsa staining and by CD16 positivity. Cells were
cultured in RPMI 1640 medium (GIBCO) supplemented
with 10% FCS to achieve a final concentration of 2×
106 cells/ml and were incubated in the presence of heat-
inactivated S. aureus (108/ml) for 6 h. In parallel experi-
ments, granulocyte cultures were pretreated for 30 min with
KynA or with the KynA analogue at concentrations of 500,
250, 125 and 50 μM. Following the incubation period, the
samples were centrifuged at 300 g and the supernatants
were tested for HNP1–3 content by ELISA.
Cell line
Human monocytic cells U 937 were propagated in RPMI
1640 medium supplemented with 10% heat-inactivated
FCS (GIBCO) at 37°C in a humidified CO2 incubator. To
analyse HMGB1 secretion from U 937 cells, the cell
number was adjusted to 106/ml. The cells were stimulated
for 24 h with 5 ng/ml PMA (SIGMA). In parallel experi-
ments, cultures were pretreated for 30 min with KynA or
with the KynA analogue at concentrations of 500, 250, 125
and 50 μM. Supernatants were tested for HMGB1 content
by ELISA.
Whole blood incubation method
EDTA-anticoagulated freshly drawn peripheral blood sam-
ples (1 ml) from healthy blood donors (whose granulocyte
count varied from 3.8×106/ml to 4.7×106/ml) were
incubated in the presence of heat-inactivated S. aureus for
6 h. In parallel experiments, blood samples were pretreated
for 30 min with KynA or with the KynA analogue at
concentrations of 500, 250, 125 and 25 μM, respectively.
Following the incubation period, the whole blood samples
were centrifuged at 300×g, and the supernatants were tested
for TNF-α and for HNP1–3 content by ELISA.
TNF-α ELISA
The TNF-α concentrations in the supernatants of whole
blood cultures or in human mononuclear cells were
quantified by using TNF-α ELISA kit (R&D) according
to the instructions of the manufacturer.
HMGB1 ELISA
The HMGB1 concentrations of the supernatants of U 937
cells and of human monocytes were determined with an
ELISA kit (IBL Hamburg) according to the instructions of
the manufacturer.
HNP1–3 ELISA
The HNP1–3 ELISA kit was obtained from HyCult
Biotechnology, The Netherlands. Plasma samples of whole
blood cultures and the supernatants of purified granulocytes
were analysed with standard measurements, according to
the manufacturer’s instructions.
TNF-α mRNA quantification by RT-PCR
Total RNA was isolated with High Pure RNA Isolation Kit
(Roche) according to the manufacturer’s instructions. RNA
concentration was determined by the A260 value of the
sample. Complementary DNA (cDNA) was generated from
1 μg total RNA using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) in a final volume of
20 μl. Reverse transcription PCR (RT-PCR) was performed in
a thermal cycler (MJMini Gradient Thermal Cycler, Bio-Rad)
according to the manufacturer’s instructions. After reverse
transcription, real-time quantitative PCR was carried out
using a LightCycler (Roche). The mixture contained FastStart
TaqMan® Probe Master (Roche), sample cDNA and the
following primers and probes: TNF-α left primer: 5′-CAG
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CCT CTT CTC CTT CCT GAT-3′, TNF-α right primer: 5′-
GCC AGA GGG CTG ATT AGA GA-3′ and probe:
UPL#29 (Roche). The thermal cycler conditions were initial
denaturation at 95°C for 10 min and 45 cycles of 95°C for
15 s and 60°C for 1 min. 18S rRNAwas used as a reference
(18S rRNA left primer 5′-CTC AAC ACG GGA AAC CTC
AC-3′, 18S rRNA right primer: 5′-CGC TCC ACC AAC
TAA GAA CG-3′, probe: UPL#77). Results were obtained
as threshold cycles (Ct) values, and the relative expression
was calculated by using the delta–delta Ct method and given
as a ratio between target and reference gene.
HNP1–3 mRNA quantification by RT-PCR
Total RNA was extracted from granulocytes with High Pure
RNA Isolation Kit (Roche) according to the manufacturer’s
instructions. RNA concentration was determined by the A260
value of the sample. cDNA was generated from 1 μg total
RNA using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) in a final volume of 20 μl. After
reverse transcription, amplification was carried out using
Light Cycler Fast Start DNA MasterPLUS SYBR Green I mix
(Roche). Samples were loaded into capillary tubes and
placed in the fluorescence thermocycler (LightCycler). Initial
denaturation at 95°C for 10 min was followed by 45 cycles
of 95°C for 10 s, annealing at 58°C for 8 s and elongation at
72°C for 12 s. For DEFA1 sense, 5′-TCC CAG AAG TGG
TTG TTT CC-3′; antisense 5′-GCA GAA TGC CCA GAG
TCT TC-3′ and for the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) sense, 5′-AAG GTC
GGA GTC AAC GGA TTT-3′; antisense, 5′-TGG AAG
ATG GTG ATG GGATTT-3′ primers were used. At the end
of each run, melting curve profiles were achieved by cooling
the sample to 40°C for 15 s and then heating the sample
slowly at 0.20°C/s up to 95°C with continuous measurement
of the fluorescence to confirm the amplification of specific
transcripts. Cycle-to-cycle fluorescence emission readings
were monitored and analysed by using LightCycler software
(Roche Diagnostics GmbH). All quantifications were nor-
malized to the housekeeping GAPDH gene. Relative gene
expression is given as a ratio between target gene and
GAPDH gene expressions, calculated by using the delta–
delta Ct method.
Statistical analysis
Data are expressed as means ± SD. Differences between
group means were determined by ANOVA test followed by
Bonferroni’s multiple comparison test, or the unpaired
Student t test. p values <0.05 were considered significant.
All statistical calculations were performed with the Graph-
Pad Prism 5 statistical program (GraphPad Software Inc.,
San Diego, CA, USA).
Results
KynA and the KynA analogue attenuates TNF-α
production in whole blood
To study the effects of KynA and the KynA analogue on
leukocyte TNF-α production, varying concentrations of the
drugs were added to human whole blood activated with heat-
inactivated S. aureus. Whole blood, which recapitulates the
extracellular milieu of the physiological environment during
infection or injury, is an ideal substrate on which to assess
the activity of agents towards white blood cells directly.
During a 6-h incubation period, KynA significantly atten-
uated the TNF-α levels in whole blood in a dose-dependent
manner (Fig. 2). The comparison of the inhibitory effect of
KynAwith that of the KynA analogue revealed that the KynA
analogue was more effective (p<0.01) than an equimolar
concentration of KynA in suppressing TNF-α production.
KynA and the KynA analogue attenuates TNF-α
production in human mononuclear cells
As it was theoretically possible that KynA attenuates TNF-α in
whole blood by acting indirectly on other cells than mononu-
clear cells, we ascertained the effect of KynA on isolated
human mononuclear cells in vitro. Because of high individual
differences in TNF producing capacity, the data in Fig. 3 are
expressed as percentages of the TNF-α concentrations
produced by untreated (only PBS-treated) cells in each
experiment. Each concentration was tested in duplicate on
mononuclear cell cultures obtained from five different blood
donors. The maximum TNF-α concentrations in the super-
natants in SA-induced cultures of mononuclear cells without



















Fig. 2 KynA and the KynA analogue attenuate TNF-α levels in SA-
stimulated human whole blood. Whole blood cultures were incubated
with PBS (0 μM), KynA or the KynA analogue at concentrations of
50, 125, 250 and 500 μM for 30 min prior to the addition of heat-
inactivated SA (108/ml), and the TNF-α levels in the plasma were
determined 6 h later. Each concentration was tested in duplicate in
whole blood obtained from three different donors. Data are shown as
means±SD. *p<0.01; **p<0.001 vs the control (0 μM); #p<0.01 vs
the KynA analogue, determined by the Student t test
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concentration (500 μM), KynA suppressed the TNF-α level
to 50±3.5%, while the KynA analogue did so to 16±4.5%
(p<0.001). At 25 μM, the compounds proved ineffective. At
each effective concentration (125, 250 and 500 μM), the
KynA analogue exhibited a significantly higher inhibitory
effect on TNF production than did KynA at equimolar
concentration (p<0.001; Fig. 3). Together with the results
obtained on whole blood, these findings indicate that the
KynA analogue is significantly more potent than KynA in
inhibiting TNF-α release from mononuclear leukocytes.
KynA and the KynA analogue inhibit TNF-α production
in mononuclear cells at the transcription level
To gain further insight into the KynA mechanism of action,
we next determined the effects of KynA on TNF-α mRNA
expression. Both KynA and the KynA analogue significantly
reduced the TNF-α relative expression (Fig. 4), indicating the
attenuation of SA-induced TNF protein synthesis in human
mononuclear lymphocytes via the inhibition of TNF-α gene
transcription.
Effects of KynA and the KynA analogue on HMGB1
secretion of U 937 cells
PMA (5 ng/ml) induced HMGB1 secretion in U 937 cells
after a 24-h incubation period. Pretreatment of the cells
with KynA or the KynA analogue resulted in a decreased
level of HMGB1 secretion. The KynA analogue exhibited a
significantly higher inhibitory effect (Fig. 5).
Effects of KynA and the KynA analogue on HMGB1
secretion of human monocytes
To confirm that the inhibition of HMGB1 secretion by
KynA is not characteristic only in the case of U 937, a
monocytic cell line, we supplemented our experiments by
applying freshly isolated human peripheral monocytes.
Purified CD14-positive monocytes from peripheral blood
of healthy donors were activated by PMA (5 ng/ml), or
with PMA and heat-killed S. aureus, and HMGB1 was
assessed by ELISA. KynA and KynA analogue exerted
strong inhibitory effects on HMGB1 release in cultures of
monocytes in doses ranging from 500 to 125 μM. The
inhibition was significantly higher for the KynA analogue
(Table 1).
Effects of KynA and the KynA analogue on secretion
of HNP1–3
EDTA-anticoagulated freshly drawn peripheral blood sam-
ples were pretreated with increasing concentrations of
KynA or the KynA analogue for 30 min and thereafter
were incubated in the presence of heat-killed S .aureus
for 6 h. Following a brief centrifugation at 300×g, the
supernatants were assessed for HNP1–3 (defensin-α) concen-
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Fig. 3 KynA and the KynA analogue attenuate the TNF-α level in SA-
stimulated human mononuclear cells. Mononuclear cells (5×106/ml)
were incubated with PBS (untreated cells), or with KynA or the KynA
analogue at the indicated concentrations 30 min prior to the addition of
heat-inactivated SA (108/ml), and the TNF-α levels in the supernatants
were determined after 18 h. Each concentration was tested in duplicate
in mononuclear cell cultures obtained from five different blood donors.
Data are expressed as percentages of the TNF values from
untreated cell cultures, without KynA or the KynA analogue, and
are shown as means±SD. *p<0.001 vs 25 μM KynA or vs 25 μM
KynA analogue; #p<0.001 vs equimolar KynA analogue. The
degree of significance between different experimental samples was
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Fig. 4 Effect of 500 μM of KynA and KynA analogue on TNF-α
mRNA levels in human mononuclear cells stimulated with SA. TNF-
α levels were normalized to reference gene of 18S rRNA by using
quantitative real-time PCR. Relative expression was calculated by
using the delta–delta Ct method and is given as a ratio between the
target and the reference gene. Data are shown as means±SD of the
results of three independent experiments. *p<0.01 vs 0 μM; **p<
0.001 vs 0 μM; determined by the Student t test. Open bar TNF-α
mRNA expression without stimulation, black bar mRNA expression
of SA-stimulated cells without KynA, grey bar SA-stimulated cells
with 500 μM KynA, hatched bar SA-stimulated cells with 500 μM
KynA analogue
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tration. The data in Fig. 6 are expressed as percentages of the
control values (without KynA or the KynA analogue,
respectively) in each experiment because of the high
individual differences in HNP1–3 release. Each concentra-
tion was tested in duplicate on whole blood obtained from
ten different blood donors. The HNP1–3 concentrations in
the SA-activated blood samples without KynA treatment
varied in the interval 350–650 ng/ml. Both KynA and the
KynA analogue significantly reduced the secretion of
HNP1–3 (Fig. 6), At 500 μM, KynA and the KynA
analogue decreased the level of HNP1–3 to 58±12% and
41±5.6% of that for the untreated samples, respectively
(p<0.001). The HNP1–3 present in the whole blood cultures
can be regarded as mainly due to the activity of the
granulocytes (Sthoeger et al. 2008). Our previous experi-
ments demonstrated HNP1–3 secretion not only in the case
of purified granulocytes but also when a whole blood
incubation method was applied. In the peripheral blood, the
neutrophil granulocytes are the main source of HNP1–3, and
we therefore suggest that the elevation of the level of HNP1–3
following SA1 induction is mainly due to the activity of the
granulocytes (Kocsis et al. 2009a). Accordingly, we conclude
that the HNP1–3 (α-defensin) in the supernatants of whole
blood cultures can be regarded as products of the granulo-
cytes (this is all the more likely, if it is borne in mind, that
the neutrophils account for the highest number of leukocytes
in the peripheral blood). However, we ascertained the effect
of KynA on isolated human neutrophils. There was a
considerable HNP1–3 secretion by granulocytes following
a 6-h induction with heat-killed SA (980±125 ng/ml). KynA
and the KynA analogue resulted in significantly decreased
HNP1–3 levels in the supernatants; at concentrations of 125–
500 μM, the lowest levels of HNP1–3 were secreted in the
presence of 500 μM KynA analogue (Table 2).
Levels of HNP1–3 mRNA in granulocytes
Wemeasured theα-defensin mRNA level in the granulocytes.
























Fig. 5 Effects of KynA and the KynA analogue on HMGB1 secretion
of U 937 cells. U-937 cells were pretreated for 30 min with KynA or
the KynA analogue and thereafter incubated for 24 h with 5 ng/ml
PMA. Supernatants were processed for HMGB1 ELISA. Data are
means±SD of the results of three experiments.*p<0.05 vs control
(0 μM); **p<0.01 vs control (0 μM); #p<0.05 vs the KynA analogue
(determined by the Student t test)
Table 1 Effects of KynA and the KynA analogue on HMGB1






Without KynA (control) 31±2.8 41.4±4.2
KynA 50 μM 29.0±2.8 33.2±4.1
Analogue 50 μM 27.1±3.1 28.2±3.5*
KynA 125 μM 26.2±2.7**** 29.1±2.8*,****
Analogue 125 μM 21.5±2.2* 21.8±2.7**
KynA 250 μM 14.9±2.6**,**** 18.2±2.4**,****
Analogue 250 μM 10.3±1.5*** 12.5±1.8***
KynA 500 μM 13.7±2.1**,**** 15.8±2.5***,****
Analogue 500 μM 9.5±1.5*** 10.5±0.9***
Human peripheral blood monocytes (separated by the MACS
(Miltenyi Biotec) magnetic bead method) were pretreated for 30 min
with KynA or the KynA analogue and thereafter incubated for 24 h
with 5 ng/ml PMA, or with 5 ng/ml PMA together with heat-
inactivated SA (108 /ml). Supernatants were processed for HMGB1
ELISA. Data are means ± SD of the results of three experiments
*p<0.05 vs control (without KynA); **p<0.01 vs control (without KynA);
***p<0.001 vs control (without KynA); ****p<0.05 vs the KynA
analogue (determined by the Student t test)
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Fig. 6 Effects of KynA and the KynA analogue on secretion of
HNP1–3. Whole blood cultures were incubated with KynA or the
KynA analogue at the indicated concentrations for 30 min prior to the
addition of heat-inactivated SA (108/ml), and the HNP1–3 levels in
plasma was determined 6 h later. Each concentration was tested in
duplicate in whole blood obtained from ten different blood donors.
Data are expressed as percentages of the results obtained on untreated
samples without KynA or the KynA analogue and are shown as
means±SD. The degree of significance between different experimen-
tal samples was determined by the ANOVA test followed by
Bonferroni’s multiple comparison test
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resulted in an elevation of mRNA levels (relative mRNA
expression 2.5±1.2; n=3), no significant influence of either
KynA or the KynA analogue even at 500 μM was observed
(data not shown).
Discussion
KynA was earlier shown to inhibit intestinal hypermotility
and xanthine oxidase activity in experimental colon
obstruction in dogs (Kaszaki et al. 2008), and it was
presumed that KynA might influence intestinal inflamma-
tion. The aim of the present pilot study is to investigate the
in vitro immunomodulatory effects of KynA and its
analogue 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-
1H-quinolin-4-one hydrochloride on human peripheral
leukocytes and the human monocyte cell line.
In the whole blood model, which resembles closely the
physiological milieu, both KynA and the KynA analogue
attenuated TNF-α induction. KynA also dose-dependently
inhibited the TNF-α production by purified human mono-
nuclear cells, but in equimolar concentrations, the KynA
analogue exhibited more pronounced inhibitory activity.
Not only the production of the “early inflammatory
cytokine” TNF was inhibited by KynA but also the active
secretion of a “late” cytokine, HMGB1. Active HMGB1
secretion induced in U 937 human monocytic cells
following phorbol ester induction was inhibited more
effectively by the KynA analogue. The inhibitory effects
of KynA and the KynA analogue were also demonstrated
when freshly isolated human peripheral blood monocytes
were activated with phorbol ester, or with phorbol ester
plus SA. HMGB1 plays important roles in various non-
infectious and infectious inflammatory conditions includ-
ing trauma, sepsis, rheumatoid arthritis and pancreatitis
(Levy et al. 2007; Pisetsky et al. 2008; Sundén-Cullberg
et al. 2006; Kocsis et al. 2009b). Inhibition of the
production of TNF-α and the active secretion of HMGB1
draw attention to the anti-inflammatory effect of KynA
and its analogue. Similarly, the secretion of human
neutrophil peptides HNP1–3 (defensin-α) was inhibited
by both compounds but significantly more strongly by the
KynA analogue. The secretion of defensin-α by granulo-
cytes was measured in our experiments in whole blood
cultures. As granulocytes are the main source of HNP1–3
in the peripheral blood, the results obtained from the
investigation of whole blood can be regarded as reflecting
the granulocyte functions (Kocsis et al. 2009a; Sthoeger et
al. 2008). To confirm this, we supplemented our study
with experiments involving purified granulocytes from
peripheral blood. The similar results proved the inhibitory
effects of KynA and the KynA analogue on the HNP1–3
secretion of the granulocytes. KynA, however, did not
result in a decreased HNP1–3 mRNA expression in the
granulocytes, which could possibly explained by inhibi-
tion of the secretion or of the degranulation, rather than by
impaired HNP1–3 transcription by KynA. HNP1–3
(defensin-α) has not only antibacterial properties but also
important immune functions and inflammatory effects
(Yang et al. 2002; Quinn et al. 2008). Inhibition of HNP1–
3 secretion can therefore additionally result in anti-
inflammatory effects.
Kynurenic acid is an NMDA antagonist (Stone 1993;
Robotka et al. 2008; Klivenyi et al. 2004). It is likely that
the inhibition of TNF transcription and production and the
attenuation of defensin-α secretion are connected with
NMDA antagonism (Mcnearney et al. 2010). Studies on the
mechanism of action of KynA atmicromolar concentrations are
a competitive antagonist of the NMDA receptor (Rózsa et al.
2008). Another possibility is that the inhibitory effect
on the TNF-α transcription is signalled through the α7-
nicotinic acetylcholine receptor pathway. Activation of the
α7-nicotinic acetylcholine receptor attenuates TNF-α and
HMGB1 production through the inhibition of nuclear
factor-κB activation (Rosas-Ballina and Tracey 2009; Wang
et al. 2004). Nonselective nicotinic agonists, including
acetylcholine and nicotine, attenuate proinflammatory
cytokine production through an α7-dependent mechanism
(Wang et al. 2003; Yoshikawa et al. 2006; Parrish et al.
2008). Interestingly, KynA is a nonselective antagonist of
the α7-nicotinic acetylcholine receptor at nanomolar con-
centrations (Hilmas et al. 2001; Robotka et al. 2008),
moreover exerts a biphasic, “Janus-face”-like effect (Rózsa
et al. 2008). It is tempting to speculate whether KynA, an
Table 2 Effects of KynA and the KynA analogue on the secretion of
HNP1–3 of human granulocytes
HNP1–3 (ng/ml)
Without KynA (control) 950±125
KynA 50 μM 915±130
Analogue 50 μM 850±125
KynA 125 μM 720±65*,****
Analogue 125 μM 410±51**
KynA 250 μM 660±62*,****
Analogue 250 μM 312±45**
KynA 500 μM 498±50**,****
Analogue 500 μM 230±32***
Human granulocytes (2×106 /ml) were incubated with KynA or the
KynA analogue at the indicated concentrations for 30 min prior to the
addition of heat-inactivated SA (108 /ml) and the HNP1–3 levels in the
supernatants were determined 6 h later. Data are means±SD of the results
of three experiments
*p<0.05 vs control (without KynA); **p<0.01 vs control (without
KynA); ***p<0.001 vs control (without KynA); ****p<0.01 vs the
KynA analogue (determined by Student t test)
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antagonist of the α7-nicotinic acetylcholine receptor, could
induce similar signalling effects towards TNF-α and
HMGB1 transcription, as an agonist. It is noteworthy,
however, that HMGB1 secretion by activated monocytes
and macrophages requires a tightly controlled relocation
program (Bonaldi et al. 2003; Ulloa and Messmer 2006).
Lacking a leader signal sequence, HMGB1, cannot be
released via the classical ER–Golgi secretory pathway.
Instead, activated macrophages/monocytes acetylate
HMGB1 at lysine-rich nuclear localization sequences, leading
to translocation of nuclear HMGB1 into cytoplasmic
vesicles and subsequent release into the extracellular milieu.
Further studies are necessary to elucidate the exact
mechanism, whereby the signalization is influenced by
KynA, resulting in inhibition of HMGB1 secretion.
In our experiments, KynA and its analogue attenuated
the secretion of TNF-α and HMGB1 of mononuclear cells
and U-937 cells and monocytes, respectively. This is in
good accordance with recent observations by Wang et al.,
who reported that KynA attenuated the LPS-induced TNF-
α secretion of human mononuclear cells, expressing the
GPR35 receptor (Wang et al. 2006). The predominant
expression of GPR35 in immune cells and the elevation of
KynA levels during inflammation (Lögters et al. 2009)
suggest that the anti-inflammatory effect of KynA provides
a feedback mechanism in modulating the immune response.
The attenuation of HNP1–3 secretion of neutrophils by
KynA may also be connected with the effect through
GPR35, as this receptor is expressed on neutrophils. Further
studies are necessary to elucidate the exact mechanisms that
result in the attenuation of TNF-α and HMGB1 production,
and it remains to be established whether the NMDA
receptor or the GPR35 activation or even the α7-nicotinic
acetylcholine receptor is involved in these effects.
Conclusion
Our preliminary results revealed that KynA attenuates TNF-α
and HMGB1 production by human mononuclear white blood
cells and by monocytic cells and the secretion of defensin-α
by human granulocytes, indicating definitive anti-
inflammatory action of the molecule, and the more potent
effect of the KynA analogue. The suppressive effect of the
KynA analogue is greater than that of an equimolar
concentration of KynA both in whole blood and in separated
mononuclear cells in vitro under comparable experimental
conditions. This may be due to the cationic centre of the side
chain, which is probably an additional binding site. Overall,
these results suggest that KynA and the KynA analogue can
regulate critical steps involved in a wide range of inflamma-
tion. The new analogue may therefore be considered a
promising candidate for clinical studies.
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